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ABSTRACT 
 
DESIGN AND SYNTHESIS OF PYRIMIDINE FUSED HETEROCYCLES AS 
SINGLE AGENTS WITH COMBINATION CHEMOTHERAPY POTENTIAL  
 
By 
Roheeth Kumar Pavana 
May 2014 
 
Dissertation supervised by Professor Aleem Gangjee 
This dissertation describes the design, synthesis and biological evaluation of 
pyrimidine fused heterocycles as single agents with combination chemotherapy potential. 
Major limitations of cancer chemotherapy include dose limiting toxicities of clinically 
used agents and the development of multidrug resistance by the tumor. Agents that 
interfere with microtubules are important antitumor agents. Tumor angiogenic 
mechanisms that are vital for tumor growth and metastasis are targeted by antiangiogenic 
agents. Antiangiogenic agents are usually not tumoricidal but are mainly cytostatic. 
Combination chemotherapy with antiangiogenic and cytotoxic agents have shown 
significant promise and several studies with such combinations are in progress in the 
clinic. Single agents with both antiangiogenic activities as well as cytotoxicity would 
afford single agents that circumvent pharmacokinetic problems of multiple agents, avoid 
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drug-drug interactions, could be used at lower doses to alleviate toxicity, be devoid of 
overlapping toxicities, and delay or prevent tumor cell resistance. The work in this 
dissertation is centered on the design and synthesis of single entities that have both 
antiangiogenic effects and cytotoxic effects. 
These efforts led to the identification of structural features that are necessary for 
inhibition of tubulin polymerization. Structural modifications also led to the identification 
of novel antiangiogenic agents which inhibit one or more of the receptor tyrosine kinases 
(RTKs)- vascular endothelial growth factor receptor-2 (VEGFR2), platelet derived 
growth factor receptor-β (PDGFRβ) and epidermal growth factor receptor (EGFR). The 
complexity of the angiogenic pathways in tumors implies that disrupting a single 
mechanism of angiogenesis may not result in significant clinical success. Multiple RTKs 
are co-activated in tumors and redundant inputs drive and maintain downstream 
signaling, thereby limiting the efficacy of therapies targeting single RTKs. 
This work reviews the role of RTKs in angiogenesis, microtubules as antitumor 
targets, the vascular normalization theory and multitargeted agents. This work also 
reviews the synthesis of substituted pyrrolo[3,2-d]pyrimidines, furo[3,2-d]pyrimidines, 
pyrimido[5,4-b]indoles and benzofuro[3,2-d]pyrimidines. A discussion of methods 
employed in the synthesis of pyrimidine fused heterocycles as single agents with 
combination chemotherapy potential is provided.  
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I. BIOLOGICAL REVIEW 
A. Angiogenesis 
 
Figure 1. The angiogenic process (modified from ref. 1) 
Angiogenesis is a complex physiological process of sprouting of new blood vessels 
from existing blood vessels.2 It involves a complex cascade of cellular events that are 
tightly regulated by proangiogenic factors including several growth factors and 
antiangiogenic factors.3 Rapidly proliferating tumor cells inherently require metabolic 
substrates for nourishment and removal of metabolic end products. During the early 
stages of development of a tumor, blood supply to the tumor tissue comes from the 
vasculature supplying the surrounding normal healthy cells. As the tumor exceeds a 
critical mass of about 2 mm in diameter, it requires its own blood supply to support its 
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growth. The fast tumor growth rate also induces hypoxia, which in turn causes an 
angiogenic switch within the tumor microenvironment and initiates other pathways 
involved in over expression of proangiogenic factors. These include vascular endothelial 
growth factor (VEGF), platelet derived endothelial growth factor (PDGF) and epidermal 
growth factor (EGF), which promote endothelial cell proliferation/migration thereby 
leading to angiogenesis (Figure 1).2, 4, 5 The new blood vessels grow and infiltrate into the 
tumor, thereby providing nutrients and oxygen to sustain tumor expansion and a route for 
cancer cell dissemination. This results in tumor progression and metastases.6 The 
sustained growth of solid tumors is highly dependent on angiogenesis. Thus 
antiangiogenic agents have been widely used in the treatment of cancer.7, 8  
The growth of tumor tissue vasculature is chaotic and leaky. Therefore, tumor 
vasculature differs from normal tissue vasculature in several aspects including the 
hierarchy of organization and nature of endothelium .9 
 
A.1 Receptor Tyrosine Kinases in Angiogenesis 
Proangiogenic growth factors such as VEGF, PDGF and EGF bind to their 
corresponding receptors and initiate signal transduction. These receptor tyrosine kinases 
(RTKs), namely vascular endothelial growth factor receptor (VEGFR), platelet-derived 
growth factor receptor (PDGFR), and epidermal growth factor receptor (EGFR), possess 
an extracellular domain, a transmembrane domain and an intracellular kinase catalytic 
domain (Figure 2).10 Growth factor binding to the extracellular domain of RTKs results in 
receptor dimerization (homodimerzation or heterodimerization) and autophosphorylation 
of the tyrosine residues within the cytoplasmic domain. Autophosphorylation then 
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triggers a cascade of downstream cell signalling pathways. These pathways are tightly 
monitored and regulated under normal physiological conditions. Disregulation of these 
signalling pathways has been linked to malignancy and significantly contributes to the 
hallmarks of cancer:11 self sufficiency in growth signals, insensitivity to antigrowth 
signals, evasion of apoptosis, unlimited replicative potential, sustained angiogenesis, 
tumor invasion and metastases. Thus, inhibition of these RTKs offers a key therapeutic 
strategy for cancer therapy.12  
 
Figure 2. General structure and role of RTKs (modified from ref. 10) 
Several RTK targeting small molecular inhibitors (representative compounds shown in 
Figure 3) including crizotinib, dasatinib, erlotinib, imatinib, gefitinib, lapatinib, nilotinib, 
pazopanib, ruxolitinib, sorafenib, sunitinib, vandetanib, and vemurafenib have 
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Figure 3. Representative RTK inhibitors approved for clinical use in USA. 
 
been approved as "targeted agents" for the clinical treatment of various types of 
cancer.12,13 
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VEGFR 
 VEGF is an important growth factor that is involved in angiogenesis and 
vasculogenesis (i.e., the formation of the embryonic circulatory system).14 The VEGF 
family consists of five members, VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placenta 
growth factor (PLGF). Three types of VEGFRs have been identified, VEGFR1, VEGFR2 
and VEGFR3. VEGFRs are almost exclusively expressed on endothelial cells. In addition, 
VEGFRs are overexpressed on several tumor types with different expression patterns, 
ligand specificity and cellular/physiological effects of these receptors. VEGFR2 has been 
recognized as the kingpin in angiogenesis.15 Targeted inhibition or disruption of 
VEGFR2 produces an abrogation of angiogenesis, decreased endothelial cell survival and 
decreased tumor growth.14, 16 Several inhibitors of VEGFR2 including sunitinib and 
semaxanib have displayed antiangiogenic activity.7, 17 
 
PDGFR 
This family of growth factors is comprised of four structurally related, soluble 
polypeptides that exist as five different homodimers and heterodimer ligands: -AA, -BB, 
-CC, -DD, and -AB.18 PDGF can bind to and activate two of its receptors PDGFRα and 
PDGFRβ.19 These receptors are expressed on pericytes, smooth muscle cells that provide 
mechanical support to vasculature. PDGFR pays an important role in angiogenesis by 
stimulating the formation of microvascular pericytes, thereby stabilizing the newly 
formed blood vessels. They are also involved in the induction of VEGF secretion and 
consequently, angiogenesis. 
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EGFR 
The EGF family is comprised of eleven known members that bind to one of four 
EGFR family receptors.20 EGFR is one of the four members of the EGFR family of RTKs. 
Overexpression of EGFR, its growth factors, and aberrant EGFR tyrosine kinase activity 
lead to increased tumor cell proliferation, survival and invasiveness.19 Inhibition of 
EGFR signaling has been shown to promote selective apoptosis in tumor endothelial 
cells.21 As a result, EGFR has been extensively studied and targeted by small molecule 
inhibitors and monoclonal antibodies. 20 
 
A.2 ATP Binding Site of RTKs 
Several crystal structures of RTKs areavailable in the protein data bank. All kinases 
share a catalytic domain that contains the adenosine triphosphate (ATP) binding site. The 
ATP binding site of RTKs has been indicated as a promising target for rational drug 
design. Structural homology and diversity among the ATP-binding sites of kinases has 
allowed the building of pharmacophore models for rational drug design.22, 23 The overall 
three-dimensional structure of the kinase domain is conserved throughout the protein 
kinase family. A twisted β-sheet of five antiparallel β-strands and one α-helix make up 
the N-terminal lobe. The C-terminal lobe is made up of four β-strands and eight α-helices. 
Advances in ATP-bound or inhibitor-bound RTK crystal structures has enabled a detailed 
analysis of the catalytic site, its binding pockets in both active and inactive states as well 
as the mode of binding of RTK inhibitors. 23 
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RTK Catalytic Cleft:  
The catalytic cleft usually consists of two regions commonly referred to as the front 
cleft and the back cleft.24 The ATP-binding site occupies the front cleft of the catalytic 
domain, while the back cleft comprises elements responsible for the regulation of 
phosphorylation of peptide substrates. These two regions share a border that includes the 
aspartate-phenylalanine-glycine (DFG) motif and the β3 segment. A gatekeeper residue 
and a β3-lysine residue form a gate between the front and back cleft. Access to the back 
cleft is controlled by kinase gatekeeper residues. Small amino acid residues such as 
threonine and alanine or bulky gatekeeper residues such as phenylalanine, leucine or 
methionine control entry to the back pocket and selectivity for inhibitors. The β3-lysine 
which is conserved in all kinase enzymes can adopt varied conformations in different 
protein kinases and helps to anchor the α and β- phosphates of ATP in the active state.  
 In a fully active state, protein kinases adopts a DFG-in conformation where the side 
chain of the DFG aspartate is directed into the ATP binding site and the aromatic ring of 
the phenylalanine is positioned in the back cleft.24 The aspartate is required to chelate 
Mg2+ and helps to orient the γ-phosphate of ATP for its transfer in the active DFG-in 
conformation.23, 24 The aromatic side chain of phenylalanine in the active DFG-in motif is 
in contact with αC. This contact in many active kinases facilitates the formation of a Lys-
Glu ion pair for kinase catalysis. 23 
In the inactive state, the DFG motif is in either a DFG-in or DFG-out 
conformation.24 In the DFG-out conformation, the phenylalanine aromatic ring is 
positioned in the ATP pocket and the aspartate residue of the DFG motif is in the back 
cleft.23  
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The Front Cleft:  
The front cleft includes the ATP binding site and small, non-ATP contact regions. 
The ATP site is broadly divided into the following subregions depending on the binding 
mode (Figure 4). 23 
1. Adenine region: This pocket is predominantly hydrophobic and is involved in binding 
various inhibitor scaffolds. This region is bordered by the hinge region and the 
  
Figure 4. ATP-binding site of RTKs [ATP is in pink ] (modified from ref. 25) 
gatekeeper. Two key hydrogen bonds are formed by the interaction of the N1 and N6 
amino nitrogens of the adenine ring with the NH and carbonyl groups of the peptide 
backbone of the hinge region residues of the RTKs. Several RTK inhibitors use at least 
one of these key hydrogen bonds. Other backbone amide groups in the hinge region can 
serve as hydrogen bond donors or acceptors for inhibitor binding. 
2. Ribose binding region: The ribose pocket accommodates the sugar moiety of ATP and 
is adjacent to a hydrophilic, solvent exposed region. This pocket includes includes three 
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hydrophobic and hydrophilic residues. These hydrophobic residues (Ile, Val and Leu) 
have traditionally been exploited in developing EGFR inhibitors.25  
3. Phosphate binding region: This region is covered by Asp, Lys and Asn residues and 
the DFG motif. This region is highly flexible, hydrophilic and solvent exposed, and is 
therefore considered less important in improving inhibitor affinity and potency. However, 
this region has been explored to improve physicochemical properties of inhibitors. 
4. Hydrophobic region II: This pocket is not used by ATP and serves as an entrance for 
ligand binding. Variation in the residues and conformation of this pocket have been 
reported for various kinase targets. Thus, this region has been used to gain selectivity in 
the design of kinase inhibitors.  
The Back Cleft:  
In addition to the ATP-binding site, the back cleft provides important binding 
regions. ATP does not bind in the pockets in the back cleft.24, 25  
1. Hydrophobic region I: The hydrophobic pocket in the back cleft adjacent to the 
adenine pocket is called Hydrophobic region I or Back pocket I (BP-I). This pocket has 
been explored in the design of inhibitors to gain selectivity for kinase targets with small 
gatekeeper residues. 24 
2. In addition to BP-I, additional binding pockets BP-II, BP-III, and BP-IV become 
available to inhibitors depending on the binding state of the RTKs.23 
Major progress has been made with small molecule inhibitors targeting the ATP- 
binding site of RTKs. The front catalytic cleft of all kinase enzymes is accessible to 
ligand binding. Small molecule inhibitors that target the front cleft use a core scaffold to 
recognize the adenine pocket. The core scaffold is then substituted to extend into the 
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different pockets of the ATP-binding site resulting in improved binding affinity and 
selectivity for RTKs.12  
 
B. Microtubules 
Cytoskeletal protein polymers which include actin filaments, intermediate filaments 
and microtubules (MTs) are crucial for cytoskeletal function. Actin filaments and 
intermediate filaments provide mechanical support and resistance against physical stress. 
Microtubules are essential for intracellular transport, maintenance of cell shape and cell 
division during mitosis. The proper functioning of the microtubules, particularly during 
mitosis, depends on exquisite dynamics and these dynamics are highly sensitive to 
chemical intervention.26 For this reason, microtubule-binding agents that interfere with 
these dynamics possess potent inhibitory activities against a wide variety of tumors.27 
Drugs targeting microtubules have been highly successful in clinic and have been 
integrated into therapeutic regimens against both solid tumors (e.g., breast, ovarian, non-
small-cell lung cancer, and Kaposi’s sarcoma) and hematological malignancies (non-
Hodgkin's lymphomas).26, 28  
 
B.1 Structures of Microtubules 
Microtubules are tube-like protein filamentous fibers made of individual tubulin 
dimers. The tubulin heterodimer, present in the cytoplasm in soluble form, consists of one 
α- and one β-tubulin subunit each with a molecular weight of about 50 kDa. 26 Tubulin 
dimers polymerize “head-to-tail” between the α- and β-tubulin to form protofilaments. 
Protofilaments further arrange in parallel to form the wall of the tube like hollow 
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cylindrical microtubule structure. The resulting microtubule consists of nine to sixteen 
protofilaments laterally, and has an outer diameter of 24 nm, a wall thickness of 5 nm, 
and a length extendable to about 25 µm. 
Guanosine triphosphate (GTP) is also an essential component of microtubule 
structure. Each α- and β-tubulin heterodimer structure includes two GTP molecules, one 
of which is tightly bound and cannot be removed without denaturing the heterodimer. 
The other bound GTP molecule is freely exchangeable with unbound GTP. The non-
exchangeable GTP is bound to α-tubulin, whereas GTP and guanosine diphosphate (GDP) 
are exchangeable on β-tubulin. This exchangeable GTP is highly involved in the 
regulation of different tubulin functions. GTP binding is required for microtubule 
polymerization whereas GTP hydrolysis is required for microtubule depolymerization.  
Several proteins associated with microtubules, commonly referred to as microtubule 
associated proteins (MAP), are important for the formation and stability of microtubules. 
The two nonequivalent ends of microtubules are structurally well organized. The slow 
growing minus end is generally anchored at the centrosome or microtubule organizing 
center, and the fast growing plus end probes the cytoplasm in a search-and capture 
process to reach different targets. 27  
 
B.2 Microtubule Dynamics 
Microtubule dynamics, which are tightly regulated processes, are responsible for the 
functional role of microtubules in cells.27 Nucleotides, MAPs, kinases, phosphatases, and 
coordinated interactions with other cytoskeletal components regulate these dynamics. 
Disturbing microtubule dynamics has critical consequences on cellfate. Thus, disrupting 
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microtubule dynamics has traditionally represented an important therapeutic strategy to 
develop antitumor agents.  
The polymerization of tubulin occurs by a nucleation-elongation mechanism.28 This 
process involves slow formation of a short microtubule nucleus followed by rapid 
microtubule elongation through reversible, non-covalent addition of soluble αβ-tubulin 
heterodimers. GTP binding to β-tubulin causes straightening of the dimer to a 
conformation that promotes polymerization.29 The polymerization is driven by the 
hydrolysis of GTP upon the attachment of the GTP-bound tubulin dimer to the ends of 
the microtubule, thereby forming tubulin–GDP and Pi, providing energy for the addition 
of a tubulin dimer. Following hydrolysis of GTP, the loss of the phosphate is not 
immediate and this delayed hydrolysis of GTP results in the formation of a “GTP-cap”, 
which contains GTP or GDP with unreleased phosphate (GDP-Pi). The presence of a 
GTP cap at the end of the microtubule stabilizes the open-sheet conformation of the 
growing microtubule plus end, increases its affinity for tubulin dimers with bound GTP, 
thus leading to lengthening of the microtubule. The cap is usually a single layer of tubulin, 
although its size depends on the polymerization rate.28, 30 As the GTP cap prevents 
microtubule shrinkage, the microtubule end shortens rapidly after loss of the GTP cap. At 
the final stage of the polymerization process, the cap dissociates and leaves a microtubule 
core of β-tubulin bound with GDP.31 
Microtubules display two major forms of non-equilibrium dynamics in vitro and in 
cells, namely dynamic instability and treadmilling.28 Dynamic instability (Figure 5) or the 
switching of microtubules between phases of lengthening and shortening is defined by 
four main factors:29, 33 1) the rate of growth; 2) the rate of shrinkage; 3) the frequency of 
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Figure 5. Microtubule growth and shrinkage (modified from ref. 32)microtubule 
catastrophe (i.e., switching from the growing or paused state to shrinking) and 4) the 
frequency of microtubule rescue (i.e., switching from shrinking to growing or pause). The 
assembly of microtubules occurs more rapidly at the plus end, where the β-tubulin is 
exposed, than at the minus end, where the α-tubulin is exposed. Treadmilling (Figure 6) 
is a process in which tubulin subunits continuously flux from the minus end to the plus 
end. Furthermore, this process is characterized by net growth at one end and balanced 
equivalent shortening at the opposite end. 
 
Figure 6. Microtubule treadmilling (modified from ref. 34) 
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Figure 7. Microtubules (shown in green) during the cell cycle (modified from ref. 35) 
The rate of microtubule dynamics changes rapidly throughout the cell cycle wherein 
the slowest dynamics occur during interphase.35 During the prophase of mitosis, 
microtubules become more dynamic and a bipolar spindle-shaped array of microtubules 
is assembled outwards from the centrosome. In prometaphase, these microtubules attach 
to the kinetochore center of chromosomes. When cells enter metaphase, microtubule 
dynamics increase by 4- to 100-fold, whereas in anaphase microtubules start shortening 
in length (the rate accelerates). As different stages of mitosis are dependant on these 
delicate microtubule dynamics (Figure 7), tubulin-binding agents, which inhibit 
microtubule function during mitosis, result in cell cycle arrest, eventually causing cell 
death.35 
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B.3 Microtubule Binding Agents 
Microtubule inhibitors, also known as antimitotic agents, have been classified on the 
basis of their mechanism of action and effects on polymerization dynamics, and binding 
site on tubulin.36 Based on their effects on microtubule stability they are classified as 
follows. 36 
1) Microtubule-destabilizing agents: These agents inhibit microtubule polymerization and 
promote microtubule disassembly. These included natural products such as the Vinca 
alkaloids, cryptophycins, halichondrins, estramustine, colchicine and its analogs and 
combretastatin.  
2) Microtubule-stabilizing agents: These agents induce microtubule polymerization and 
include paclitaxel, docetaxel, epothilones and discodermolide. Thes agents promote 
microtubule assembly and prevent depolymerization.  
 
Distinct classes of microtubule binding agents classified by their binding sites on 
tubulin are as follows. 36 
1) The Vinca alkaloids  
The Vinca alkaloids, including vinblastine, vincristine, vindesine, and vinorelbine have a 
broad spectrum of activity and have been widely used in cancer chemotherapy for 
leukemia, lymphomas and non-small-cell lung cancer.36 At low concentrations, 
vinblastine inhibits microtubule assembly and depolymerization of microtubules. At 
higher concentrations, vinblastine causes paracrystal formation by tubulin assembly. The 
Vinca alkaloids bind to the β-subunit of soluble tubulin heterodimers at a region 
commonly referred to as the Vinca-binding domain.37 The rapid and reversible binding of  
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Figure 8.Vinca binding site and representative vinca alkaloids (modified from ref. 36) 
vinblastine to soluble tubulin has been suggested to induce a conformational change that 
preventsintegration of the dimer into the microtubule.37 Vinblastine binds with high 
affinity to the end of the microtubules but binds poorly to tubulin that is buried in the 
tubulin lattice (Figure 8). The Vinca alkaloids depolymerize microtubules and destroy 
mitotic spindles at high concentrations of 10–100 nM in HeLa cells, At low but clinically 
relevant concentrations(i.e., IC50 = 0.8 nM in HeLa cells) vinblastine does not 
depolymerize microtubules, yet it powerfully blocks mitosis by suppression of 
microtubule dynamics. The binding of one or two molecules of vinblastine per 
microtubule is sufficient to reduce tubulin dynamics by about 50% without causing 
appreciable microtubule depolymeriza-tion. Other antitubulin agents suchas the 
cryptophycins, halichondrins and dolastatins also bind at the Vinca binding site. 
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2) Taxanes and Epothilones 
 
Figure 9. Taxane binding site and representative taxanes (modified from ref. 36) 
Paclitaxel and its derivatives bind poorly to soluble tubulin, but bind strongly to 
tubulin along the length of the microtubule.38 The binding site for paclitaxel is in the β- 
subunit on the internal surface of the microtubule (Figure 9).37, 39 Paclitaxel is suggested 
to bind by diffusing through nano-size pores in the microtubule lattice. Binding of 
paclitaxel stabilizes the microtubule by inducing a conformational change in β-tubulin 
that increases its affinity for adjacent tubulin molecules. Low concentrations of Taxol are 
sufficient to cause cell cycle arrest and induce apoptosis without changing microtubule 
mass. The IC50 for an antimitotic effect of paclitaxel in HeLa cells is 8 nM while the IC 50 
for an increase in microtubule polymerization is 80 nM.  
Most antimitotic agents that increase microtubule polymerization, such as the 
epothilones, discodermolide, eleutherobin, and sarcodictyins, bind to the Taxol-binding 
site.39 The taxanes are widely used for breast cancer, ovarian cancer, non small cell lung 
cancer, and Kaposi`s sarcoma. Ixabepilone, which belongs to the Epothilone class of 
paclitaxel-site binders, was approved for the treatment of drug-refractory metastatic 
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breast cancer in 2007.39  
 
3) Colchicine binding site agents 
Colchicine binding site agents include podophyllotoxin, combretastatin and 
flavonols. Colchicine is not used clinically in cancer treatment due to its toxicity at doses 
that produce antimitotic effects.40 Colchicine binds to soluble tubulin at a distinct site 
referred to as the colchicine binding site. The colchicine binding site is on β-tubulin at the 
interface between α- and β- tubulins (Figure 10).37 With tubulin, colchicine forms a 
poorly reversible tubulin–colchicine complex, which copolymerizes into the microtubule 
ends along with free tubulin molecules. The ends continue to grow with the complex, but 
their dynamics are suppressed. These effects lead to cell cycle arrest and apoptotic cell 
death.  
 
 Figure 10. Colchicine binding site and combreatastatins (modified from ref. 36) 
Combretastatins are also potent vascular-disrupting agents (VDA) in addition to 
creating antimitotic effect.41, 42 Combretastatin A4 phosphate (CA4P) rapidly 
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depolymerizes the microtubules of endothelial cells, reduces blood flow to the tumor 
within one hour by 95%, increases vascular permeability and hemorrhage of peripheral 
vessels.43 Based on this property of some colchicine binding site agents, both 
combretastatin A4 (CA4) and CA4P have been developed as antivascular agents for 
clinical trials.44, 45 It is believed that selectivity for tumor vasculature over normal blood 
vessels was suggested to lie in the differences between the mature vasculature of normal 
tissues and the immature or forming vasculature of tumors.43, 46 The actin cytoskeleton in 
endothelial cells of immature tumor vasculature is underdeveloped, which is likely to 
make the cells more susceptible to antitubulin intervention.47 In addition, the differences 
in the endothelial cell proliferation rate may also be a causative factor to the observed 
tumor selectivity.43 
4. Additional binding sites: Several antimitotic agents such as welwistatin, noscapine, 
laulimalide, the taccalonolides, and estramustine show potent microtubule inhibitory 
effects but do not bind to the above mentioned three sites on tubulin.37, 39 Owing to the 
important roles of GTP on the regulation of microtubule dynamics, nucleoside analogs 
have also been studied as antimitotic agents. Two GTP analogs were reported to weakly 
bind to the GTP binding site of β-tubulin.48 It has been suggested that tubercidin binds 
weakly to the nucleotide binding site on α-tubulin.49 
  
B.4 Resistances to microtubule-binding agents 
Multiple-drug resistance (MDR) is a common cause of cancer chemotherapy failure, 
which includes microtubule-binding agents.26, 38, 50 Among different resistance mechanis-
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sms for this category of drugs, the most clinically significant are drug efflux by ATP 
binding cassette (ABC) proteins and structural alteration of the microtubules.35, 51 
Membrane efflux by ABC proteins (e.g., P-glycoprotein (Pgp)) was identified as the 
chief mechanism of resistance to vinca alkaloids and taxanes in vitro.52 For example, in 
Pgp-overexpressing SK-OV-3 MDR-1-6/6 cell lines the potency of paclitaxel was 
reduced 800-fold versus parental cell lines.53 Lower responses to microtubule-binding 
agents is frequently correlated with the expression of the ABC pumps. Interestingly the 
combination of Pgp inhibitors with microtubule-binding agents failed to reverse 
resistance in clinical trials.54 The clinical consequence of this resistance mechanism is 
still under question due to inadequate data on the ABC pumps in cancer patients.35, 51, 55  
Structural alterations of microtubules promote changes in microtubule-associated 
proteins (MAP) or the expression of certain isotypes of tubulin in cells. MAP binding 
stabilizes the microtubules, and depending on the type of the microtubule-binding agent, 
changeable levels in the expression of the MAPs such as tau, MAP2, and MAP4 could 
lead to resistance or increased activity.50 For example, the down-regulation of MAP4 lead 
to resistance against paclitaxel, yet augmented response to vinblastine.35, 51, 56, 57  
More than 13 diverse isotypes of tubulins are known to be implicated in the 
assembly of microtubules. Among them, increased levels of class III β-tubulin (βIII-
tubulin) is of highest concern since it is strongly associated with clinical resistance 
against taxanes in lung, breast and ovarian cancers.58, 59 In HeLa cell lines, the activity of 
paclitaxel decreased five-fold times when the cells were adapted to express βIII-tubulin.60 
It was hypothesized that resistance to taxanes was due to loss of a key Ser275 on βIII-
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tubulin. This key ineraction facilitates the diffusion of paclitaxel across the pores.61 
However, this theory failed to explain the βIII-tubulin-mediated resistance of vinca 
alkaloids.59 In addition, βIII-tubulin was shown to cause resistance against a wide range 
of drugs with different mechanisms of action.62 Several studies confirmed the vital role 
played by βIII-tubulin in protecting cells from drug-induced genotoxic stresses.63-65 It is 
likely that the role of βIII-tubulin in cancer may extend further than drug resistance and 
will continue be an active area of future research.27 
 
C. Combination Chemotherapy 
The concept of using a combination of drugs each with activity against a different 
biological target has been used in the treatment of several diseases.66 Modulating a single 
biological target associated with a disease will not be effective unless that target is of 
critical importance, which often is not the case because living systems are complex 
interconnected networks of molecular components.66, 67 In order to bypass inhibition of a 
single biological target, these systems often find alternative compensatory signalling 
routes. These findings provide the rationale for the use of drugs able to target multiple 
unrelated proteins. It is not surprising that this strategy has found utility in complex 
disease states such as cancer with remarkable clinical success.66 As a result, the central 
idea of combination chemotherapy is that by modulating multiple pathways 
simultaneously, the utilization of alternate survival pathways that allow tumor cells to 
evade the therapy can be prevented.67 
In general, antiangiogenic RTK inhibitors are cytostatic agents that prevent further 
growth of the tumor and are required to be used in combination with cytotoxic agents for 
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complete abrogation of tumors.67, 68 Of significant interest is the remarkable clinical 
success of combinations of antiangiogenic agents and cytotoxic agents.69-72 Metronomic 
chemotherapy, the delivery of low doses over a long term so as to avoid toxic side effects, 
along with antiangiogenic agents also results in significant success in the clinic. 
 
D. Vascular Normalization Theory 
According to the central idea of combination therapy combined administration of 
antiangiogenic and cytotoxic therapies is expected to yield maximal antitumor response 
because such combinations would attack independant pathways. Antiangiogenic agents 
would target endothelial cell-mediated angiogenesis and indirectly stop growth of tumor 
cells by depriving them of nutrients, while cytotoxic agents would kill cancer cells 
directly. However, destroying the tissue vasculature is expected to severely compromise 
the delivery of the cytotoxic agent to the solid tumor and render these compounds 
inactive. Surprisingly, synergistic antitumor effects via the use of antiangiogenic and 
cytotoxic drug combinations lead to the proposal of the "vascular normalization" 
theory.73, 74 
Tumor vasculature differs significantly from normal tissue vasculature.9 Under 
healthy physiological conditions, a balance between endogenous proangiogenic and 
antiangiogenic factors maintains normal vessels. These vessels are arranged in a 
hierarchical manner (i.e., arteries, capillaries, and veins) forming an orderly distributed 
compact network, whereas tumor vasculature is disorganized and morphologically 
abnormal with a leaky endothelium. Although the factors controlling tumor vascular 
growth are the same as those involved in healthy tissue growth, the growth of tumor 
vasculature is poorly regulated. In tumor environments, an abundance of proangiogenic 
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growth factors results in vascular growth being vigorous and random in all possible 
directions at all junctures. Consequently, the difference in pressure between the arterioles 
and venules is reduced, resistance to blood flow is increased, and blood supply to the 
tumor is impaired.75 The vascular network appears haphazard with high vascular density 
in certain regions of the tumor and lack of vasculature in others.76 The border of tumor-
normal tissue is usually highly vascularized, while the interior core of the tumor could be 
avascular. Inefficient tumor blood flow due to abnormal vasculature can negatively affect 
the delivery of cytotoxic drugs and also cause systemic toxicities. Inefficient blood flow 
also affects the delivery of antiangiogenic drugs. However, as the targets of 
antiangiogenic agents are located in contact with the bloodstream, these drugs are 
considered to suffer less from delivery obstacles than drugs targeting tumor cells in the 
extravascular space. 
 
Figure 11. Antiangiogenic therapy and vessel normalization (modified from ref. 73) 
 
The vascular normalization theory73, 74 proposes that the effect of antiangiogenic 
agents is twofold: first, they can prune some of the abnormal vessels and second, due to 
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their antiangiogenic nature these agents can balance the effect of proangiogenic factors 
and result in a normalized vasculature (Figure 11). This normalization is both structural 
and functional. The normalized vasculature is central for blood flow with the least 
obstruction and blood supply to the tumor. As a result, there is improved delivery of the 
cytotoxic agent to the tumor thereby explaining the synergy observed in the use of 
antiangiogenic and cytotoxic drug combinations.  
Several studies have shown that anti-VEGF treatment induces a normalization 
process that leads to pruning of immature vessels, and improvement of the integrity and 
function of the remaining vasculature by enhancing perivascular cell and basement 
membrane coverage.77, 78 Normalization of tumor vasculature increases uptake and 
delivery of cytotoxic antitumor drugs.79, 80 However, enhancement in the delivery of 
cytotoxic agents to the tumor is both dose- and time-dependent. The cytotoxic agent 
should be delivered to the tumor during the "window of normalization" in order to 
maximise the intratumoral cytotoxic drug levels. Excessive pruning of vessels can lead to 
inadequate vasculature and shorten the window of normalization. As a result, optimal 
scheduling of antiangiogenic therapy with chemotherapy and/or radiation therapy 
requires knowledge of the timing window during which the vessels initially become 
normalized, and an understanding of the duration of the normalized vasculature. In order 
to utilize the normalization window for appropriate scheduling of the cytotoxic agent, it is 
proposed that combination treatment of antiangiogenic agents with cytotoxic agents will 
require imaging and/or circulating biomarkers based on an in-depth understanding of the 
dynamics of the vascular response to the antiangiogenic agent, particularly the balance 
between vascular pruning and normalizing effects. If these cautions are not exercised the 
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chemotherapeutic agent could miss the therapeutic window and suboptimal effects of 
combination chemotherapy would result. 
 
E. Multiple target inhibition with single agents 
Multitargeted drugs or designed multiple ligands are defined as rationally designed 
single chemical entities capable of selectively target two or more biological targets or 
processes.81 The most commonly used strategy in the design of multitargeted agents is 
that of "designing in" or combining structural elements from different compounds that 
bind to their respective targets. If the pharmacophores for the respective targets overlap, 
the common structural features of the lead compounds can be "merged" resulting in a 
designed multiple ligand.  
As with combination chemotherapy, targeting different pathways in tumor cells using 
multitargeted agents can increase therapeutic effectiveness, as this strategy may prevent 
cancer cells from developing resistance.82 Other advantages include a lower risk of drug-
drug interactions in vivo and improved patient compliance resulting from reduction in the 
number of medications required. A challenging factor in the design of multitargeted 
agents is optimizing the pharmacokinetics of the lead compound while retaining a 
balanced target profile (i.e, optimizing the ratio of activities at the different targets and 
the effects of metabolism to ensure a therapeutic, but non-toxic, effect at each of these 
targets).81  
Several anticancer multitarget strategies have been studied in cancer therapy.83, 84 A 
clinical strategy that has been successful is the combination of antiangiogenic and 
cytotoxic agents.66, 85-90 Multitarget agents that combine antiangiogenic effects by RTK 
inhibition and cytotoxic effects, are reviewed in the following section. 
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E.1 Dual DHFR and RTK inhibition 
Almost a decade ago, Gangjee et al.91 reported the design and synthesis of 5-
substituted, 2,4-diaminofuro[2,3-d]pyrimidines 1 and 2 (Figure 12) as inhibitors of 
multireceptor tyrosine kinases and dihydrofolate reductase (DHFR) with antiangiogenic 
and antitumor activity. A 2:1 E/Z mixture of 1 and the E-isomer of 2 demonstrated dual 
VEGFR2 and PDGFRβ inhibitory activity comparable to semaxanib and  
   
Figure 12. Single agents with dual RTK and DHFR inhibitory activity 
AG1295 as standard compounds respectively. These compounds also showed potent 
antiangiogenic activity in the chicken embryo chorioallantoic membrane (CAM) assay. In 
vivo, these compounds are as active as the standard antitumor agent methotrexate, both 
against primary tumors and metastases, in a B16 melanoma model. Further attempts to 
increase DHFR inhibitory activity of these compounds lead to the identification of 
saturated derivatives 3 and 4 possessing dual EGFR and PDGFRβ inhibitory activity 
along with DHFR inhibition.92 
 
E.2 Dual TS and RTK inhibition 
 Gangjee et al.93 have reported the design and synthesis of substituted pyrimido[4,5-
b]indoles as single agents with antiangiogenic and cytotoxic activities. Pyrimido[4,5- 
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Figure 13. Single agents with dual RTK and TS inhibitory activity 
b]indoles 5 and 6 (Figure 13) inhibit VEGFR2 and PDGFRβ for antiangiogenic effects 
and human thymidylate synthase (hTS) for cytotoxic effects with inhibitory potencies 
comparable or better than semaxanib (VEGFR2 inhibitor), DMBI (PDGFRβ inhibitor) 
and raltitrexed (hTS inhibitor) as standard compounds. In a COLO-205metastatic colon 
cancer xenograft mouse model, thioether 5 significantly decreased tumor growth as 
measured by tumor growth inhibition (i.e., TGI = 76% at 35 mg/kg). Remarkably without 
any toxicity, compound 5 significantly decreased liver metastases, and also displayed 
significant antiangiogenic effects when compared with untreated control and DMBI. 
 
E.3 Unknown cytotoxic mechanism and RTK inhibition  
 More recently, a series of 4-anilino substituted tricyclic indeno[2,1-d]pyrimidines (7–
19 , Figure 14) were reported as single entities with dual antiangiogenic and cytotoxic 
activities.94 Most of the analogs demonstrated potent inhibitory activity against PDGFRβ 
compared to SU4312 as a standard compound. The 4-chloro analog 13 was about 4.5-fold 
more potent against PDGFRβ than 19. The 4-isopropyl analog 9 was equipotent with 
semaxanib as a standard against VEGFR2. Compound 9 was also a dual inhibitor of  
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Figure 14. Single agents with dual RTK inhibitory activity and cytotoxicity 
VEGFR2 and PDGFRβ. Analogs 7, 10, 13, 17, and 19 exhibited potent cytotoxicity 
comparable to cisplatin as a standard in A431 cells. Unsubstituted aniline 7 also inhibited 
most of the NCI 60 tumor cell lines with GI50s at nanomolar to micromolar levels. 
Inhibition of hTS or DHFR or dihydroorotate dehydrogenase are not the mechanisms of 
cytotoxic effects of these compounds. The cytotoxic mechanism(s) of action of 13 is 
currently under investigation. In a B16-F10 syngeneic mouse melanoma model, 4-chloro 
derivative 13 decreased tumor growth rate and inhibited angiogenesis similar to 
SU6668 and much more than in the untreated control animals. These studies91-94 attest to 
the potential of designing compounds with antiangiogenic and cytotoxic activities as 
combination chemotherapy via a single chemical entity.  
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II. CHEMICAL REVIEW 
 
The chemistry related to the work described in this dissertation is reviewed in this 
section and includes synthetic approaches to the following hetrocyclic ring systems. 
A. Pyrrolo[3,2-d]pyrimidines 
B. Pyrimido[5,4-b]indoles 
C. Furo[3,2-d]pyrimidines 
D. Benzofuro[3,2-d]pyrimidines 
 
A. Synthesis of pyrrolo[3,2-d]pyrimidines 
Synthetic strategies that were used in the synthesis of pyrrolo[3,2-d]pyrimidines can 
be broadly classified into two strategies:  
1. Strategy A: From pyrimidine precursors  
2. Strategy B: From pyrrole precursors 
A.1. Pyrrolo[3,2-d]pyrimidines from pyrimidine precursors 
 
Figure 15. Disconnection strategies towards pyrrolo[3,2-d]pyrimidines 
Different methods used in the synthesis of pyrrolo[3,2-d]pyrimidines from 
pyrimidine precursors utilize disconnections A or B (Figure 15). For disconnection A, the 
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precursors to cyclization are generally enamines95 or alkynes.96  
Scheme 1. Enamines in the synthesis of pyrrolo[3,2-d]pyrimidines
Reagents: (a) TFA, HNO3; (b) POCl3, DIPEA, toluene; (c) DIPEA, toluene; (d) piperid-
ine, triethylamine, toluene:dioxane; (1:2); (e) SnCl2, DMF 
Nitration of appropriately substituted pyrimidine 20 (Scheme 1) using nitric acid 
provides 2-methyl-4,6-dihydroxy-5-nitropyrimidine (21) and subsequent chlorination 
using phosphorous oxychloride affords key intermediate 22.95 Enamines with general 
structure 23 are treated with dichloro intermediate 22 to provide intermediate 24. 
Appropriately substituted enamines are obtained by tin tetrachloride-mediated 
condensation of corresponding methyl ketones with pyrrolidine. Nucleophilic aromatic 
substitution of 24 with piperidine affords 25 which can then be subjected to reductive 
cyclization using tin(II) chloride to afford pyrrolo[3,2-d]pyrimidine 26.  
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Alternative to reductive cyclization of enamines, metal catalyzed cyclization of 
acetylenes can be utilized as a key strategy in the construction of pyrrolo[3,2-
d]pyrimidines from pyrimidine precursors (Scheme 2).96  
Scheme 2. Copper (I)-catalyzed cyclization towards pyrrolo[3,2-d]pyrimidines 
 
Reagents: (a) H2NR2, triethylamine, THF; (b) SnCl2.H2O, (C2H5)2O, HCl (conc);  
(c) HC=CR2, Pd(PPh3)2Cl2, CuI, triethylamine; (d) CuI, DMF 
Nucleophilic aromatic substitution of dichloropyrimidine 27 (Scheme 2) with amines 
is used to provide appropriately substituted pyrimidines (28).96 Reduction of the nitro 
group in these polysubstituted pyrimidines affords the corresponding anilines (29). 
Palladium catalyzed treatment with terminal acetylenes the affords key intermediate 30. 
Copper (I) iodide mediated intramolecular cyclization of 30 subsequently provides 
pyrrolo[3,2-d]pyrimidines with general structure 31. 
Zhao et al. have reported a one-pot protocol for the syntheses of 2-chloro-
pyrrolo[3,2-d]pyrimidines.97 As a part of this work 2,4-Dichloro-5-nitropyrimidine (32, 
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Scheme 3) was subjected to nucleophilic aromatic substitution with ethyl benzoylacetate 
33 to afford intermediate 34 which was converted into the 2-chloro-pyrrolo[3,2-
d]pyrimidine 36 through a reductive cyclization process . 
Scheme 3. One-pot protocol for the syntheses of pyrrolo[3,2-d]pyrimidines 
 
Reagents: (a) NaH, THF; (b) Fe, CH3COOH  
Scheme 4. Furneaux method98 for synthesis of 2-amino 4-oxo pyrrolo[3,2-d]pyrimidines
 
Reagents: (a) H2SO4, HNO3; (b) DMF dimethylacetal, DMF; (c) Na2S2O4, H2O  
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Furneaux et al. reported the synthesis of 2-amino-3H,5H-pyrrolo[3,2-d]pyrimidin-4-
one 40 (Scheme 4).98 Nitration of 2-amino-6-methylpyrimidin-4(3H)-one 37 affords 
compound 38. On treatment of nitro derivative 38 with 6 equiv of DMF dimethyl acetal 
in DMF at 100 °C, compound 39 is obtained which upon subsequent dithionite reduction 
and cyclization affords pyrrolo[3,2-d]pyrimidine 40 in 36% overall yield. 
Scheme 5. Taylor strategy for synthesis of 2-amino 4-oxo pyrrolo[3,2-d]pyrimidines 
 
Reagents: (a) DMF dimethylacetal, DMF; (b) Na2S2O4, THF/H2O; (c) 1 N NaOH 
However, Taylor et al.99 obtained pyrimidinone lactam N-alkylated product 41 
(Scheme 5) upon reaction of compound 38 with DMF dimethyl acetal in DMF. 
Subsequent treatment with sodium dithionite provides annulated product 42, which is 
then subjected to base hydrolysis to provide N-methylated pyrrolo[3,2-d]pyrimidine 43. 
The synthetic sequence was modified (Scheme 6) to include protection of the pyrimidine 
lactam nitrogen to prevent methylation. 
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Scheme 6. Taylor modified strategy for synthesis of pyrrolo[3,2-d]pyrimidines 
Reagents: (a) DMF dimethylacetal, CH2Cl2; (b) NaH. chloromethyl pivalate; (c) DMF 
dimethylacetal, DMF; (d) Na2S2O4; (e) 1 N NaOH. 
Treatment of nitropyrimidine 38 with DMF dimethylacetal in CH2C12 generates 
compound 44 (Scheme 6).99 Reaction of pyrimidine 44 with sodium hydride followed by 
addition of excess chloromethyl pivalate provides a 4:l mixture of N-alkylated 45 and its 
O-alkylated isomer 46. Pyrimidine 45 can then be converted to 47 upon treatment with 
DMF dimethylacetal at room temperature. Subsequent reductive annulation affords 
bicyclic 48 which can bedeprotected using aqueous sodium hydroxide to afford 2-amino-
3H,5H-pyrrolo[3,2-d]pyrimidin-4-one 40 in 25% overall yield.  
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Scheme 7. Madelung cyclization strategy for synthesis of pyrrolo[3,2-d]pyrimidines 
 
Reagents: (a) NaNO2, AcOH, H2O; (b) Zn, H2SO4, H2O; (c) R2(C=O)Cl, NaOAc;  
(d) R1(C=NH)NH2. HCl, NaOC2H5, C2H5OH; (e) NaOC2H5, 360 °C. 
Madelung cyclization (Disconnection B, Figure 1) can be utilized in the synthesis of 
several pyrrolo[3,2-d]pyrimidines (Scheme 7).100 Treatment of ethyl acetoacetate 49 with 
sodium nitrite and acetic acid affords ethyl 2-hydroxyimino-3-butyrate 50. Zinc and 
sulfuric acid mediated reduction of 50 provides the corresponding 2-aminoacetoacetate. 
which upon isolation and acylation with an appropriate acid chloride affords 51. However, 
in situ acylation of the intermediate without isolation affords higher yields. Base 
catalyzed condensation of the ethyl N-acylated-2-aminoacetoacetates 51 with acetamidine 
hydrochloride provides acylpyrimidine intermediates 52. Madelung cyclization of 
pyrimidines 52 at elevated temperatures affords pyrrolo[3,2-d]pyrimidines 53. 
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A.2. Pyrrolo[3,2-d]pyrimidines from pyrrole precursors 
Scheme 8. Pyrimidine ring construction 
 
Several pyrrolo[3,2-d]pyrimidine analogs with varying substitution patterns have 
been successfully synthesised using they key pyrroles with general structure 54 (Scheme 
8). Synthetic strategies towards the synthesis of pyrrole 54 utilize key disconnection 
strategy shown in Figure 16. Preparation of appropriately substituted pyrroles can be 
accomplished using cyanoacetylenes101 or α-cyano ketones102 or α-cyano aldehydes103 in 
20 to 63% yields. 
 
Figure 16. Disconnection strategies towards precursor pyrroles 
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Scheme 9. Pyrrole ring construction from cyanoacetylenes 
 
Reagents: (a) NaOC2H5, C2H5OH 
Treatment of cyanoacetylenes 61 (Scheme 9) with diethylaminomalonate 60 
followed by a base catalysed intramolecular cyclization affords pyrroles 62.101 This 
methodology can provide pyrroles with R2 = H [56, Figure 16].  
Scheme 10. Pyrrole ring construction from α-cyano ketones 
 
Reagents: (a) Ts2O, triethylamine, CH2Cl2; (b) NaOC2H5, C2H5OH 
Treatment of α-cyano ketones 63 (Scheme 10) with p-toluenesulfonic anhydride 
provides the corresponding p-toluenesulfonyl enol esters 64.102 The crude enol esters 64 
are immediately condensed with diethyl aminomalonate 60 using sodium ethoxide to 
provide substituted pyrroles 62.  
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Scheme 11. Pyrrole ring construction from α-cyano aldehydes 
 
Reagents: (a) diethyl aminomalonate, NaOCH3; (b) NaOCH3, CH3OH 
Treatment of appropriately substituted α-cyano aldehydes 65 (Scheme 11) with 
diethyl aminomalonate provides the enamine 66.103 Base catalysed intramolecular 
cyclization using sodium methoxide affords pyrroles 67.  
With a variety of pyrroles with appropriate 4- or 5-substituents, several pyrrolo[3,2-
d]pyrimidines with desired substituents on the 2-position of the pyrimidine ring can be 
prepared (48 to 85% yields) as shown in Schemes 12-18. Some examples of pyrrolo[3,2-
d]pyrimidine analogs synthesized by this strategy are 2-alkyl-4-oxo-pyrrolo[3,2-
d]pyrimidines,104 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidines,104-106 6-phenyl-2-sulfanyl-4-
oxo-pyrrolo[3,2-d]pyrimidines107 and 6-phenylpyrrolo[3,2-d]pyrimidine-2,4-diol.106  
Scheme 12. Synthesis of 2-alkyl-4-oxo-pyrrolo[3,2-d]pyrimidines 
 
Reagents: (a) Alkylnitrile, HCl; (b) NaOH, C2H5OH 
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Pyrrolo[3,2-d]pyrimidines with 2-alkyl substituents are obtained by treatment of 
pyrroles 68 (Scheme 12) with an alkyl nitriles in anhydrous hydrochloric acid at room 
temperature followed by heating with sodium hydroxide.104  
Scheme 13. Synthesis of 3H-pyrrolo[3,2-d]pyrimidin-4(5H)-ones 
 
Reagents: (a) formamidine acetate, C2H5OH 
Similarly pyrrolo[3,2-d]pyrimidines with 2-H are obtained by cyclocondensation of 
pyrroles 70 (Scheme 13) with formamidine in refluxing ethanol.98, 108 
Scheme 14. Synthesis of 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidines 
 
Reagents: (a) Cyanamide, HCl; (b) aq. NaOH 
Pyrrolo[3,2-d]pyrimidines with 2-amino substituents are obtained by treatment of 
pyrroles 72 (Scheme 14) with cyanamide and hydrochloric acid in dioxane at reflux 
followed by heating with aqueous sodium hydroxide.104 
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Scheme 15. Synthesis of 2-carbamate-4-oxo-pyrrolo[3,2-d]pyrimidines 
 
Reagents: (a) 1,3-dicarbomethoxy-2-methyl-2-thiopseudourea, CH3COOH; (b) NaOCH3, 
CH3OH  
Another approach that has been utilized in the synthesis of pyrrolo[3,2-
d]pyrimidines with 2-carbamate or 2-amino is shown in Scheme 15. This method 
involves the use of 1,3-dicarbomethoxy-2-methyl-2-thiopseudourea as the guanylating 
agent to afford intermediate 74 which upon base catalysed cyclization affords 
pyrrolo[3,2-d]pyrimidines 75. 105  
Scheme 16. Synthesis of 2-sulfanyl-4-oxo-pyrrolo[3,2-d]pyrimidines 
 
Reagents: (a) S=C=NCOOC2H5, HCl; (b) aq. NaOH 
Similarly pyrrolo[3,2-d]pyrimidines with 2-sulfanyl substituent can be obtained by 
treatment of pyrroles 76 (Scheme 16) with an ethyl isothiocyanatoformate and 
hydrochloric acid in benzene at reflux followed by heating with aqueous sodium 
hydroxide.107 
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Scheme 17. Synthesis of pyrrolo[3,2-d]pyrimidine 2,4-dione 
 
Reagents: (a) KNCO, CH3COOH; (b) aq. NaOH 
Similarly pyrrolo[3,2-d]pyrimidines with 2,4-dioxo substituent are obtained by 
cyclocondensation of pyrroles 76 with potassium cyanate under acidic conditions at room 
temperature followed by heating with aqueous sodium hydroxide.106 
Schemes 18-20 outline different synthetic strategies used in the synthesis of 7-benzyl 
pyrrolo[3,2-d]pyrimidines. Nitration of 2-amino-4-oxo 6-chloro pyrimidine 80 (Scheme 
18) using a mixture of nitric and sulphuric acid provides nitro pyrimidine 81.109, 110 
 Nucleophilic displacement of benzyl bromide 82 with the carbanion of ethyl 
cyanoacetate 83 affods intermediate 84 which can be used in a nucleophilic aromatic 
substitution of the 6-chloro group of 81 to afford 85. Compound 85 can be subjected to a 
ester hydrolysis and decarboxylation to afford 86. Nitro pyrimidine 86 can be subjected 
to a catalytic hydrogenation reaction to afford an intermediate amine 87 which undergoes 
a reductive cyclodeamination under acidic conditions to form 89.109-111 
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Scheme 18. Synthesis of 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidines from pyrimidines 
 
Conditions: a (a) H2SO4, HNO3; (b) K2CO3, DMF; (c) K2CO3, DMSO; (d) NaOH, H2O; 
(e) HCl, H2O; (f) Pd/C, H2, 6N HCl 
Arylpropenenitrile 90 (Scheme 19) can be prepared by the condensation of the 
appropriate aldehyde with cyanoacetic acid and subsequent catalytic (Pd/C) 
hydrogenation affords the corresponding propanenitrile 91. Sodium hydride in THF is 
Scheme 19. Synthesis of 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidines from pyrroles 
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Reagents: (a) Pd/C, H2; (b) NaH, THF, HCOOC2H5; (c) methyl glycinate hydrochloride, 
CH3COONa, CH3OH, H2O; (d) ClCOOC2H5, DBN, 0 
°C; (e) rt; (f) Na2CO3, CH3OH;  
(g) benzoyl isothiocyanate, CH2Cl2; (h) DBN, CH3I; (i) NH3, CH3OH 
used to deprotonate α to the cyano group and the resulting anion can be treated with ethyl 
formate to provide the desired 2-formyl-propanenitrile 92. The reaction of 2-
formylpropanenitrile 92 with methyl glycinate hydrochloride in aqueous methanol at 
room temperature in the presence of sodium acetate readily affords the enaminonitriles 93. 
Compound 93 can be treated with ethyl chloroformate and DBN first at 0 oC for 1 h (to 
afford intermediate 94) and then 16 h at room temperature to provide the cyclized pyrrole 
95. Compound 95 can then be decarbethoxylated to 96 by treatment with sodium 
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carbonate in methanol. Treatment of 96 with benzoyl isothiocyanate in dichloromethane 
at room temperature affords the desired 2-(carbomethoxy)-3-[N-benzoyl(thiocarbamoyl) 
aminol]-1H-pyrrole 97. S-methylation of 97 by treatment with methyl iodide in the 
presence of DBN in dichloromethane affords compound 98. Treatment of 98 with 
methanolic ammonia provides 2-amino 4-oxo pyrrolo[3,2-d]pyrimidine 89.  
Pyrrolo[3,2-d]pyrimidine 99 (Scheme 20) can be subjected to Friedel–Crafts 
acylation or alkylation, using triflic acid as catalyst to afford the corresponding 7-
substituted pyrrolo[3,2-d]pyrimidine 100 or 89 respectively in 20% yields.112 The 
benzoylated compound 100 can be transformed into the corresponding benzyl 89 analog 
by a Wolff–Kishner reduction. 
Scheme 20. Alkylation/acylation of 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidines  
 
Reagents: (a) Benzoyl chloride, triflic acid (b) hydrazine, KOH (c) Benzyl bromide, 
triflic acid 
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B. Synthesis of pyrimido[5,4-b]indoles 
 
Figure 17. Indole precursors to pyrimido[5,4-b]indoles 
Several pyrimido[5,4-b]indole analogs with varying substitution patterns have been 
successfully synthesized using they key indoles 102 (Figure 17).113-115  
Scheme 21. Synthesis of indole precursors 
 
Reagents: (a) ethyl bromoacetate, NaHCO3; (b) t-BuOK 
Anthranilonitrile 103 (Scheme 21) can be alkylated under basic conditions with ethyl 
bromoacetate to afford intermediate 104.113, 115 On treatment with a base, compound 104 
cyclizes to form the indole 105 which is the key precursor to pyrimido[5,4-b]indoles. 
An efficient one-step synthesis of 2-amino-5H-pyrimido[5,4-b]indoles through a 
copper-catalyzed cascade reaction between 3-haloindole-2-carbaldehydes 106 (Scheme 
22) and guanidine hydrochloride was reported by Biswas et al.116 However these reaction 
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Scheme 22. Copper catalyzed cascade reaction 
 
(a) Guanidine hydrochloride, CuI, L-proline, Cs2CO3, DMSO 
conditions did not provide the 2-methyl pyrimidoindole when guanidine was replaced 
with acetamidine. 
Scheme 23. Palladium catalyzed pyrimidine formation 
 
Reagents: (a) R2CONH2, Pd2(dba)3, BINAP, Cs2CO3, Toluene; (b) HCOONH4, t-BuOH 
Kumar et al.117 have published a palladium catalyzed amidation method which 
converts 3-bromoindole 108 (Scheme 23) to intermediate 109 which on treatment with 
ammonium acetate cyclizes to form pyrimido[5,4-b]indole 110.  
An aldol condensation at room temperature between ketone derivatives 111 (Scheme 
24) with aldehyde 112 in the presence of a catalytic amount of sodium hydroxide 
provides the benzylidene adduct, which upon heating to reflux in ethanol with a solution 
of guanidine under basic condition affords 113.118 
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Scheme 24. Synthesis of 2-amino-4-oxo-pyrrolo[3,2-d]pyrimidines 
 
Reagents: (a) NaOH, C2H5OH; (b) guanidine, C2H5OH 
 
C. Synthesis of furo[3,2-d]pyrimidines 
 
Figure 18. Furan precursors to furo[3,2-d]pyrimidines 
Several furo[3,2-d]pyrimidine analogs with varying substitution patterns have been 
successfully synthesised using substituted furans with general structure 115 (Figure 
18).119-123  
Carbanions of appropriately substituted alkylnitriles 116 (Scheme 25) are treated 
with ethyl formate 117 to form the sodium enolate 118.119, 121, 123-125 This reaction can be 
accomplished using strong base sodium hydride and weak base sodium methoxide. The 
enolate 118 can be O-alkylated with diethyl chloromalonate to afford intermediate 119. 
Subsequent treatment of 119 with a base promotes cyclization and decarboxylation to 
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Scheme 25. Synthesis of key furan precursors 
  
Reagents: (a) CH3ONa, CH3OH (or) NaH, THF; (b) ClCH(COOC2H5)2; (c) DBN 
C2H5OH 
provide key furan 120. This synthetic methodology has been reported for R = H,121 R = 
aryl, 124, 125 R= alkyl123 and R = benzyl119, 126, 127 
Scheme 26. Synthesis of 3-amino-2-carboxy furans  
  
Reagents: (a) DPPA, triethylamine, t-BuOH; (b) n-BuLi, TMEDA, CO(OCH3)2; (c) TFA, 
CH2Cl2 
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Alternatively, furan-3-carboxylic acid 121 (Scheme 26) can be converted to the 
requisite amino group by a Curtius rearrangement to give the Boc-protected furanamine 
122.120, 122 Lithiation of 122 followed by quenching of the reaction with dimethyl 
carbonate followed by amine deprotection provides 124 with methyl ester introduced at 
the 2-position. 
Scheme 27. Synthesis of 3-amino 2-cyanao furans 
Reagents: (a) DPPA, triethylamine, toluene; (b) propyl magnesium chloride; (c) POCl3, 
DMF; (d) NH2OH, 4-methylbenzenesulfonic acid 
Similarly, furan-3-carboxylic acid 121 can be reacted under Curtius conditions to 
generate N-furan-3-ylbutanamide 125 (Scheme 27).128 Vilsmeier Haack reaction of 125 
provides furaldehyde 126 which upon amination provides the cyano analog 127. 
Another approach utilized in the synthesis of furan precursors for furo[3,2-
d]pyrimidines was developed by Redman et al.127 Mitsunobu reaction of 3-(4-chloro-
phenyl)-3-oxo-propanenitrile 128 (Scheme 28) with ethyl glycolate affords intermediate 
129 which on treatment with sodium hydride leads to ring closure to provide aminofuran 
130. This synthetic sequence is limited to the synthesis of 5-alkyl-, 5-aryl-, and 4,5-fused 
bicyclic furans. 
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Scheme 28. Synthesis of 3-amino-2-carboxy furans 
 
Reagents: (a) PPh3, DIAD, THF, ethyl glycolate; (b) NaH, THF 
Furo[3,2-d]pyrimidines 132 (Scheme 29) with 2-H can be obtained by cyclocondensa-
tion of furan 131 with formamidine in ethanol at reflux. 127 
Scheme 29. Synthesis of 4-oxo-furo[3,2-d]pyrimidines 
 
Reagents: (a) formamidine acetate, C2H5OH 
Similarly, furo[3,2-d]pyrimidines with 2-oxo substituent are obtained by treating 
furan 133 (Scheme 30) with chlorosulfonyl isocyanate for converting the amine to a urea 
134 which then undergoes cyclization in basic methanol to afford the furo[3,2-
d]pyrimidine 2,4-dione 135.120 
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Scheme 30. Synthesis of furo[3,2-d]pyrimidine 2,4-dione 
 
Reagents: (a) ClO2SNCO, CH2Cl2; (b) NaOH, CH3OH 
Scheme 31. Synthesis of 2-alkyl-4-oxo-furo[3,2-d]pyrimidine  
 
Reagents: (a) KOH, t-BuOH 
Similarly furo[3,2-d]pyrimidine 137 (Scheme 31) with 2-alkyl substituent can be 
obtained by treating 3-amido furan 136 with a hydroxide base to form cyclized furo[3,2-
d]pyrimidine.128 
Furo[3,2-d]pyrimidines with 2-carbamate or 2-amino substituent involves the use of 
1,3-dicarbomethoxy-2-methyl-2-thiopseudourea as the guanylating agent to provide the 
guanidine adduct 139 (Scheme 32).119, 121 Treatment of 139 with sodium methoxide leads 
to cyclization with loss if a carbamate group to afford 2-carbamido-furo[3,2-d]pyrimidine 
140 which upon reacting with sodium hydroxide provides 2-amino-furo[3,2-d]pyrimidine 
141.  
  
52 
 
Scheme 32. Synthesis of 2-amino-4-oxo-furo[3,2-d]pyrimidines 
 
Reagents: (a) 1,3-dicarbomethoxy-2-methyl-2-thiopseudourea, CH3COOH; (b) NaOCH3, 
CH3OH; (c) aq. NaOH 
 
D. Synthesis of benzofuro[3,2-d]pyrimidines 
Several benzofuro[3,2-d]pyrimidine analogs 142 (Figure 19) with varying 
substitution patterns have been successfully synthesised using the key benzofurans with 
general structure 143.115  
 
Figure 19. Benzofuran precursors to benzofuro[3,2-d]pyrimidines 
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Scheme 33. Synthesis of benzofuran precursors 
 
Reagents: (a) methyl bromoacetate, K2CO3, acetone; (b) NaH, DMSO 
2-Hydroxy benzonitrile 144 (Scheme 33) can be alkylated under basic conditions 
with methyl bromoacetate to afford intermediate 145.115 On treatmentwith a base, 
compound 145 cyclizes to form the benzofuran 146 which is the key precursor to 
benzofuro[3,2-d]pyrimidines. 
Scheme 34. Copper(I)-mediated cascade reactions  
 
Reagents: (a) CuBr, DBU, DMF 
Recently Chao et al.129 have reported an efficient approach to the synthesis of 
functionalized benzofuro[3,2-d]pyrimidines 149 (Scheme 34) which involves copper(I)-
mediated cascade reactions. This reaction utilizes 3-chlorochromenones 148 and various 
amidines 147 and their analogs as starting materials. The process is promoted by copper(I) 
bromide and takes place via a chemoselective Michael addition-elimination double 
intramolecular cyclization sequence as shown in Figure 20. 
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Figure 20. Steps involved in cascade reaction 
Scheme 35. Synthesis of benzofuro[3,2-d]pyrimidines 
 
Reagents: (a) Pd(OOCCH3)2, PPh3, K3PO4; (b) BBr3, CH2Cl2; (c) copper(I) thiophene-2-
carboxylate, NMP 
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Liu et al.130 have reported a concise synthesis for the facile assembly of fused 
benzofuropyrimidine 157 (Scheme 35). Chemo/regioselective Suzuki coupling between 
1,2-dihaloarene 153 and α -methoxyphenylboronic acid 154 gives biaryl phenoxy ether 
155, followed by demethylation to form the biaryl phenol 156, which then undergoes 
copper(I) thiophene-2-carboxylate mediated intramolecular cyclization to afford 157.130, 
131  
Scheme 36. Synthesis of 2-amino- benzofuro[3,2-d]pyrimidines 
 
Reagents: (a) NaOH, C2H5OH 
An aldol condensation at room temperature between ketone derivatives 158 (Scheme 
36) with aldehyde 112 in the presence of a catalytic amount of sodium hydroxide 
provides the benzylidene adduct, which when heated to reflux in ethanol with a solution 
of guanidine under basic condition affords benzofuro[3,2-d]pyrimidines 159.118 
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III. STATEMENT OF THE PROBLEM 
  
When a tumor grows beyond 2 mm3 it requires nutrients and oxygen for 
maintenance and growth and initiates the process of having a blood supply system.3 
Under hypoxic conditions it secretes several proangiogenic factors of which VEGF is the 
key mediator of angiogenesis.132 VEGF binds to its receptor VEGFR2 and stimulates the 
process of angiogenesis which supports rapid tumor growth and metastases.14 One of the 
key strategies to obtain antiangiogenic effects is to develop VEGFR2 kinase inhibitors.15 
These inhibitors were found to arrest tumor growth and cause tumor shrinkage.133 
However resistance to VEGFR2 inhibitors results in increased invasion and 
metastases.134 At the onset of VEGFR2 inhibition there are two possible effects: 
regression of tumor vessels and normalization of surviving vessels.73, 74 This process of 
vessel normalization was found to transiently improve blood flow. Investigations into the 
combined use of VEGFR2 with cytotoxic therapies have yielded more promising results 
than VEGF-targeting monotherapy.74, 135 Combinations of cytotoxic agents and VEGFR2 
inhibitors have shown synergistic effects suggesting that there is improved delivery of the 
cytotoxic agent during this transient phase of vessel normalization.135  
Yoshizawa et al.79 have reported enhanced tumor penetration and in vivo antitumor 
activity of cytotoxic paclitaxel in combination with the VEGFR2 inhibitor semaxanib in 
Colon-26 solid tumor-bearing mice. Tumors treated with semaxanib contained 
significantly smaller hypoxic regions compared with the nontreated control group, 
suggesting that structural normalization of the tumor vasculature resulted in an 
improvement in tumor vessel functions, including oxygen supply. Immunostaining for 
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endothelial cells and pericytes showed that the treatment with semaxanib enhanced the 
pericyte coverage of the tumor vasculature. Treatment with semaxanib increased the 
distribution of paclitaxel in the core region of the tumor, hence decreasing the ratio of 
their peripheral distribution. These results suggest that the structural and functional 
normalization of the tumor vasculature by the treatment with semaxanib to reach the 
deeper regions within tumor tissues lead to more potent antitumor activity of paclitaxel. 
This strategy of utilizing the VEGFR2 inhibition based vascular normalization phase to 
enhance blood supply and the delivery of cytotoxic agent may also address the problem 
of dose limiting toxicities as there is decreased peripheral distribution.79  
The outcome of combination treatment is likely to be affected by the effects of the 
antiangiogenic agent on the tumor (cells/vasculature) and the intratumoral levels of the 
cytotoxic agent. 136 In order to maximise the intratumoral levels of the cytotoxic agent, it 
is necessary to appropriately schedule administering the cytotoxic agent to ensure that it 
is used during the period of vessel normalization.137 Tumor targeted drug delivery has the 
potential to improve cancer care by reducing off-target toxicities and increasing the 
efficacy of the cytotoxic agent.138 Judicious scheduling is an influential and critical factor 
because of the impact on intratumoral cytotoxic drug level.133, 137, 139 The effect of the 
VEGFR2 inhibitor depends on factors such as the type of tumor, levels of VEGFR 
production and VEGFR2 overexpression.140 Hence, if not appropriately scheduled the 
cytotoxic agent may miss the timing window of normalization.141 Also, administering 
separate antiangiogenic and cytotoxic agents may not alleviate the issues of dose limiting 
toxicities of cytotoxic agents. Therefore compounds with antiangiogenic and cytotoxic 
activities in single entities allow the cytotoxicity to be mainfested as soon as the 
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antiangiogenic effects are operable. Such multitargeted agents could exert their cytotoxic 
action as soon as or even during transient tumor vasculature normalization due to the 
antiangiogenic effects. Thus such agents might not need to be as potent as conventional 
cytotoxic agents. Dosing of such an antiangiogenic RTK inhibitor with an incorporated 
cytotoxic mechanism would be equivalent to providing a combination of antiangiogenic 
agents along with a metronomic dosing of a cytotoxic agents. Several literature reports 
indicate the success of using antiangiogenic agents with metronomic doses of cytotoxic 
agents.69-72, 101Moreover these multitargeted single agents would circumvent the 
pharmacokinetic problems of multiple agents, would avoid drug - drug interactions, could 
be used at lower doses to alleviate toxicity, could be devoid of overlapping toxicities, and 
could delay or prevent tumor cell resistance. Other advantages of such single agents are 
in the reduced cost and increased patient compliance, which are sometimes as significant 
contributors to chemotherapy failure as resistance, toxicity, and lack of efficacy.  
The antiangiogenic component is usually targeted to tumor cells and under most 
circumstances it is not targeted to normal cells. However, the cytotoxic component is 
targeted to the tumor cells but not exclusively. Thus the challenge in designing single 
agents with a cytotoxic component is that the cytotoxic component should be potent 
enough to kill tumor cells that have been compromised via the antiangiogenic effect but 
not potent enough to cause serious toxicity to normal cells not affected by the 
antiangiogenic effect.93 Undoubtedly one of the problems with conventional cytotoxic 
chemotherapeutic agents is dose-limiting toxicities. These single agents should avoid 
these toxicities since they do not need to be as potent as conventional chemotherapeutic 
agents. 
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Gangjee et al.91-94 have reported the discovery of single agents with dual 
antiangiogenic and cytotoxic activities. The antiangiogenic effets of these compounds 
were due to inhibition of RTKs and the cytotoxic effects were due to inhibition of 
dihydrofolate reductase91 or thymidylate synthase93 or an unknown target.94 In this study 
VEGFR2 was chosen as the target for the antiangiogenic component as it is the principal 
mediator of angiogenesis. Tubulin was chosen as the target for cytotoxic effects as 
several clinical and preclinical combinations of tubulin inhibitors and VEGFR2 inhibitors 
have been successful.87, 142, 143 Several clinical trials are ongoing for a variety of cancers 
including colorectal, breast, lung among others that involve FDA approved 
antiangiogenic agents as well as those in development, and cytotoxic chemotherapeutic 
agents and include CA4P, paclitaxel, docetaxal, vineristine, vinblastine with 
antiangiogenic agents bevacizumab, axitinib, sorafenib, sunitinib, cediranib, pazopanib, 
vandetanib and vatalanib.146 Additionally, half of all human tumors have mutations in the 
p53 gene, and p53 status effects vulnerability of tumour cells to have its cell cycle 
arrested. The most effective drugs in cell lines with p53 gene mutations are tubulin 
binding agents.144, 145 Our approach can be looked at as a combination of two strategies: 
rational target combinations designed to attack several key mechanisms contributing to 
cancer growth and survival simultaneously such as angiogenesis and proliferation; 
another involves the development of compounds that cover multiple mechanisms within a 
single agent. 
Several highly potent antitubulin agents have failed in the early stages of clinical 
trials due to toxicities. Discodermolides and cryptophycin 52 (LY355703) are recent 
examples of such agents.147, 148 All microtubule-binding agents share a neurological 
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toxicity as the most prominent dose-limiting side effect.26 This potentially rigorous and 
dose-accumulative side effect usually manifests as painful peripheral axonal 
neuropathy.149 The impact of this can persist for several years after the end of treatment. 
The reasons for this nervous-system-preferred toxicity are uncertain. However, the 
relative abundance and sensitivity of the neuronal microtubules could be a cause.26 Other 
common toxicities of microtubule-binding agents include myelosuppression and 
neutropenia. The myeloid toxicity, which is usually reversible, is seen in vinca alkaloids 
and taxanes.150, 151 Neutropenia was observed in several combination chemotherapy 
clinical trials with other drugs and was mostly manageable.152-154 
Design of single agents with dual tubulin and RTK inhibitory potential 
 
 
Figure 21. Lead compounds 
Efforts to elucidate the plausible binding modes of multiple RTK-inhibitors led 
Gangjee et al.155 to the discovery of a highly potent water-soluble antimitotic antitumor 
pyrrolo[2,3-d]pyrimidine: 160 (Figure 21). 156, 157 It was discovered to be a colchicine site 
binding, microtubule depolymerizing agent that inhibited the growth of cancer cells with 
GI50 in the nanomolar range. Compound 160 also overcomes the two most clinically 
relevant tumor resistance mechanisms that limit activity of microtubule targeting agents: 
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overexpression of Pgp158, 159 and βIII-tubulin.160-164 Additionally, compound 160 was 
readily convertible to the water-soluble hydrochloride salt. These attributes encouraged 
the choice of 160 as the lead molecule for the design of dual acting VEGFR2 and tubulin 
inhibitors. Pyrrolo[3,2-d]pyrimidine derivatives have been reported to possess inhibitory 
activity against several RTKs such as VEGFR2,165-167 PDGFRβ,167 EGFR.168 Hence, the 
design of pyrrolo[3,2-d]pyrimidine analogs of compound 160 may provide compounds 
with dual RTK inhibitory activity and tubulin inhibitory activity. Compound 161 was 
designed as a regioisomer of the pyrrolo[2,3-d]pyrimidine 160.  
 
Table 1. Effects on tubulin and VEGFR2 in cellular assays  
 EC50 Microtubule  
Depolymerization 
(µM) 
MDA-MB-435 
IC50 ± SD 
(nM) 
VEGFR2 
kinase 
inhibition  
IC50 ± SD 
160 5.8 183 ± 3.4  
161·HCl 1.2 96.6 ± 5.3 183 ± 3.4 nM 
CSA4 0.0131 3.47 ± 0.6  
Sunitinib   18.9 ± 2.7 nM 
 
It was determined that 161 is about 5-times more potent than 160 against tubulin 
polymerization and it was not a potent VEGFR2 inhibitor (Table 1). Before designing 
compounds to structurally engineer VEGFR2 inhibitory potential, it was of interest to 
identify the structural features that are crucial for antitubulin activity. Hence Series I 
(Figure 22) was designed as antitubulin agents. Compounds 162, 163 and 164 were 
designed to evaluate the importance of the 2-CH3, 4′-OCH3 and 4-NCH3 moieties 
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Figure 22. Series I 
respectively to antitubulin activity. Compound 165 was designed by incorporating a 2′-
OCH3 group to explore the effect of substituents in this position to antitubulin activity.  
 
Figure 23. Series II 
Series II (Figure 23) focuses on conformationally restricted analogs of 161. 
Compounds 166 and 167 were designed by incorporating the bicyclic 6-methoxy-
tertrahydroquinoline or the bicyclic 5-methoxy-dihydroindole respectively onto the 4-
position of the 2-methyl pyrrolo[3,2-d]pyrimidine. Compared to the N-methylaniline, 
these bicyclics incorporated on the 4-position restrict the conformation of the phenyl ring 
thereby eliminating the rotation around the N-phenyl bond, thus affording a much more 
rigid structure than 161 but still maintaining the phenyl and alkyl substitutions on the N4 
as in 161. 
Toward the goal of identifying single agents with VEGFR2 and tubulin inhibitory 
activities in the same entity, several compounds were designed and synthesized.  
  
63 
 
 
Figure 24. Tricyclic VEGFR2 inhibitors 
Tricyclic pyrimido[4,5-b]indoles with general structures 168 and 169 (Figure 24) 
have been reported by Gangjee et al. 88, 163 to be inhibitors of VEGFR2.93, 169 Hence it was 
hypothesized that small hydrophobic methyl groups at positions 5 or 6 of the pyrrolo[3,2-
d]pyrimidine scaffold could afford additional VEGFR2 inhibitory activity. Series III 
(compounds 170-173, Figure 25) was designed to ascertain whether a 5-methyl group is 
conducive to tubulin and VEGFR2 inhibitory activities. The 5-methyl group could have 
two effects: allow additional hydrophobic interactions with the targets and restrict the 
rotation around the N-phenyl bond, thus providing conformational rigidity which could 
increase potency. 
 
Figure 25. Series III 
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Figure 26. Series IV 
Series IV (compounds 174-176, Figure 26) was designed to check whether a 6-
methyl group is conducive to tubulin and VEGFR2 inhibitory activities. The 6-methyl 
group could allow additional hydrophobic interactions with the targets. 
 
Figure 27. Pyrimido[5,4-b]indoles as RTK inhibitors 
Showalter et al.115 have reported the RTK inhibitory activities of tricyclic 
pyrimido[5,4-b]indoles with general structure 177 (Figure 27). It was hypothesized that 
fusion of a third aromatic ring at the appropriate positions of pyrrolo[3,2-d]pyrimidine 
161 will allow additional hydrophobic interactions with VEGFR2 and improve VEGFR2 
inhibitory potency without loss of tubulin inhibition. Series V (compounds 178-180, 
Figure 28) was designed to study the effect of the tricyclic pyrimido[5,4-b]indole scaffold 
on tubulin and VEGFR2 inhibitory activities.  
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Figure 28. Series V 
Series VI (Figure 29) was designed by an isosteric replacement of the N5 in 161 
with an oxygen which would not only change the electronics of the bicyclic ring but 
would also have different hydrogen bonding capabilities compared to Series I. 
Compounds 181-185 will evaluate the effect of replacing the pyrrolo[3,2-d]pyrimidine 
scaffold in 161 with a furo[3,2-d]pyrimidine scaffold and the importance of hydrogen 
bond donor vs acceptor at the 5-position.  
 
Figure 29. Series VI 
Substituted 7-benzyl pyrrolo[2,3-d]pyrimidines with general structure 186 (Figure 30) 
were reported as antiangiogenic, antimetastatic and antitumor agents.170 Substituents on 
the benzyl group and the location of the benzyl group dictate RTK inhibitory activity in 
pyrrolo[2,3-d]pyrimidines. Hence, having determined the antitubulin effects of 161, it  
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Figure 30. Series VII 
was of interest to engineer RTK inhibitory activity without loss of antitubulin activity by 
incorporating the 7-benzyl group onto the pyrrolo[3,2-d]pyrimidine scaffold in 161. The 
results of this hybrid design afforded compound 187. Compounds 188 and 189 were 
designed to evaluate the importance of the 4'-OCH3 and the 4-NCH3 moieties, 
respectively. Compound 190 was designed by incorporating a 2'-OCH3 group to explore 
the effect of substituents at this position. 
The general RTK pharmacophore model consists of an Adenine region, a Sugar 
binding pocket and a Phosphate binding region which binds the adenine ring, the sugar 
moiety and the triphosphate moiety of ATP respectively. Additionally, there are two 
hydrophobic regions I and II, neither of which are used by ATP for binding. The 
pyrrolo[3,2-d]pyrimidine ring of the designed compounds could bind to the Adenine 
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Binding mode 1 
 
 
 
Binding mode 2 
In both binding modes 187 makes a 
hydrogen bond interaction with the 
backbone of Cysteine in the hinge region. 
 
Figure 31. Predicted binding modes of 187 in VEGFR2 
region similar to heterocyclic scaffold inhibitors such as pyrimidines, quinazolines and 
pyrrolo[2,3-d]pyrimidines.171 The 7-benzyl group was could access the Sugar binding 
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pocket as shown in mode 1 [Figure 31]. Alternatively, the pyrrolo[3,2-d]pyrimidine 
compounds could adopt mode 2 in which the compounds are rotated around the 2-CH3-
C2 bond. In this mode the 7-benzyl group and the 4-anilino groups could occupy 
Hydrophobic region I and Sugar binding pockets respectively. These compounds could 
also adopt binding mode 3 in which the molecule is rotated by 60o (from mode 2). In this 
mode, the 7-benzyl group could orient towards the Phosphate binding pocket and the 4-
anilino groups could occupy Hydrophobic region II. Docking studies performed on the 
X-ray crystal structure of VEGFR2 [pdb: IYWN]172 suggested the possibility of several 
binding modes. Representative low energy binding modes are shown in Figure 31.  
Biological evaluation indicated that a single agent 187 that was designed to have 
both cytotoxic and antiangiogenic effects did indeed display these activities. Compound 
187 has an inhibitory potency comparable with the clinically used sunitinib and clinically 
evaluated semaxinib against VEGFR2. The antiangiogenic effect was probably mediated 
via VEGFR2 inhibition. The cytotoxic effect was mediated by tubulin inhibition and was 
independent of overexpression of Pgp and βIII-tubulin. The compound caused cellular 
microtubule depolymerization, arrested cells in the G2/M phase and triggered apoptotic 
cell death.  
 Compound 187, showed a 3-digit nanomolar GI50 in all the NCI 60 tumor cell lines, 
showing moderate cytotoxic activity (as desired) against tumor cells. The antiangiogenic 
component of 187 is not active in these cell culture assays. This perhaps is an indication 
of low toxicity to normal cells. 
In vivo, compound 187 reduced tumor size and vascularity in two flank xenograft 
models [the BLBC MDA-MB-435 and U251 glioma models] and in a 4T1 triple negative 
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breast orthotopic allograft model. In these in vivo models, the activity of 187 was superior 
to those of clinically used agents temozolomide (U251), docetaxel and sunitinib (MDA-
MB-435 and 4T1) without overt toxicity to the animals. 
 
Design of single agents with combination chemotherapy and multiple RTK 
inhibitory potential 
 The complexity of the angiogenic pathways implies that disrupting only a single 
aspect of angiogenesis may not result in significant clinical success. Multiple RTKs are 
co-activated in tumors and redundant inputs drive and maintain downstream signaling, 
thereby limiting the efficacy of therapies targeting single RTKs.19, 173 Resistance to anti-
VEGF treatment is associated with increased PDGFR expression within the tumor, 
increased recruitment of pericytes to tumor vasculature, and increases in other 
proangiogenic factors.174 Preclinical models suggest that PDGF-mediated recruitment of 
pericytes may contribute to resistance to VEGF blockade. EGFR inhibition can lead to 
VEGFR2 up-regulation which subsequently promotes tumor growth signaling 
independent of EGFR and thus contributes to the resistance of EGFR inhibitors.175, 176 
The effect of EGFR inhibition can also be partially overcome by activation of PDGFR 
signaling and the subsequent transactivation of HER-3 signaling to promote alternate 
tumor growth signaling.20, 175 Hence, targeting multiple RTKs maximizes the proportion 
of angiogenic signalling that is effectively targeted.173, 175 Moreover, high intratumoral 
heterogeneity has been reported with different subpopulations producing distinct growth 
factors. 177-179 Targeting a single RTK could be ineffective due to subpopulations of cells 
that are either not affected by the drug mechanism and possess or acquire a greater drug 
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resistance.180 Hence it was of interest to explore the effect of different structural changes 
on activity against the RTKs VEGFR2, PDGFRβ and EGFR in addition to having 
cytotoxic antitubulin effects with the goal of identifying single agents with antitubulin 
and multiple RTK inhibitory potential.  
 
Figure 32. Series VIII 
Series VIII (compounds 191-195, Figure 32) was designed to study the biological 
effects of sterically induced conformational restriction of the molecule, on tubulin and 
multiple RTK inhibition. Introduction of alkyl substituents at the N5-position of the 
pyrrolo[3,2-d]pyrimidine scaffold was expected to restrict rotation around the N-phenyl 
bond, thus affording a much more rigid structure than 161. Conformational restriction of 
the 4-anilino moiety could lock the compound in a conformation which could be 
conducive to multiple RTKs and tubulin inhibition.  
Attempts to structurally modify the tubulin inhibitor 161 to achieve dual tubulin and 
VEGFR2 inhibition led to the identification of 181 (Series VI, Figure 9) as a novel 
compound with dual tubulin and EGFR inhibitory activities in a single agent. This result 
was of significant interest as it combines two different mechanisms of antitumor activity 
in the same compound (Table 2).181 Several clinical and preclinical combinations of 
EGFR inhibitors and antitubulin agents have been successful.146, 182-185 It was of interest 
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 Table 2. Effects of 181·HCl on tubulin and EGFR in cellular assays  
 Bovine tubulin  
Assembly 
IC50 ± SD 
(µM) 
OVCAR-8 
IC50 ± SD 
(nM) 
EGFR kinase  
IC50 ± SD 
(nM) 
181·HCl 1.1 ± 0.04 11 ± 0.1 5 ± 0.8 
CSA4 1.1 ± 0.1 1.3 ± 0.6  
Erlotinib   1.2 ± 0.2 
to design structural modifications that could potentially incorporate VEGFR2 
inhibitory activity without the loss of EGFR and tubulin inhibitory activities. Towards 
this goal several compounds were designed and synthesized.  
 
 
Figure 33. Series IX 
Series IX (Figure 33) was designed by replacing the furo[3,2-d]pyrimidine in 181 
with a 6,7-dihydro-furo[3,2-d]pyrimidine. Structurally, 6,7-dihydro-pyrrolo[2,3-
d]pyrimidines 196 and 197 are akin to the cyclopenta[d]pyrimidine analogs, which are 
highly potent colchicine-site binding antimitotic antitumor agents.156, 157 Reduction of the 
6,7-bond allows less delocalization of the furo O5-lone pair thus changing the ring 
electronics and also provides some flexibility in the dihydrofuro ring. 
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Figure 34. Series X 
Series X (compounds 198-200, Figure 34) was designed as conformationally restricted 
analogs of 181. Introduction of a 4-N alkyl substituent restricts rotation around the N-
phenyl bond, thus affording a more rigid structure than 181. Conformational restriction of 
the 4-anilino moiety could lock the compound in a conformation that is conducive to 
multiple RTK inhibition without loss of tubulin and EGFR inhibitory activities.  
 
Figure 35. Benzofuro[3,2-d]pyrimidines as RTK inhibitors 
Tricyclic benzofuro[3,2-d]pyrimidines with general structure 201 (Figure 35) have 
been reported to be inhibitors of RTKs.115 It was hypothesized that fusion of a third 
aromatic ring at the appropriate positions of the furo[3,2-d]pyrimidine 181 would allow 
additional hydrophobic interactions with RTKs and perhaps improve RTK inhibitory 
potency without loss of tubulin inhibition. Hence we designed compounds 202-204 
(Series XI, Figure 36) with the tricyclic benzofuro[3,2-d]pyrimidine scaffold.  
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Figure 36. Series XI 
Another approach that was chosen for the design of multiple RTK and tubulin 
inhibitors is that of hybrid design. Series XII (Figure 37) was designed as hybrids of the 
tubulin and EGFR dual inhibitors 181, and the tubulin and VEGFR2 dual inhibitor 187. 
Incorporating the 7-benzyl group onto the furo[3,2-d]pyrimidine scaffold in 181 afforded 
205 and 206 with potential for multiple RTK and tubulin inhibition. 
 
Figure 37. Series XII 
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Figure 38. Series XIII 
Furo[3,2-d]pyrimidines are a relatively unexplored scaffold as EGFR inhibitors. 
Hence Series XIII (Figure 38) was designed by substitutions on the 4-anilino moiety 
using a Topliss approach.186 The biological activities of compounds 182 (Series VI, 
Figure 29) and 207-210 will allow a determination of the effect of hydrophobicity and/or 
electronics on EGFR, VEGFR2 and PDGFRβ inhibition and guide the choice of 
substituents for inhibition of tubulin and multiple RTKs.  
 
Figure 39. Series XIV 
Series XIV (Figure 39) was designed as analogs of dual acting agent 187 with 
restricted rotation around the 4-N-phenyl bond. This was accomplished by placing a 
methyl on the N4 (211, 212) and incorporating the known active quinazoline moiety at 
the 4-position with (214) and without (213) an N5-methyl group. Compounds 211-214 
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could potentially favour a conformation which inhibits multiple RTKs without loss of 
tubulin and VEGFR2 inhibitory activities. 
 
Figure 40. Series XV 
Similarly Series XV (Figure 40) was designed as conformationally restricted analogs 
of dual VEGFR2 and tubulin inhibitors 174 and 176 (Series IV, Figure 6). The 5-methyl 
group in 215 and 216 could have two effects: allow additional hydrophobic interactions 
with the targets and restrict the rotation around the N-phenyl bond, thus providing 
conformational rigidity and better potency. 
Series XVI (Figure 41) was designed to study the effect of a 2-amino group on 
multiple RTK inhibition. Gangjee et al.187 have reported that a 2-amino group on fused 
pyrimidine ring systems improves hinge region binding and provides multiple-RTK 
inhibition. Compounds 217 and 218 were designed by replacing the 2-CH3 group in the 
dual acting VEGFR2 and tubulin inhibitors 187 and 213 with a 2-amino group which 
could potentially increase binding to the hinge region of EGFR or PDGFRβ via hydrogen 
bonds, without loss of tubulin and VEGFR2 inhibitory activities. Similarly, compounds 
219 and 220 were designed by replacing the 2-CH3 group in the dual acting VEGFR2 and 
tubulin inhibitors 174 and 176 (Series IV, Figure 26) with a 2-amino group.  
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Figure 41. Series XVI 
Series XVII was designed based on previous reports by Gangjee et al.188 Compound 
221 (Figure 42) was reported to have potent VEGFR2 and PDGFRβ inhibitory activities 
(Table 3). Substituents on the benzyl group and the location of the benzyl group on
 
Figure 42. VEGFR2 and PDGFRβ dual 
inhibitor 
Table 3. Inhibition of kinases in cellular 
assays  
Compound 
VEGFR2  
IC50 ± 
SD 
(µM) 
PDGFRβ  
IC50 ± SD 
(µM) 
221 25.7 1.8 
Semaxanib 12.9  
DMBI  3.75 
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the pyrrolo[2,3-d]pyrimidine scaffold were found to dictate RTK inhibitory activity. 
Compounds 222-224 (Series XVII, Figure 43) were designed by incorporating the 7-
(3′,4′,5′-trimethoxybenzyl) group as such a motif has demonstrated potential for multiple 
RTK inhibition.188 
 
Figure 43. Series XVII 
While the pyrrolo[2,3-d]pyrimidine scaffold has been used in the design of RTK 
inhibitors there is a dearth in the literature of the regioisomeric pyrrolo[3,2-d]pyrimidine 
scaffold as RTK inhibitors. Thus it was of interest to design appropriately substituted 
pyrrolo[3,2-d]pyrimidines as multitargeted RTK inhibitors. However, multiple or 
promiscuous RTK inhibitors are in some instances more prone to yield side effects, in the 
clinic, compared to selective RTK inhibitors.19, 24 Selectivity has proven to be a 
significant challenge due to the large number of important protein kinases in human cells, 
the conserved structure of the kinase ATP binding domain and the high cellular 
concentrations (micromolar) required for these compounds to compete with millimolar 
cellular ATP concentrations.189 The optimal selectivity profile of a promising inhibitor, 
must exclude off-target kinases such as insulin signaling kinases,190 cAMP-dependent 
protein kinase191 and several others192 critical for normal cell function. Thus, there 
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remains considerable interest in the development of RTKs with optimal targeted RTK 
inhibitory effects and minimal off target inhibitions and side-effects.  
In order to rule out off target toxicity, compound 187 was evaluated with the 
assistance of a kinase profiling service (Luceome Biotechnologies) against 50 other 
kinases and found no significant activity at 10 µM. This data supported the design of 2-
methyl 7-benzyl pyrrolo[3,2-d]pyrimidine as a scaffold with potential for "selectively 
non-selective" kinase inhibitor design. A variety of specific substituents on the phenyl 
ring were incorporated in the target compounds based on reported7, 18, 193 potent RTK 
inhibitors (Figure 44).  
 
Figure 44. Reported RTK inhibitors used in the design of Series XVIII  
  
79 
 
 
Figure 45. Series XVIII 
Substituents from vandetanib, CB676475, erlotinib, PD153035, gefitinib and lapatinib 
were incorporated in the design of compounds 225-230 (Figure 45) respectively. As the 
4-anilino substituents in 225-229 are electron-withdrawing, compound 231 was designed 
to evaluate the effect of electron-donating substituents that have previously194 shown 
multi-RTK inhibitory potential in the pyrrolo[3,2-d]pyrimidine class of inhibitors. 
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IV. CHEMICAL DISCUSSION 
The synthesis of target compounds was envisioned to be accomplished via 
nucleophilic substitution reactions169 of 4-chloro-fused-pyrimidines with general 
structure B (Figure 46) which could be prepared by condensation of appropriately 
substituted precursors C with acetamidine type reagents.115  
 
Figure 46. Retrosynthesis of target compounds 
Synthesis of 161 
With the above synthetic strategy for the synthesis of pyrrolo[3,2-d]pyrimidine 161 
in mind, the key intermediate pyrrole 236 (Scheme 37) was synthesized by modifications 
of reported98 procedures. Isoxazole 233 was treated with a base to afford aldehyde 234 
which on treatment with diethylaminomalonate provided imine 235. Imine 235 was 
subject to a base catalysed cyclization and decarboxylation using sodium ethoxide to give 
ethyl 3-amino-1H-pyrrole-2-carboxylate 236. Furneaux et al.98 suggest reaction times of 
two days for the preparation of enamine 235 from the aldehyde 234 and three days for the 
preparation of pyrrole 236 from the enamine 235. However, it was found that these long 
reaction times afforded several side products [monitored by thin layer chromatography 
(TLC)] and significantly reduced the yield. The reactions were carefully monitored by  
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Scheme 37. Synthesis of 161 
 
Reagents and conditions: (a) NaOC2H5, C2H5OH, 0 °C, 1 h; (b) diethylaminomalonate, 
CH3COONa, C2H5OH, rt, 24 h; (c) NaOC2H5, C2H5OH, rt, 24 h; (d) CH3CN, HCl, rt, 2 h; 
(e) POCl3, 110 °C, 4 h; (f) 4-methoxy N-methylaniline, (CH3)2CHOH, reflux, 4 h 
TLC and the reaction times were optimized to significantly decrease formation of side 
products and to afford crude pyrrole 236 which could be used without futher purification 
by column chromatography. Reported condensation of guanidine/cyanamide104 and 
formamidine with similar pyrroles98, 108 encouraged us to attempt condensation of pyrrole 
236 with acetamidine. This condensation reaction requires heating the pyrrole with 
acetamidine hydrochloride in ethanol at reflux.98 These reaction conditions resulted in 
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degradation of the pyrrole 236 without the formation of 237. Condensation was also 
attempted under basic conditions195 using sodium ethoxide, but similar degradation was 
observed. The synthesis of bicyclic pyrrolo[3,2-d]pyrimidine 237 was accomplished by 
treatment of pyrrole 236 with acetonitrile under acidic conditions104 (32% yield over 4 
steps from 233). The 2-methyl-4-oxo-pyrrolo[3,2-d]pyrimidine 237 was chlorinated188 
with phosphorus oxychloride to generate 2-methyl-4-chloro-pyrrolo[3,2-d] pyrimidine 
238 which was subjected to a nucleophilic aromatic substitution reaction169 using 4-
methoxy N-methylaniline to afford 161.  
Synthesis of 162 
Scheme 38. Synthesis of 162 
 
Reagents and conditions: (a) fomamidine acetate, C2H5OH, reflux, 18 h (b) POCl3, 
110 °C, 6 h; (c) 4-methoxy N-methylaniline, (CH3)2CHOH, reflux, 6 h 
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Ethyl 3-amino-1H-pyrrole-2-carboxylate 236 (Scheme 38) was subjected to a 
condensation with formamidine to afford bicyclic pyrrolo[3,2-d]pyrimidine 239.98 In 
contrast to the condensation with acetamidine, this reaction afforded the bicyclic 
pyrrolo[3,2-d]pyrimidine. Although side products (possibly due to pyrrole degradation in 
ethanol at reflux) were observed, the reaction sequence afforded 239 in 15% yield over 4 
steps from 233. Purification of 239 required extensive column chromatography. The 2-H-
4-oxo pyrrolo[3,2-d]pyrimidine 239 was chlorinated with phosphorus oxychloride to 
generate 2-H-4-chloro-pyrrolo[3,2-d]pyrimidine 240 which was subjected to a 
nucleophilic aromatic substitution reaction using 4-methoxy N-methylaniline in 
isopropanol at reflux to afford 162. 
Synthesis of 163-167 
Scheme 39. Synthesis of 163-167 
 
Reagents and conditions: (a) appropriately substituted amine, (CH3)2CHOH, reflux,  
4-24 h 
  
84 
 
Nucleophilic aromatic substitution reactions169 of 2-methyl-4-chloro-pyrrolo[3,2-d] 
pyrimidine 238 (Scheme 37) with appropriately substituted amines in isopropanol at 
reflux afforded compounds 163-167 (Scheme 39). Displacement reactions with bulky 
nucleophiles 5-methoxyindoline and 6-methoxy-1,2,3,4-tetrahydroquinoline required 
longer reaction times compared to other amines for complete disappearance of starting 
material estimated from TLC.  
Synthesis of 170-173 
Scheme 40. Synthesis of 170-173 
 
Reagents and conditions: (a) NaH, CH3Br, (CH3)2NCOH (b) appropriately substituted 
amine, (CH3)2CHOH, reflux, 4-24 h 
4-Chloro-2-methyl-5H-pyrrolo[3,2-d]pyrimidine 238 (Scheme 37) was deprotonated 
with sodium hydride188 and methylated with methyl bromide to afford 241 (Scheme 40) 
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which on treatment with appropriately substituted amines in isopropanol at reflux 
afforded compounds 170-173. 
Synthesis of 174-176 
Scheme 41. Synthesis of 174-176 
 
Reagents and conditions: (a) C2H5OH, rt, 6 h; (b) NaOC2H5, C2H5OH, 60 °C, 6 h;  
(c) CH3CN, HCl, rt, 2 h; (d) POCl3, 110 °C, 4 h; (e) appropriately substituted amine, 
(CH3)2CHOH, reflux, 4-24 h 
A conjugate addition–elimination reaction105 of 3-aminobut-2-enenitrile 242 
(Scheme 41) using diethylaminomalonate in ethanol afforded enamino nitrile 243 which 
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was subjected to a base catalyzed cyclization and decarboxylation103 using sodium 
ethoxide to afford ethyl 3-amino-5-methyl-1H-pyrrole-2-carboxylate 244. Compared to 
the synthesis of enamine 235 and pyrrole 236, reactions for the synthesis of 243 and 244 
were clean and the products could be isolated by column chromatography. Condensation 
of pyrrole 244 with acetamidine was attempted but was unsuccessful. Although the 
pyrrole was stable under the reaction conditions of heating with acetamidine 
hydrochloride in ethanol, formation of new products were not observed. Pyrrole 244 was 
treated with acetonitrile under acidic conditions104 to afford bicyclic pyrrolo[3,2-
d]pyrimidine 245. The 2-methyl- 4-oxo-pyrrolo[3,2-d]pyrimidine 245 was chlorinated169 
with phosphorus oxychloride to generate 2-methyl-4-chloro-pyrrolo[3,2-d]pyrimidine 
246 which was subjected to nucleophilic aromatic substitution reactions188 using the 
appropriately substituted amine to afford 174 - 176. 
Synthesis of 178-180 
A nucleophilic displacement of ethyl bromoacetate 247 (Scheme 42) using 
anthranilonitrile 103 afforded 104 which was subjected to a base catalyzed cyclization 
using potassium tert-butoxide to afford ethyl 3-amino-1H-indole-2-carboxylate 103.113 
Condensation of substituted indoles, analogous to 105, with chlorformamidine have been 
successful and have afforded 2-amino-pyrimido[5,4-b]indoles.196 Hence it was expected 
that the indole could be condensed with acetamidine. However, similar to reactions with 
previously discussed pyrroles, it was unsuccessful. Indole 103 was treated with 
acetonitrile under acidic conditions to afford tricyclic pyrimido[5,4-b]indole 248.104 The 
2-methyl-4-oxo-pyrimido[5,4-b]indole 248 was chlorinated with phosphorus oxychloride  
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Scheme 42. Synthesis of 178-180 
 
Reagents and conditions: (a) K2CO3, C2H5OH, reflux, 6 h; (b) t-BuOK, THF, rt, 6 h; 
(c) CH3CN, HCl, rt, 2 h; (d) POCl3, 110 °C, 4 h; (e) appropriately substituted amine, 
(CH3)2CHOH, reflux, 4-24 h 
to generate 4-chloro-2-methyl-5H-pyrimido[5,4-b]indole 249 which was subjected to 
nucleophilic aromatic substitution reactions156 as before to afford 178 - 180. Compounds 
248 and 249 had improved solubility in organic solvents compared to their pyrrolo[3,2-
d]pyrimidine analogs hence allowing for shorter time for chromatographic purification.  
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Synthesis of 181-185 
Scheme 43. Synthesis of 181-185 
 
Reagents and conditions: (a) CH3CN, HCl, rt, 8 h; (b) POCl3, 110 °C, 4 h;  
(c) appropriately substituted amine, (CH3)2CHOH, reflux, 4-24 h 
Commercially available ethyl 3-aminofuran-2-carboxylate 250 was treated with 
acetonitrile under acidic conditions to afford bicyclic furo[3,2-d]pyrimidine 251. The 1H 
NMR of 250 obtained from the commercial source was identical to the reported120 NMR 
confirming the substitution pattern on the furan ring. The 2-methylfuro[3,2-d]pyrimidin-
4(3H)-one 251 was chlorinated169 with phosphorus oxychloride to generate 2-methyl 4-
chloro furo[3,2-d]pyrimidine 252 which was subjected to nucleophilic aromatic 
substitution reactions188 using the appropriately substituted amines as before to afford 
181 - 185. Similar to pyrrolo[3,2-d]pyrimidine scaffold, displacement reactions with 
bulky nucleophiles 5-methoxyindoline and 6-methoxy-1,2,3,4-tetrahydroquinoline 
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required longer reaction times compared to other amines for complete disappearance of 
starting material as estimated from TLC. 
Synthesis of 187-190 
Scheme 44. Synthesis of 187-190 
 
Reagents and conditions: (a) C2H5ONa, C2H5OH, rt, 6 h; (b) 6N HCl, rt, 2 h; (c) H2, Pd/C, 
55 psi, rt, 1 h (d) diethylaminomalonate, CH3COONa, CH3OH, rt, 16 h; (e) CH3ONa, 
CH3OH, rt, 12 h, reflux, 3 h; (f) CH3CN, HCl, rt, 3 h; (g) POCl3, 110 °C, 4 h;  
(h) appropriately substituted amine, (CH3)2CHOH, reflux, 4-24 h 
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The key intermediate pyrrole 259 (Scheme 44) was synthesized by modifications in 
reported procedures.103 Base catalysed condensation of benzaldehyde 253 and 3,3 
dimethoxypropiononitrile 254 using sodium ethoxide in ethanol afforded 255 which was 
subjected to an acid catalyzed aldehyde deprotection to provide 256. Catalytic 
hydrogenation of 256 using 10% Pd/C afforded aldehyde 257 which was treated with 
diethylaminomalonate in methanol to afford the enamino nitrile 258. Compound 258 was 
treated to a base catalyzed cyclization and decarboxylation using sodium methoxide to 
afford methyl 3-amino-4-benzyl-1H-pyrrole-2-carboxylate 259. Pyrrole 259 was treated 
with acetonitrile under acidic conditions104 to afford bicyclic pyrrolo[3,2-d]pyrimidine 
260. The 2-methyl-4-oxo-pyrrolo[3,2-d]pyrimidine 260 was chlorinated169 with 
phosphorus oxychloride to generate 2-methyl-4-chloro- pyrrolo[3,2-d]pyrimidine 261 
which was subjected to nucleophilic aromatic substitution reactions188 using the 
appropriately substituted amine to afford 187 - 190. The 7-benzyl group of 260 and 261 
significantly improved solubility compared to 237 and 238 in organic solvents. 
Synthesis of 191-195 
Scheme 45. Synthesis of 191-195 
 
Reagents and conditions: (a) NaH, alkyl halide, DMF, 2-8 h  
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Pyrrolo[3,2-d]pyrimidine 161 (Scheme 37), which was synthesized from isoxazole 
in 6 steps as shown in Scheme 37, was deprotonated188 with sodium hydride and treated 
with the the appropriate alkyl halide to afford the corresponding N5-alkylated 
pyrrolo[3,2-d]pyrimidine 191-195 (Scheme 45). Reactions involving combinations of 
cesium carbonate or potassium carbonate and dimethylformamide with microwave 
irradiation or conventional bench-top conditions did not show complete consumption of 
starting material. The mixture of 161 and the alkylated product could not be separated by 
column chromatography. The use of excess base or alkyl halide did not afford the 
alkylated product exclusively. Hence the deprotonation-alkylation sequence was chosen.  
Synthesis of 196-197 
Scheme 46. Synthesis of 196-197 
 
Reagents and conditions: (a) H2, Pd(OH)2, CH3OH, rt, 24 h 
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The synthesis of 6,7-dihydrofuro[3,2-d]pyrimidine 196 (Scheme 46) was attempted 
by catalytic hydrogenation of furo[3,2-d]pyrimidines 181(Scheme 43). The use of 
palladium on carbon as the catalytic bed for hydrogenation [upto 50 psi, 12 hours]196 
afforded multiple spots which were significantly non-polar compared to the starting 
material. The isolated yield of 196 could not be improved beyond 36%. The synthesis of 
6,7-dihydrofuro[3,2-d]pyrimidines 196 and 197 were accomplished by catalytic 
hydrogenation of furo[3,2-d]pyrimidines 181 and 185 respectively using palladium 
hydroxide. The use of palladium hydroxide resulted in clean reactions with no side 
products upto 24 hrs beyond which non-polar side products were observed.  
Synthesis of 198-200 
Scheme 47. Synthesis of 198-200 
 
Reagents and conditions: (a) NaH, alkyl halide, DMF, 6-12 h 
Furo[3,2-d]pyrimidine 182, which was synthesized as shown in Scheme 43, was 
deprotonated188 with sodium hydride and treated with the the appropriate alkyl halide to 
afford the corresponding pyrrole 4-N-alkylated furo[3,2-d]pyrimidines 198-200 (Scheme 
47). Reactions involving combinations of cesium carbonate or potassium carbonate and 
dimethylformamide at conventional bench-top conditions did not show complete 
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consumption of starting material. Microwave irradiation afforded multiple spots. Hence 
sodium hydride was chosen as the reaction could be carried out at room temperature to 
afford good to excellent yields.  
Synthesis of 202-204 
Scheme 48. Synthesis of 202-204 
Reagents and conditions: (a) K2CO3, C2H5OH, reflux, 6 h; (b) t-BuOK, THF, rt, 6 h; (c) 
CH3CN, HCl, rt, 2 h; (d) POCl3, 110 °C, 4 h; (e) appropriately substituted amine, 
(CH3)2CHOH, reflux, 4-24 h 
A nucleophilic displacement on ethyl bromoacetate 247 (Scheme 48) using 2-
hydroxy benzonitrile 144 afforded 262 which was subjected to a base catalyzed 
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cyclization using potassium tert-butoxide to afford ethyl 3-aminobenzofuran-2-
carboxylate 263.113, 115 Benzofuran 263 was treated with acetonitrile under acidic 
conditions104 to afford tricyclic benzofuro[3,2-d]pyrimidine 264. The 2-
methylbenzofuro[3,2-d]pyrimidin-4(3H)-one 264 was chlorinated197 with phosphorus 
oxychloride to generate 4-chloro-2-methylbenzo-furo[3,2-d]pyrimidine 265 which was 
subjected to nucleophilic aromatic substitution reactions197 using the appropriately 
substituted amines to afford 202 - 204. There was no significant change in reaction 
conditions for the synthesis of benzofuro[3,2-d]pyrimidines 202-204 compared with 178-
180 (Scheme 42). 
Synthesis of 205-206 
Base catalysed condensation of 3-phenyl propionitrile 266 (Scheme 49) and ethyl 
formate using sodium ethoxide in ethanol afforded 267 which was alkylated with chloro 
diethylmalonate to provide 268.125 Compound 268 was subjected to a base catalyzed 
cyclization and decarboxylation using sodium ethoxide in ethanol to afford methyl 3-
amino-4-benzylfuran-2-carboxylate 269.103 The cyclization-decarboxylation reaction was 
attempted with bases such as 1,5-diazabicyclo[4.3.0]non-5-ene and potassium 
bis(trimethylsilyl)amide. The yields of the reactions were comparable. Substituted furan 
269 was treated with acetonitrile under acidic conditions104 to afford bicyclic furo[3,2-
d]pyrimidine 270. The 7-benzyl-2-methylfuro[3,2-d]pyrimidin-4(3H)-one 270 was 
chlorinated197 with phosphorus oxychloride to generate 7-benzyl-4-chloro-2-
methylfuro[3,2-d]pyrimidine 271 which was subjected to nucleophilic aromatic 
substitution reactions197 using the appropriately substituted amine to afford 205 - 206. 
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Scheme 49. Synthesis of 205-206 
 Reagents and conditions: (a) HCOOC2H5, C2H5ONa, C2H5OH, rt, 6 h (b) chloro 
diethylmalonate, CH3COONa, CH3OH, rt, 16 h; (c) C2H5ONa, C2H5OH, rt, 8 h, reflux, 
30 min; (d) CH3CN, HCl, rt, 2 h; (e) POCl3, 110 °C, 4 h; (f) appropriately substituted 
amine, (CH3)2CHOH, reflux, 2-6 h 
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Synthesis of 207-210 
Scheme 50. Synthesis of 207-210 
 
Reagents and conditions: (a) appropriately substituted aromatic amines, (CH3)2CHOH, 
reflux, 4-12 h 
Nucleophilic aromatic substitution reactions197 of 4-chloro-2-methylfuro[3,2-
d]pyrimidine 252 (Scheme 43) with appropriately substituted aromatic amines in 
isopropanol at reflux afforded compounds 207-210 (Scheme 50). 
Synthesis of 211-214 
7-Benzyl-4-chloro-2-methyl-5H-pyrrolo[3,2-d]pyrimidine 261 (Scheme 44) was 
deprotonated with sodium hydride and methylated with methyl bromide to afford 272 
(Scheme 51) which on treatment with appropriately substituted amines in isopropanol at 
reflux afforded compounds 211-212.188 Treatment of pyrrolo[3,2-d]pyrimidines 261 and 
272 with 6-methoxy tetrahydroquinoline afforded 213 and 214 respectively.  
Comparison of 1H NMRs of 187 and 212 with their synthetic precursors suggest a 
conformational preference of the 4-anilino moiety. As shown in Figure 47, the chemical 
shifts of the 5-H and 6-H in 187 compared with those in 261 indicate that these protons 
are in the shielding zone of the 4-methoxy-phenyl ring. Similarly, comparing the 
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Scheme 51. Synthesis of 211-214
Reagents and conditions: (a) NaH, CH3Br, (CH3)2NCOH (b) appropriately substituted 
amine, (CH3)2CHOH, reflux, 4-24 h  
 
Figure 47. Comparison of 1H NMRs 
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chemical shifts of the N5-CH3 protons in 212 compared with those in 272 suggest similar 
conformational preference. 
Synthesis of 215-216 
Scheme 52. Synthesis of 215-216
 
Reagents and conditions: (a) NaH, CH3Br, (CH3)2NCOH (b) appropriately substituted 
amine, (CH3)2CHOH, reflux, 4-24 h 
4-Chloro-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidine 246 (Scheme 41) was deproton-
ated188 with sodium hydride and methylated with methyl bromide to afford 273 (Scheme 
52) which on treatmentwith appropriately substituted amines in isopropanol at reflux 
afforded compounds 215-216. 
Synthesis of 217-220 
3-Amino pyrroles 259 (Scheme 44) and 244 (Scheme 41) were treated with 
guanidine and chlorformamidine93 and were found to be unreactive towards these  
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Scheme 53. Synthesis of 217-220 
Reagents and conditions: (a) 1,3-dicarbomethoxy-2-methyl-2-thiopseudourea, 
CH3COOH, rt, 24 h; (b) CH3ONa, CH3OH, rt, 12 h; (c) 1N NaOH, CH3OH, reflux, 2 h; 
(d) trimethylacetic anhydride, 120 °C, 2 h; (e) POCl3, 110 °C, 2 h; (f) substituted amine, 
(CH3)2CHOH, reflux, 4-24 h; (g) 1N NaOH, CH3OH, reflux, 10 h 
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standard guanylating agents. Hence a three-step sequence was followed in the synthesis 
of 278 - 279. 3-Amino pyrroles 259 and 244 were subjected to condensation with 1,3-
bis(methoxy-carbonyl)-2-methylthiopseudourea to afford guanidine adducts 274 and 275 
(Scheme 53) respectively.103 Base-catalyzed cyclization in presence of sodium methoxide 
afforded bicyclic pyrrolo[3,2-d]pyrimidines 276 and 277. Chlorination of the carbamate 
protected amines gave poor yields (<20%). Further the suqsequent aniline displacement 
reactions did not go to completion and separation of product from the starting materials 
required extensive column chromatography. Hence, the carbamate group in 276 and 277 
was hydrolysed with aqueous sodium hydroxide to afford 278 and 279 which upon 
reaction with trimethylacetic anhydride provided amides 280 and 281 respectively. The 
4-oxo pyrrolo[3,2-d] pyrimidines 280 and 281, which had significantly improved 
solubility in organic solvents compared to 276 - 279, were chlorinated with phosphorus 
oxychloride to generate 4-chloro-pyrrolo[3,2-d]pyrimidines 282 and 283 respectively 
which were subjected to nucleophilic aromatic substitution reactions using the 
appropriately substituted amines to afford 284 - 287. Subsequent base catalyzed amide 
hydrolysis afforded 217 - 220. 
Synthesis of 222-224 
Base catalysed condensation of 3,4,5-trimethoxy benzaldehyde 286 (Scheme 54) and 
3,3 dimethoxypropiononitrile 254 using sodium ethoxide in ethanol followed by an acid 
catalyzed aldehyde deprotection provided 287.103 The use of sodium methoxide in 
methanol for the for the aldol-type condenstation required a longer reaction time (about 
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 Scheme 54. Synthesis of 222-224 
 
Reagents and conditions: (a) C2H5ONa, C2H5OH, rt, 6 h; (b) 6N HCl, rt, 2 h; (c) H2, Pd/C, 
55 psi, rt, 1 h (d) diethylaminomalonate, CH3COONa, CH3OH, rt, 16 h; (e) CH3ONa, 
CH3OH, rt, 12 h, reflux, 3 h; (f) CH3CN, HCl, rt, 3 h; (g) fomamidine acetate, C2H5OH, 
reflux, 18 h; (h) 1,3-dicarbomethoxy-2-methyl-2-thiopseudourea, CH3COOH, rt, 24 h;  
(i) CH3ONa, CH3OH, rt, 12 h; (j) 1N NaOH, CH3OH, reflux, 2 h; trimethylacetic 
anhydride, 120 °C, 2 h; (k) trimethylacetic anhydride, 120 °C, 2 h; (l) POCl3, 110 °C, 2-4 
h; (m) 4-methoxy N-methyl aniline, (CH3)2CHOH, reflux, 4-12 h; (n) 1N NaOH, CH3OH, 
reflux, 10 h 
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24 hours) compared to sodium ethoxide in ethanol (6 hours). Catalytic hydrogenation of 
alkenyl aldehyde 287 using 10% Pd/C afforded an intermediate alkyl aldehyde which was 
treated with diethylaminomalonate in methanol to afford an enamino nitrile. The enamino 
nitrile was subjected to a base catalyzed cyclization and decarboxylation using sodium 
methoxide to afford methyl-3-amino-4-(3,4,5-trimethoxybenzyl)-1H-pyrrole-2-
carboxylate 288. Pyrrole 288 was condensed with acetonitrile or fomamidine or 1,3-
dicarbomethoxy-2-methyl-2-thiopseudourea under acidic conditions to afford bicyclic 
pyrrolo[3,2-d]pyrimidines 289-291. The 4-oxo-pyrrolo[3,2-d]pyrimidines 289-291 were 
chlorinated with phosphorus oxychloride to generate the corresponding 4-chloro-
pyrrolo[3,2-d]pyrimidines 292-294 which were subjected to nucleophilic aromatic 
substitution reactions using the appropriately substituted amine to afford 222-224. 
Synthesis of 225-232 
Scheme 55. Synthesis of 225-232
Reagents and conditions: (a) appropriately substituted amine, (CH3)2CHOH, reflux, 4-12 
h 
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Nucleophilic aromatic substitution reactions of 7-benzyl-4-chloro-2-methyl-5H-
pyrrolo[3,2-d]pyrimidine 261 (Scheme 44) with appropriately substituted amines in 
isopropanol at reflux afforded compounds 225-232 (Scheme 55). It was interesting to 
note that there was no correlation between the electronics of the amines used and the 
reaction time or yields for the displacement reactions.  
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V. EXPERIMENTAL 
All evaporations were carried out in vacuum with a rotary evaporator. Analytical samples 
were dried in vacuo in a CHEM-DRY drying apparatus over P2O5 at 50 °C. Melting 
points were determined either using a MEL-TEMP II melting point apparatus with 
FLUKE 51 K/J electronic thermometer or using an MPA100 OptiMelt automated melting 
point system and are uncorrected. Nuclear magnetic resonance spectra for proton (1H 
NMR) were recorded on the Bruker Avance II 400 (400 MHz) or Bruker Avance II 500 
(500 MHz) NMR systems with TopSpin processing software. The chemical shift values 
(δ )are expressed in ppm (parts per million) relative to tetramethylsilane as an internal 
standard: s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, multiplet; 
br, broad singlet; td, triplet of doublet; dt, doublet of triplet; quin, quintet. Thin-layer 
chromatography (TLC) was performed on Whatman® PE SIL G/UV254 flexible silica 
gel plates and the spots were visualized under 254 and 365 nm ultraviolet illumination. 
Proportions of solvents used for TLC are by volume. All analytical samples were 
homogeneous on TLC in at least two different solvent systems. Column chromatography 
was performed on the silica gel (70 to 230 meshes, Fisher Scientific) column. Flash 
chromatography was carried out on the CombiFlash® Rf systems, model COMBIFLASH 
RF. Pre-packed RediSep® Rf normal-phase flash columns (230 to 400 meshes) of 
various sizes were used. The amount (weight) of silica gel for column chromatography 
was in the range of 50-100 times the amount (weight) of the crude compounds being 
separated. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA. 
Element compositions are within ± 0.4% of the calculated values. Fractional moles of 
water or organic solvents frequently found in some analytical samples could not be 
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prevented despite 24 to 48 hours of drying in vacuo and were confirmed where possible 
by their presence in the 1H NMR spectra.  
 
2-Methyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (237) 
A solution of sodium ethoxide (5.17 g, 76 mmol) in ethanol (40 mL) was added dropwise 
to a stirred solution of isoxazole 233 (5g, 72.5 mmol) in ethanol (10 mL) in an ice bath. 
After an additional 1 h of stirring acetic acid (5.5 mL), diethylaminomalonate 
hydrochloride (15 g, 71 mmol), and sodium acetate (4.8, 58.51 mmol) were added, and 
the mixture was stirred at room temperature for 24 hours, after which most of the solvent 
removed under vacuum. The residue was partitioned between dichloromethane and water, 
and the organic phase was dried over sodium sulphate and filtered through a thick pad of 
silica. The filtrate was evaporated to afford a brown syrup of 235 which was dissolved in 
a solution of sodium ethoxide in ethanol (0.5 M, 100 mL), and the solution was stirred at 
room temperature for 24 hours. Acetic acid was added to adjust the pH to 7 and the 
solvent was removed under vacuum. The residue was partitioned between 
dichloromethane and water, and the organic phase was dried over sodium sulphate and 
filtered through a thick pad of silica. The filtrate was evaporated to afford crude syrupy 
236 which was dissolved in acetonitrile (100 mL) and hydrogen chloride gas was bubbled 
through for 2 hours. The reaction mixture was neutralized with ammonium hydroxide and 
the solvent was evaporated and flash chromatographed (CHCl3: CH3OH; 100:1 to 50:3; 
v/v) to yield 237 as a light brown solid (4.1g, 32%). TLC Rf = 0.42 (CH3OH: CHCl3; 
1:10); mp198, 240-242 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 2.27 (s, 3 H, CH3) 6.21 
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- 6.24 (m, 1 H, 7-CH) 7.27 - 7.31 (m, 1 H, 6-CH) 11.74 (br, 1 H, exch, NH) 11.89 (br, 1 
H, exch, NH) 
 
4-Chloro-2-methyl-5H-pyrrolo[3,2-d]pyrimidine (238) 
2-Methyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (237, 1 g, 6.54 mmol) was added to 
phosphorus oxychloride (20 mL) and heated at reflux for 4 h. The solvent was evaporated 
in vacuo, and the pH of the residue was adjusted to 8 with ammonia solution. The 
resulting precipitate was filtered and purified by column chromatography (CHCl3: 
CH3OH; 100:1 to 50:3; v/v) to give a light yellow solid (840 mg, 75%). TLC Rf = 0.32 
(CH3OH: CHCl3; 1:10); mp, 138-139 °C; 
1H NMR, DMSO-d6: δ 2.60 (s, 3 H, CH3) 6.6 
(m, 1 H, 7-CH) 7.9 (m, 1 H, 6-CH) 12.26 (s, 1 H, exch, NH). 
 
N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (161) 
Compound 238 (0.1 g, 0.45 mmol) and 4-methoxy-N-methylaniline (0.12 g, 1.05 mmol) 
were dissolved in isopropanol (20 mL) and heated at reflux for 4 h. The solvent was 
evaporated in vacuo, and the residue was purified by column chromatography (CHCl3: 
CH3OH; 50:1; v/v) to give a brown solid (97.6 mg, 86%). TLC Rf = 0.42 (CH3OH: 
CHCl3; 1:10). The product obtained was dissolved in a minimum amount of ethyl acetate 
and diethyl ether (10 mL) was added to the solution. Hydrogen chloride gas was bubbled 
through for 2-3 mins. The precipitate obtained was collected by filtration. white solid; mp, 
184-185 °C; 1H NMR, DMSO-d6: δ 2.63 (s, 3 H, 2-CH3) 3.62 (s, 3 H, NCH3) 3.84 (s, 3 H, 
OCH3), 6.46 (s, 1 H, Ar) 7.1 (d, J = 8.9 Hz, 2 H, Ar) 7.42 (d, J = 8.86 Hz, 2 H, Ar) 9.661 
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(s, 1 H, exch, NH) 14.99 (s, 1 H, exch, NH). Anal. Calcd. for C15H16N4O∙HCl∙H2O: C, 
55.81; H, 5.93; N, 17.36; Cl, 10.98. Found C, 55.94; H, 5.87; N, 17.17; Cl, 10.97. 
 
3H-Pyrrolo[3,2-d]pyrimidin-4(5H)-one (239) 
Crude 236 (prepared from 233 as described previously) was dissolved in ethanol (50 mL), 
formamidine acetate (2 equivalents) was added and heated to reflux for 18 hours. The 
reaction mixture was neutralized with ammonium hydroxide and the solvent was 
evaporated and flash chromatographed (CHCl3: CH3OH; 100:1 to 50:3; v/v) to yield 239 
as a brown solid (15% over 4 steps from 233). TLC Rf = 0.36 (CH3OH: CHCl3; 1:10); 
mp199, 212-214 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 6.33 - 6.37 (m, 1 H, CH) 7.35 
(t, J = 2.89 Hz, 1 H, CH) 7.77 (s, 1 H, CH) 11.83 (br, 1 H, exch, NH) 12.06 (br, 1 H, 
exch, NH) 
 
4-Chloro-5H-pyrrolo[3,2-d]pyrimidine (240) 
3H-Pyrrolo[3,2-d]pyrimidin-4(5H)-one (239, 500 mg, 3.7 mmol) was added to 
phosphorus oxychloride (20 mL) and heated at reflux for 6 h. The solvent was evaporated 
in vacuo, and the pH of the residue was adjusted to 8 with ammonia solution. The 
resulting precipitate was filtered and purified by column chromatography (CHCl3: MeOH; 
100:1 to 50:3; v/v) to give a light yellow solid (318 mg, 56%). TLC Rf = 0.36 (CH3OH: 
CHCl3; 1:10); mp
199, 161-162 °C; 1H NMR, DMSO-d6: δ 2.60 (s, 3 H, CH3) 6.6 (m, 1 H, 
CH), 7.81 (s, 1 H, CH) 7.9 (m, 1 H, CH) 12.26 (s, 1 H, exch, NH). 
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N-(4-Methoxyphenyl)-N-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (162) 
Compound 162 (synthesized from 240 as described for 161): yield 72%; TLC Rf = 0.33 
(CH3OH: CHCl3; 1:5).
 ; white solid; mp, 150-151 °C; 1H NMR, DMSO-d6 δ 3.65 (s, 3 H, 
NCH3) 3.84 (s, 3 H, OCH3) 6.55 (s, 1 H, CH) 7.1 (d, J = 8.8 Hz, 2 H, C6H4) 7.4 (d, J = 
8.7Hz, 2 H, C6H4) 7.56 (s, 1 H, CH) 8.71 (s, 1 H, CH) 9.96 (s, 1 H, exch, NH) 14.39 (s, 1 
H, exch, HCl). Anal. Calcd. for C14H14N4O∙HCl∙H2O: C, 54.46; H, 5.55; N, 18.15; Cl, 
11.48. Found C, 54.29; H, 5.46; N, 17.90; Cl, 11.26. 
 
N,2-Dimethyl-N-phenyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (163) 
Compound 163 (synthesized from 238 and N-methyl aniline as described for 161): yield 
78%; TLC Rf = 0.42 (MeOH: CHCl3; 1:5).; white solid; mp, 253-254 °C; 
1H NMR, 
DMSO-d6: δ 2.62 (s, 3 H, 2-CH3) 3.7 (s, 3 H, NCH3) 6.49 (s, 1 H, Ar) 7.47-7.59 (m, 6 H, 
Ar) 10.07 (s, 1 H, exch, NH) 15.02 (s, 1 H, exch, HCl). Anal. Calcd. for C15H16N4O∙0.95 
HCl∙0.25H2O: C, 60.61; H, 5.61; N, 20.1. Found C, 60.59; H, 5.6; N, 20.00. 
 
N-(4-Methoxyphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (164) 
Compound 164 (synthesized from 238 and p-anisidine as described for 161): yield 81%; 
TLC Rf = 0.4 (CH3OH: CHCl3; 1:5); white solid; mp 260 °C (decomp); 
1H NMR, 
DMSO-d6: δ 2.61 (s, 3 H, 2-CH3) 3.77 (s, 3 H, OCH3) 6.51 (s, 1 H, 7-CH) 7.0 (d, J = 9 
Hz, 2 H, C6H5) 7.82 (d, J = 8.8 Hz, 2 H, C6H5) 7.89 (s, 1 H, 6-CH) 11.43 (s, 1 H, exch, 
NH) 12.94 (s, 1 H, exch, NH) 14.44 (s, 1 H, exch, HCl). Anal. Calcd. For 
C14H14N4O∙HCl: C, 57.83; H, 5.20; N, 19.27; Cl, 12.19. Found C, 57.73; H, 5.38; N, 
19.05; Cl, 12.07. 
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N-(2,4-Dimethoxyphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (165) 
Compound 165 (synthesized from 238 and 2,4-dimethoxy aniline as described for 161): 
yield 76%; TLC Rf = 0.6 (CH3OH: CHCl3; 1:10); white solid; mp, 262-264 °C; 
1H NMR, 
DMSO-d6: δ 2.5 (s, 3 H, 2-CH3) 3.8 (s, 6 H, OCH3) 6.5 (m, 1 H, Ar) 6.59 (dd, J = 8.7, 2.6 
Hz, 1 H, Ar) 6.7 (d, J = 2.6 Hz, 1 H, Ar) 7.48 (d, J = 8.7 Hz, 1 H, Ar) 7.85 (s, 1 H, Ar) 
10.4 (s, 1 H, exch, NH) 12.65 (s, 1 H, exch, NH) 14.86 (s, 1H, exch, NH). Anal. Calcd. 
for C15H16N4O2∙HCl∙0.2H2O: C, 55.54; H, 5.41; N, 17.27; Cl, 10.93. Found C, 55.74; H, 
5.28; N, 17.21; Cl, 10.85. 
 
4-(5-Methoxyindolin-1-yl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidine (166) 
Compound 166 (synthesized from 238 and 5-methoxyindoline as described for 161): 
yield 72%; TLC Rf = 0.54 (CH3OH: CHCl3; 1:10); grey solid; mp, 310-312 °C; 
1H NMR, 
DMSO-d6: δ 2.71 (s, 3 H, 2-CH3) 3.34 (t, J = 8.16 Hz, 2 H, CH2) 3.79 (s, 3 H, OCH3) 
4.73 (t, J = 8.16 Hz, 2 H, CH2) 6.90 (dd, J = 8.91, 2.64 Hz, 1 H, Ar) 7.03 (d, J = 2.76 Hz, 
1 H, Ar) 7.21 (d, J = 2.26 Hz, 1 H, Ar) 8.53 (d, J = 9.03 Hz, 1 H, Ar) 8.62 (d, J = 2.01 Hz, 
1 H, Ar) 11.05 (s, 1 H, exch, NH) 14.85 (s, 1 H, exch, HCl). Anal. Calcd. for 
C16H16N4O∙HCl∙H2O: C, 57.40; H, 5.72; N, 16.73; Cl, 10.59. Found C, 57.21; H, 5.85; N, 
16.43; Cl, 10.14. 
 
6-Methoxy-1-(2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-1,2,3,4-tetrahydroquinol-
ine (167) 
Compound 167 (synthesized from 238 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): yield 79%; TLC Rf = 0.36 (CH3OH: CHCl3; 1:10); yellow solid; mp, 
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230-232 °C; 1H NMR, DMSO-d6: δ 2.01 (m, 2 H, CH2) 2.63 (s, 3 H, 2-CH3) 2.79 (t, 2 H, 
J = 6.5 Hz, CH2) 3.8 (s, 3 H, OCH3) 4.1 (t, J = 6.3 Hz, 2 H, CH2) 6.53 (dd, J = 8.7, 2.6, 
1H, CH) 6.8 (dd, J = 8.8, 2.9, 1 H, CH) 6.94 (d, J = 2.8 Hz, 1 H, CH) 7.15 (d, J = 8.8 Hz, 
H, CH) 7.65 (t, J = 2.7 Hz, 1 H, CH) 11.05 (s, 1 H, exch, NH) 14.85 (s, 1 H, exch, HCl). 
Anal. Calcd. for C16H18N4O∙HCl∙0.2H2O: C, 59.61; H, 6.06; N, 17.38; Cl, 11.00. Found 
C, 59.82; H, 6.05; N, 17.25; Cl, 10.85. 
 
4-Chloro-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidine (241) 
4-Chloro-2-methyl-5H-pyrrolo[3,2-d]pyrimidine (238, 300 mg, 1.79 mmol) was 
dissolved in dimethylformamide (20mL) and sodium hydride (47 mg, 1.97 mmol) was 
added under nitrogen. The mixture was allowed to stir for 15 minutes after no further 
production of hydrogen gas was observed. Methyl bromide (0.3 mL) was added and the 
reaction was stirred for 3 hours. The reaction was quenched by addition of water and 
ethylacetate was added. The organic layer was collected, washed with brine and dried 
over sodium sulphate. A silica gel plug was made and purified by column 
chromatography (CHCl3: MeOH; 100:1 v/v) to give an off-white solid (244 mg, 75%). 
TLC Rf = 0.45 (CH3OH: CHCl3; 1:10); mp, 156-158 °C; 
1H NMR (400 MHz, DMSO-d6) 
 ppm 2.62 (s, 3 H, CH3) 4.01 (s, 3 H, CH3) 6.6 (m, 1 H, 7-CH) 7.9 (m, 1 H, 6-CH)  
 
N-(4-Methoxyphenyl)-N,2,5-trimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (170) 
Compound 170 (synthesized from 241 and 4-methoxy N-methyl aniline as described for 
161): yield 76%; TLC Rf = 0.55 (CH3OH: CHCl3; 1:10); white solid; mp, 218-220 °C; 
1H 
NMR (400 MHz, DMSO-d6)  ppm 2.69 (s, 3 H, CH3) 2.84 (s, 3 H, CH3) 3.63 (s, 3 H, 
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CH3) 3.79 (s, 3 H, CH3) 6.51 (d, J = 3.26 Hz, 1 H, Ar) 7.00 - 7.03 (m, 2 H, Ar) 7.27 - 
7.31 (m, 2 H, Ar) 7.65 (d, J = 3.26 Hz, 1 H, Ar) 15.11 (s, 1 H, exch, HCl) Anal. Calcd. 
for C16H18N4O∙HCl: C, 60.28; H, 6.01; N, 17.57; Cl, 11.12. Found C, 60.52; H, 5.97; N, 
17.53; Cl, 10.88. 
 
N-(4-methoxyphenyl)-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (171) 
Compound 171 (synthesized from 241 and p-anisidine as described for 161): yield 81%; 
TLC Rf 0.48 (CH3OH: CHCl3; 1:10); white solid; mp, 317-319 °C; 
1H NMR (400 MHz, 
DMSO-d6)  ppm 2.50 (s, 3 H, CH3) 3.80 (s, 3 H, CH3) 4.23 (s, 3 H, CH3) 6.50 (d, J = 
3.01 Hz, 1 H, Ar) 7.00 - 7.04 (m, 2 H, Ar) 7.47 - 7.51 (m, 2 H, Ar) 7.83 (d, J = 3.01 Hz, 1 
H, Ar) 9.52 (s, 1 H, exch, NH) 14.70 (br, 1 H, exch, HCl) Anal. Calcd. for 
C15H16N4O∙HCl: C, 59.11; H, 5.62; N, 18.38; Cl, 11.63. Found C, 59.32; H, 5.68; N, 
18.36; Cl, 11.37. 
 
N-(2,4-dimethoxyphenyl)-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (172) 
Compound 172 (synthesized from 241 and 2,4-dimethoxy aniline as described for 161): 
yield 77%; TLC Rf = 0.4 (CH3OH: CHCl3; 1:10); white solid; mp, 246-248 °C; 
1H NMR, 
DMSO-d6: δ 2.5 (s, 3 H, 2-CH3) 3.8 (s, 6 H, OCH3) 4.23 (s, 3 H, CH3) 6.5 (m, 1 H, Ar) 
6.59 (dd, J = 8.7, 2.6 Hz, 1 H, Ar) 6.7 (d, J = 2.6 Hz, 1 H, Ar) 7.48 (d, J = 8.7 Hz, 1 H, 
Ar) 7.85 (s, 1 H, Ar) 10.4 (s, 1 H, exch, NH) 12.65 (s, 1 H, exch, NH) 14.86 (s, 1H, exch, 
NH). Anal. Calcd. for C16H18N4O2∙HCl: C, 57.40; H, 5.72; N, 16.73; Cl, 10.59. Found C, 
57.31; H, 5.80; N, 16.56; Cl, 10.37. 
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1-(2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroqu-
inoline (173) 
Compound 173 (synthesized from 241 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): yield 77%; TLC Rf = 0.5 (CH3OH: CHCl3; 1:10); yellow solid; mp, 
230-232 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 2.08 (quin, J = 6.59 Hz, 2 H, CH2) 
2.67 (s, 3 H, CH3) 2.86 (t, J = 6.53 Hz, 2 H, CH2) 3.00 (s, 3 H, CH3) 3.76 (s, 3 H, CH3) 
4.03 (t, J = 6.02 Hz, 2 H, CH2) 6.56 (d, J = 3.01 Hz, 1 H, Ar) 6.69 - 6.72 (m, 1 H, Ar) 
6.76 - 6.79 (m, 1 H, Ar) 6.94 (d, J = 2.76 Hz, 1 H, Ar) 7.74 (d, J = 3.01 Hz, 1 H, Ar) 
14.97 (b., 1 H, exch, HCl) Anal. Calcd. for C18H20N4O∙HCl: C, 62.69; H, 6.14; N, 16.25; 
Cl, 10.28. Found C, 62.62; H, 6.09; N, 6.10; Cl, 10.10. 
 
Diethyl 2-((1-cyanoprop-1-en-2-yl)amino)malonate (243) 
To a suspension of an E/Z mixture of 3-aminobut-2-enenitrile 242 (3 g, 35.1 mmol) in 
ethanol (60 mL) was added diethyl aminomalonate hydrochloride (7.9 g, 36.8 mmol). 
The resulting mixture was stirred at room temperature for 6 hours. Most of the solvent 
was removed under vacuum at room temperature and dichloromethane was added and 
washed with brine. The organic layer was separated and dried over sodium sulphate. A 
silica gel plug was made and flash-chromatographed (EtOAc in hexanes 0% to 15%). 
Fractions containing the desired product were pooled and evaporated to afford 6.74 g 
(80%) as an off-white solid. TLC Rf = 0.26 (EtOAc: Hexane; 1:2) mp
105, 50–52 °C; 1H 
NMR (400 MHz, DMSO-d6)  ppm 1.16 - 1.24 (m, 6 H, CH3) 2.05 (s, 3 H, CH3) 3.95 (s, 
1 H, CH) 4.13 - 4.25 (m, 4 H, CH2) 4.95 (s, 1 H, CH) 7.51 - 7.55 (m, 1 H, exch, NH) 
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Ethyl 3-amino-5-methyl-1H-pyrrole-2-carboxylate (244) 
To a stirred solution of diethyl 2-((1-cyanoprop-1-en-2-yl)amino)malonate (244, 1 g, 4 
mmol) in 20 mL of ethanol, a 0.5 M solution of sodium ethoxide in ethanol (120 mL) was 
added slowly and the reaction mixture was stirred for 6 h at 60 °C. The reaction mixture 
was cooled to room temperature and the solvent was evaporated under reduced pressure. 
The crude product was purified by column chromatography on silica gel (EtOAc in 
Hexanes 10%) to afford 450 mg (65%) as an off-white solid. TLC Rf = 0.36 (EtOAc: 
Hexane; 1:1) mp105, 85–87 °C; 1H NMR (DMSO-d6) δ 1.24 (t, J = 6.4 Hz, 3 H, CH3), 
2.03 (s, 3 H, CH3), 4.12 (q, J = 6.4 Hz, 2 H, CH2), 4.91 (s, 2 H, exch, NH2), 5.26 (s, 1 H, 
CH), 10.21 (s, 1 H, exch, NH). 
 
2,6-dimethyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (245)  
Dry hydrogen chloride gas was bubbled through a solution of ethyl 3-amino-5-methyl-
1H-pyrrole-2-carboxylate (244, 500 mg, 7.81 mmol) in acetonitrile (15 mL) at room 
temperature for 15 min. A precipitate was formed, and it dissolved as the reaction 
progressed. Hydrogen chloride gas was bubbled through the solution for an additional 
hour, and the mixture was stirred at room temperature for 8 hours. Most of the solvent 
was evaporated in vacuo, water (40 mL) was added, and the aqueous mixture was 
neutralized with ammonia solution to afford a precipitate that was removed by filtration, 
washed with water and dried in vacuo to afford a white solid. Silica gel (4.5 g) and 
methanol (20 mL) were added; the solvent was evaporated to afford a plug. The silica gel 
plug obtained was loaded onto a silica gel column and eluted with 1% (v/v) CH3OH in 
CHCl3. Fractions containing the product (TLC) were pooled, and the solvent was 
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evaporated to afford 315 mg of 245 (65%). TLC Rf = 0.42 (CH3OH: CHCl3; 1:20); white 
solid; mp 254-256 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 2.26 (s, 3 H, CH3) 2.29 (s, 
3 H, CH3) 5.98 (s, 1 H, 7-CH) 11.62 (br, 1 H, exch, NH) 11.66 (br, 1 H, exch, NH) 
 
4-chloro-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidine (246) 
Compound 246 (synthesized from 245 as described for 238): yield 77%; TLC Rf = 0.7 
(CH3OH: CHCl3; 1:10); brown solid; mp, 230-232 °C; 
1H NMR, DMSO-d6: δ 2.60 (s, 3 
H, CH3) 2.92 (s, 3 H, CH3) 6.6 (m, 1 H, 7-CH) 12.26 (s, 1 H, exch, NH). 
 
N-(4-methoxyphenyl)-N,2,6-trimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (174) 
Compound 174 (synthesized from 246 and 4-methoxy N-methyl aniline as described for 
161): yield 73%; TLC Rf = 0.52 (CH3OH: CHCl3; 1:20); light yellow solid; mp, 229-
230 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 2.38 (s, 3 H, CH3) 2.55 (s, 3 H, CH3) 3.68 
(s, 3 H, CH3) 3.83 (s, 3 H, CH3) 6.33 (d, J = 1.00 Hz, 1 H, Ar) 7.05 - 7.09 (m, 2 H, Ar) 
7.34 - 7.38 (m, 2 H, Ar) 10.29 (br, 1 H, exch, NH) 14.59 (br, 1 H, exch, NH) Anal. Calcd. 
for C16H18N4O∙HCl∙0.2H2O: C, 59.61; H, 6.06; N, 17.38; Cl, 11.00. Found C, 59.82; H, 
6.05; N, 17.25; Cl, 10.85.  
 
4-(5-methoxyindolin-1-yl)-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidine (175) 
Compound 175 (synthesized from 246 and 5-methoxyindoline as described for 161): 
yield 69%; TLC Rf = 0.6 (CH3OH: CHCl3; 1:20); grey solid; mp 308-310 °C; 
1H NMR, 
DMSO-d6: δ 2.71 (s, 3 H, 2-CH3), 2.99 (s, 3 H, 2-CH3), 3.34 (t, J = 8.16 Hz, 2 H, CH2) 
3.79 (s, 3 H, OCH3) 4.73 (t, J = 8.16 Hz, 2 H, CH2) 6.90 (dd, J = 8.91, 2.64 Hz, 1 H, Ar) 
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7.03 (d, J = 2.76 Hz, 1 H, Ar) 7.21 (d, J = 2.26 Hz, 1 H, Ar) 8.53 (d, J = 9.03 Hz, 1 H, Ar) 
11.05 (s, 1 H, exch, NH) 14.85 (s, 1 H, exch, HCl). Anal. Calcd. for C17H18N4O∙HCl∙H2O: 
C, 58.53; H, 6.07; N, 16.06; Cl, 10.16. Found C, 58.76; H, 6.06; N, 16.00; Cl, 10.01.  
 
1-(2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroqui-
noline (176) 
Compound 176 (synthesized from 246 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): yield 66%; TLC Rf = 0.6 (CH3OH: CHCl3; 1:20); yellow solid; mp, 
141-143 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 1.97 - 2.06 (m, 2 H, CH2) 2.42 (s, 3 
H, CH3) 2.58 (s, 3 H, CH3) 2.81 (t, J = 6.40 Hz, 2 H, CH2) 3.79 (s, 3 H, CH3) 4.12 (t, J = 
6.27 Hz, 2 H, CH2) 6.36 (s, 1 H, Ar) 6.76 (dd, J = 8.78, 2.76 Hz, 1 H, Ar) 6.91 (d, J = 
2.51 Hz, 1 H, Ar) 7.11 (d, J = 9.03 Hz, 1 H, Ar) 11.20 (br, 1 H, exch, NH) 14.60 (s, 1 H, 
exch, HCl) Anal. Calcd. for C18H20N4O∙HCl∙H2O: C, 59.58; H, 6.39; N, 15.44; Cl, 9.77. 
Found C, 59.89; H, 6.39; N, 15.14; Cl, 9.44.  
 
Ethyl 2-((2-cyanophenyl)amino)acetate (104) 
Ethyl bromoacetate (1.95 mL, 20 mmol) was added dropwise to a stirred solution of 2-
anthranilonitrile (103, 2.38 g, 20 mmol) and potassium carbonate (2.78 g, 20.1 mmol) in 
ethanol (100 mL) at room temperature and heated to reflux for 6h. Most of the solvent 
was removed in vacuo and a silica gel plug was made. Flash chromatography with EtOAc: 
Hex 0% to 10 % afforded 3.82 g (98%) of brown solid.  TLC Rf = 0.36 (EtOAc: Hexane; 
1:1) mp113, 105–107 °C; 1H NMR (500 MHz, DMSO-d6)  ppm 1.21 (t, J = 7.07 Hz, 3 H, 
CH3) 4.05 (d, J = 5.97 Hz, 2 H, CH2) 4.14 (q, J = 6.92 Hz, 2 H, CH2) 6.34 (t, J = 6.13 Hz, 
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1 H, exch, NH) 6.65 (d, J = 8.49 Hz, 1 H, CH) 6.68 - 6.73 (m, 1 H, CH) 7.39 - 7.44 (m, 1 
H, CH) 7.50 (dd, J = 7.70, 1.41 Hz, 1 H, CH) 
 
Ethyl 3-amino-1H-indole-2-carboxylate (105) 
Ethyl 2-((2-cyanophenyl)amino)acetate (104, 3.8 g, 19 mmol) was added dropwise to a 
stirred solution of potassium tert-butoxide (2.78 g, 20.1 mmol) in tetrahydrofuran (100 
mL) at room temperature and stirred for 6h. Most of the solvent was removed in vacuo 
and a silica gel plug was made. Flash chromatography with EtOAc: Hexanes 0% to 10 % 
afforded 3 g (73%) of brown semisolid.  TLC Rf = 0.5 (EtOAc: Hexanes; 1:1) 1H NMR 
(500 MHz, DMSO-d6)  ppm 1.34 (t, J = 7.07 Hz, 3 H, CH3) 4.30 (q, J = 6.92 Hz, 2 H, 
CH2) 5.67 (s, 2 H, exch, NH2) 6.89 (dd, J = 8.10, 6.05 Hz, 1 H, CH) 7.18 - 7.23 (m, 2 H, 
CH) 7.74 (d, J = 8.17 Hz, 1 H, CH) 10.33 (s, 1 H, exch, NH) 
 
2-Methyl-3H-pyrimido[5,4-b]indol-4(5H)-one (248) 
Compound 248 (synthesized from 105 as described for 245): yield 72%; TLC Rf = 0.6 
(MeOH: CHCl3; 1:20); white solid; mp, 200-202 °C; 
1H NMR (400 MHz, DMSO-d6)  
ppm 2.43 (s, 3 H, CH3) 7.16 - 7.22 (m, 1 H, CH) 7.40 - 7.45 (m, 1 H, CH) 7.47 - 7.52 (m, 
1 H, CH) 7.96 (d, J = 8.03 Hz, 1 H, CH) 11.90 (s, 1 H, exch, NH) 12.27 (br, 1 H, exch, 
NH) 
 
4-Chloro-2-methyl-5H-pyrimido[5,4-b]indole (249) 
Compound 249 (synthesized from 248 as described for 238): yield 81%; TLC Rf = 0.7 
(CH3OH: CHCl3; 1:20); white solid; mp, 212-214 °C; 
1H NMR (400 MHz, DMSO-d6)  
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ppm 2.68 (s, 3 H, CH3) 7.28 - 7.41 (m, 1 H, CH) 7.48 - 7.50 (m, 1 H, CH) 7.52 - 7.57 (m, 
1 H, CH) 8.11 (d, J = 8.03 Hz, 1 H, CH) 12.35 (br, 1 H, exch, NH) 
 
N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrimido[5,4-b]indol-4-amine (178) 
Compound 178 (synthesized from 249 and 4-methoxy N-methyl aniline as described for 
161): yield 75%; TLC Rf = 0.46 (CH3OH: CHCl3; 1:20); grey solid; mp, 283-285 °C; 
1H 
NMR (400 MHz, DMSO-d6)  ppm 2.79 (s, 3 H, CH3) 3.74 (s, 3 H, CH3) 3.87 (s, 3 H, 
CH3) 7.12 (d, J = 8.78 Hz, 2 H, Ar) 7.34 (t, J = 6.90 Hz, 1 H, Ar) 7.46 (d, J = 8.53 Hz, 2 
H, Ar) 7.55 - 7.62 (m, 1 H, Ar) 7.63 - 7.69 (m, 1 H, Ar) 8.40 (d, J = 8.28 Hz, 1 H, Ar) 
9.76 - 10.11 (s, 1 H, exch, NH) 15.67 (br, 1 H, exch, HCl) Anal. Calcd. for 
C15H17N3O2∙HCl∙0.5H2O: C, 61.27; H, 6.47; N, 16.81; Cl, 10.64. Found C, 60.89; H, 6.31; 
N, 16.58; Cl, 10.32.  
 
4-(5-methoxyindolin-1-yl)-2-methyl-5H-pyrimido[5,4-b]indole (179) 
Compound 179 (synthesized from 249 and 5-methoxyindoline as described for 161): 
yield 71%; TLC Rf = 0.53 (CH3OH: CHCl3; 1:20); grey solid; mp, 328-330 °C; 
1H NMR 
(500 MHz, DMSO-d6)  ppm 2.74 (s, 3 H, CH3) 3.72 (s, 3 H, CH3) 3.86 (s, 3 H, CH3) 
7.07 - 7.11 (m, 2 H, Ar) 7.46 (d, J = 8.80 Hz, 2 H, Ar) 7.55 (t, J = 7.55 Hz, 2 H, Ar) 7.67 
- 7.74 (m, 1 H, Ar) 8.33 (d, J = 7.86 Hz, 1 H, Ar) Anal. Calcd. for 
C17H17N3O2∙HCl∙0.05H2O: C, 63.97; H, 5.11; N, 11.78; Cl, 9.94. Found C, 64.13; H, 5.12; 
N, 11.66; Cl, 9.81. 
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4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methyl-5H-pyrimido[5,4-b]indole 
(180) 
Compound 180 (synthesized from 249 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): yield 78%; TLC Rf = 0.56 (CH3OH: CHCl3; 1:20); yellow solid; mp, 
275-276 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 2.08 (m, 2 H, CH2) 2.72 - 2.95 (m, 5 
H, CH3, CH2) 3.82 (s, 3 H, CH3) 4.21 (m, 2 H, CH2) 6.79 (m, 1 H, Ar) 6.99 (m, 1 H, Ar) 
7.11 (d, J = 7.03 Hz, 1 H, Ar) 7.35 (m, 1 H, Ar) 7.63 (m, 2 H, Ar) 8.47 (m, 1 H, Ar) 
10.85 (br, 1 H, exch, NH) 15.96 (br, 1 H, exch, HCl) Anal. Calcd. for 
C21H20N4O∙HCl∙0.3H2O: C, 65.30; H, 5.64; N, 14.50; Cl, 9.18. Found C, 65.37; H, 5.50; 
N, 14.48; Cl, 9.06. 
 
2-methylfuro[3,2-d]pyrimidin-4(3H)-one (251) 
Compound 251 (synthesized from 250 as described for 245): yield 83%; TLC Rf = 0.55 
(CH3OH: CHCl3; 1:20); white solid; mp, 180-182 °C; 
1H NMR (500 MHz, DMSO-d6)  
ppm 2.34 (s, 3 H, CH3) 6.88 (d, J = 2.20 Hz, 1 H, CH) 8.17 (d, J = 2.20 Hz, 1 H, CH) 
12.42 (s, 1 H, exch, NH) 
 
4-chloro-2-methylfuro[3,2-d]pyrimidine (252) 
Compound 252 (synthesized from 251 as described for 238): yield 72%; TLC Rf = 0.7 
(MeOH: CHCl3; 1:50); white solid; mp, 198-200 °C; 
1H NMR (400 MHz, DMSO-d6)  
ppm 2.68 (s, 3 H, CH3) 7.27 (d, J = 2.26 Hz, 1 H, CH) 8.60 - 8.61 (m, 1 H, CH) 
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N-(4-methoxyphenyl)-N,2-dimethylfuro[3,2-d]pyrimidin-4-amine (181) 
Compound 181 (synthesized from 252 and 4-methoxy N-methyl aniline as described for 
161): yield 76%; TLC Rf = 0.7 (MeOH: CHCl3; 1:25); white solid; mp 241-243 °C; 
1H 
NMR (500 MHz, DMSO-d6)  ppm 2.65 (s, 3 H, CH3) 3.66 (s, 3 H, CH3) 3.82 (s, 3 H, 
CH3) 7.05 - 7.09 (m, 3 H, Ar) 7.41 - 7.45 (m, 2 H, Ar) 8.24 (m, 1 H, Ar) Anal. Calcd. for 
C15H15N3O2∙HCl: C, 58.92; H, 5.27; N, 13.74; Cl, 11.59. Found C, 58.93; H, 5.35; N, 
13.73; Cl, 11.38. 
 
N-(4-methoxyphenyl)-2-methylfuro[3,2-d]pyrimidin-4-amine (182) 
Compound 182 (synthesized from 252 and p-anisidine as described for 161): yield 80%; 
TLC Rf = 0.7 (CH3OH: CHCl3; 1:25); white solid; mp, 265-267 °C; 
1H NMR (400 MHz, 
DMSO-d6)  ppm 2.62 (s, 3 H, CH3) 3.79 (s, 3 H, OCH3) 7.00 - 7.04 (m, 2 H, Ar) 7.20 
(d, J = 2.26 Hz, 1 H, Ar) 7.64 (d, J = 7.78 Hz, 2 H, Ar) 8.57 (s, 1 H, Ar) 11.21 (br, 1 H, 
exch, NH) Anal. Calcd. for C15H15N3O2∙HCl: C, 58.92; H, 5.27; N, 13.74; Cl, 11.59. 
Found C, 58.93; H, 5.35; N, 13.73; Cl, 11.38. 
 
N-(2,4-dimethoxyphenyl)-2-methylfuro[3,2-d]pyrimidin-4-amine (183) 
Compound 183 (synthesized from 252 and 2,4-dimethoxy aniline as described for 161): 
yield 78%; TLC Rf = 0.7 (CH3OH: CHCl3; 1:25); white solid; mp, 247-249 °C; 
1H NMR 
(400 MHz, DMSO-d6)  ppm 2.57 (s, 3 H, CH3) 3.74 (s, 3 H, OCH3) 3.82 (s, 3 H, OCH3) 
6.60 (dd, J = 8.53, 2.51 Hz, 1 H, Ar) 6.73 (d, J = 2.51 Hz, 1 H, Ar) 7.15 (s, 1 H, Ar) 7.31 
(d, J = 8.78 Hz, 1 H, Ar) 8.47 (m, 1 H, Ar) 10.83 (br, 1 H, exch, NH ) Anal. Calcd. for 
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C15H15N3O3∙HCl: C, 55.99; H, 5.01; N, 13.06; Cl, 11.02. Found C, 56.14; H, 5.22; N, 
12.85; Cl, 10.80. 
 
4-(5-methoxyindolin-1-yl)-2-methylfuro[3,2-d]pyrimidine (184) 
Compound 184 (synthesized from 252 and 5-methoxyindoline as described for 161): 
yield 78%; TLC Rf = 0.7 (CH3OH: CHCl3; 1:25); grey solid; mp 297-299 °C; 
1H NMR 
(400 MHz, DMSO-d6)  ppm 2.71 (s, 3 H, CH3) 3.34 (t, J = 8.16 Hz, 2 H, CH2) 3.79 (s, 3 
H, OCH3) 4.73 (t, J = 8.16 Hz, 2 H, CH2) 6.90 (dd, J = 8.91, 2.64 Hz, 1 H, Ar) 7.03 (d, J 
= 2.76 Hz, 1 H, Ar) 7.21 (d, J = 2.26 Hz, 1 H, Ar) 8.53 (d, J = 9.03 Hz, 1 H, Ar) 8.62 (d, 
J = 2.01 Hz, 1 H, Ar) Anal. Calcd. for C16H15N3O2.HCl: C, 60.48; H, 5.07; N, 13.22; Cl, 
11.16. Found C, 60.47; H, 5.16; N, 13.17; Cl, 11.02. 
 
4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylfuro[3,2-d]pyrimidine (185) 
Compound 185 (synthesized from 252 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): yield 75%; TLC Rf = 0.66 (CH3OH: CHCl3; 1:25); yellow solid; mp 
213-215 °C; 
1H NMR (400 MHz, DMSO-d6)  ppm 2.03 (quin, J = 6.40 Hz, 2 H, CH2) 2.64 (s, 3 H, 
CH3) 2.80 (t, J = 6.65 Hz, 2 H, CH2) 3.79 (s, 3 H, CH3) 4.20 (m, 2 H, CH2) 6.82 (dd, J = 
9.03, 2.76 Hz, 1 H, Ar) 6.88 - 6.92 (m, 1 H, Ar) 7.15 (d, J = 2.01 Hz, 1 H, Ar) 7.35 (d, J 
= 9.03 Hz, 1 H, Ar) 8.40 (m., 1 H, Ar) Anal. Calcd. for C17H17N3O2.HCl: C, 60.48; H, 
5.07; N, 13.22; Cl, 11.16. Found C, 60.47; H, 5.16; N, 13.17; Cl, 11.02. 
 
 
  
121 
 
methyl 3-amino-4-benzyl-1H-pyrrole-2-carboxylate (259) 
Benzaldehyde (253, 20 g, 0.25 mol) and 3,3-dimethoxypropionitrile (254, 35 g, 0.30 mol) 
were mixed together and added to a solution of sodium ethoxide in ethanol (0.5 M) 
during 15 min. The mixture was stirred at room temperature for 6 hours. Most of the 
solvent was removed in vacuo, and the residue was partitioned between EtOAc (500 mL) 
and water (450 mL). The organic layer was separated, washed with brine, dried with 
sodium sulphate and the solvent evaporated in vacuo. The residual oil (255) was treated 
cautiously with 6 N HCl (75 mL), and the mixture was stirred at room temperature for 2 
hours. The solid was filtered off, washed well with water, and dried in vacuuo to give an 
off-white powder (256) which was shaken with methanol and 10% Pd/C under 50 psi H2 
in a hydrogenation bottle for 1 hour. The catalyst was removed by filtration, a mixture of 
diethyl aminomalonate, sodium acetate, and water was added, and the mixture was stirred 
at room temperature for 16 hours. Most of the solvent was removed in vacuo, and the 
residue was partitioned between EtOAc and water. The organic layer was separated and 
dried over sodium sulphate and evaporated in vacuo. The residual yellow oil (258) was 
dissolved in methanol containing sodium methoxide, stirred at room temperature for 12 
hours and then heated to reflux for 3 hours. Most of the solvent was evaporated in vacuo, 
and the residue was treated with water (200 mL) to give 259 as a light yellow solid which 
was flash chromatographed with 1% (v/v) CH3OH in CHCl3. mp
103 120-122 °C; 1H NMR 
(400 MHz, DMSO-d6)  ppm 3.62 (s, 2 H, CH2) 3.68 (s, 3 H, CH3) 4.84 (br, 2 H, exch, 
NH2) 6.46 (d, J = 3.51 Hz, 1 H, 6-H) 7.11 - 7.16 (m, 1 H, C6H5) 7.19 - 7.27 (m, 4 H, 
C6H5) 10.47 (br, 1 H, exch, NH) 
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7-Benzyl-2-methyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one [260]  
To a 250 mL flask was added 259 (1.5g, 6.51 mmol) and acetonitrile (30 mL). Dry HCl 
gas was bubbled through the solution at room temperature for 15 min. A precipitate was 
formed, and it dissolved as the reaction progressed. HCl gas was bubbled through the 
solution for an additional hour, and the mixture was stirred for 3 h. Most of the solvent 
was evaporated in vacuo, water (20 mL) was added, and the aqueous mixture was 
neutralized with ammonia to afford a precipitate that was removed by filtration, washed 
with water and dried in vacuo to afford a light yellow solid. Silica gel and methanol were 
added; the solvent was evaporated to afford a plug. The silica gel plug obtained was 
loaded onto a silica gel column and eluted with 1% (v/v) MeOH/CHCl3. Fractions 
containing the product (TLC) were pooled, and the solvent was evaporated to afford 259 
(1.12 g, 59%). TLC Rf = 0.42 (CH3OH: CHCl3; 1:20); white solid; mp, 254-256 °C; 
1H 
NMR, DMSO-d6: δ 2.29 (s, 3 H, 2-CH3) 3.90 (s, 2 H, CH2) 7.07(d, J = 2.90 Hz, 1 H, Ar) 
7.10 – 7.15, (m, 1 H, Ar) 7.21 – 7.24, (m, 4 H, Ar) 12.086 (s, 1H, exch, NH) Anal. Calcd. 
for C14H13N3O . 0.1 H2O: C, 69.75; H, 5.52; N, 17.43. Found C, 69.81; H, 5.52; N, 17.44.  
 
7-Benzyl-4-chloro-2-methyl-5H-pyrrolo[3,2-d]pyrimidine [261] 
Compound 260 (1.5 g, 6.27 mmol) was added to POCl3 (12 mL) and heated at reflux for 
3 h. The solvent was evaporated in vacuo, and the residue was adjusted to pH 8 with an 
ammonia solution. The resulting precipitate was removed by filtration, washed with 
water and dried in vacuo over P2O5 to afford a light yellow solid. Silica gel (4.5 g) and 
methanol (20 mL) were added; the solvent was evaporated to afford a plug. The silica gel 
plug obtained was loaded onto a silica gel column and eluted with 1% (v/v) CH3OH 
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/CHCl3. Fractions containing the product (TLC) were pooled, and the solvent was 
evaporated to afford 260 (1.41 g, 87%). TLC Rf =0.56 (CH3OH: CHCl3; 1:20); white 
solid; mp 181-183 °C; 1H NMR, DMSO-d6: δ 2.61 (s, 3 H, 2-CH3) 4.04 (s, 2 H, CH2) 
7.13 – 7.28 (m, 5 H, Ar) 7.68 (d, J = 2.72 Hz, 1 H, CH) 12.086 (s, 1H, exch, 5-NH) Anal. 
Calcd. for C14H12N3Cl : C, 65.25; H, 4.69; N, 16.30. Found C, 65.23; H, 4.70; N, 16.31. 
 
7-benzyl-N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(187)  
Compound 261 (0.1 g, 0.39 mmol) and 4-methoxyphenylamine (64 mg, 0.47 mmol) were 
dissolved in isopropanol (15 mL) and heated at reflux for 3 h, after which the solvent was 
evaporated in vacuo. Silica gel (0.3 g) and methanol (7 mL) were added; the solvent was 
evaporated to afford a plug. The silica gel plug obtained was loaded onto a silica gel 
column and eluted with 1% (v/v) CH3OH /CHCl3. Fractions containing the product (TLC) 
were pooled, and the solvent was evaporated to afford 187 (114 mg, 82%). TLC Rf 0.48 
(CH3OH: CHCl3; 1:10). The product obtained was dissolved in a minimum amount of 
ethyl acetate, and diethyl ether (10 mL) was added to the solution. Hydrogen chloride gas 
was bubbled through for 2-3 min. The precipitate obtained was collected by filtration and 
washed with diethyl ether to afford 187∙HCl.; white solid; mp, 223-225 °C; 1H NMR 
(DMSO-d6): δ 2.66 (s, 3 H, 2-CH3) 3.6 (s, 3 H, NCH3) 3.82 (s, 3 H, OCH3) 4.08 (s, 2 H, 
CH2) 7.08 (d, 2 H, J = 8.84 Hz, Ar) 7.17 – 7.26 (m, 6 H, Ar and 6-CH) 7.4 (d, 2 H, J = 
8.73, Ar) 9.41 (br, 1H, exch, NH) 14.43 (s, 1H, exch, HCl). Anal. Calcd. for 
C22H22N4O·HCl : C, 66.91; H, 5.87; N, 14.19; Cl, 8.98. Found C, 66.65; H, 5.90; N, 
13.90; Cl, 9.02. 
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7-benzyl-N,2-dimethyl-N-phenyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (188) 
Compound 188 (synthesized from 261 and N-methyl aniline as described for 187): yield 
= 69%; TLC Rf = 0.5 (CH3OH: CHCl3; 1:10). white solid; mp, 225-227 °C; 
1H NMR 
(DMSO-d6): δ 2.63 (s, 3 H, 2-CH3) 3.64 (s, 3 H, NCH3) 4.07 (s, 2 H, CH2) 7.14 – 7.26 (m, 
6 H, Ar and 6-CH) 7.41 – 7.54, (m, 5 H, Ar) 9.63 (s, 1H, exch, NH) 14.52 (s, 1H, exch, 
HCl). Anal. Calcd. for C21H20N4O· 0.9HCl : C, 69.82; H, 5.83; N, 15.51; Cl, 8.83. Found 
C, 69.90; H, 5.76; N, 15.38; Cl, 8.68. 
 
7-benzyl-N-(4-methoxyphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (189) 
Compound 189 (synthesized from 261 and p-anisidine as described for 187): yield = 
76% ; white solid; mp 296-298 °C; 1H NMR (DMSO-d6): δ 2.65 (s, 3 H, 2-CH3) 3.77 (s, 
3 H, OCH3) 4.11 (s, 2 H, CH2) 7.00 (d, 2 H, J = 9.02 Hz, Ar) 7.17 – 7.31, (m, 5 H, Ar) 
7.67 (d, 1 H, J = 2.52 Hz, Ar) 7.79 (d, 2 H, J = 8.80 Hz, Ar) 11.31(s, 1 H, exch, 4-NH) 
12.72 (br, 1 H, exch, NH) 14.34 (s, 1 H, exch, HCl). Anal. Calcd. for C21H20N4O·HCl : C, 
66.22; H, 5.56; N, 14.71; Cl, 9.31. Found C, 66.09; H, 5.52; N, 14.60; Cl, 9.24. 
 
7-benzyl-N-(2,4-dimethoxyphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(190) 
Compound 190 (synthesized from 261 and 2,4-dimethoxy aniline as described for 187): 
yield = 82%; yellow solid; mp, 191-193 °C; 1H NMR (DMSO-d6): δ 2.55 (s, 3 H, 2-CH3) 
3.80 (s, 6 H, OCH3) 4.12 (s, 2 H, CH2) 6.59 (d, 1 H, J = 8.58 Hz, Ar) 6.71 (d, 1 H, J = 
2.52 Hz, Ar) 7.17 – 7.30, (m, 5 H, Ar) 7.50 (d, 1 H, J = 8.50 Hz, Ar) 7.62 (s, 1 H, Ar) 
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10.30(s, 1H, exch, NH) 12.46 (s, 1H, exch, NH). Anal. Calcd. for C22H22N4O2·HCl·H2O: 
C, 62.93; H, 5.76; N, 13.34; Cl, 8.44. Found C, 63.12; H, 5.69; N, 13.29; Cl, 8.45. 
 
5-ethyl-N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(191) 
N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (161, 100 mg, 
0.373 mmol) was dissolved in dimethylformamide (6 mL) and sodium hydride (10.73 mg, 
0.447 mmol) was added under nitrogen. The mixture was allowed to stir for 15 minutes 
after no further production of hydrogen gas was observed. Ethyl iodide (0.1 mL) was 
added and the reaction was stirred for 3 hours. The reaction was quenched by addition of 
water and ethylacetate was added. The organic layer was collected, washed with brine 
and dried over sodium sulphate. A silica gel plug was made and purified by column 
chromatography (CHCl3: CH3OH; 100:1 v/v) to give an off-white solid (726 mg, 75%). 
TLC Rf 0.42 (CH3OH: CHCl3; 1:20); mp, 145-147 °C; 
1H NMR (400 MHz, DMSO-d6)  
ppm 1.30 - 1.42 (m, 3 H, CH3) 2.69 (s, 3 H, CH3) 2.87 (q, J = 7.15 Hz, 2 H, CH2) 3.64 (s, 
3 H, CH3) 3.79 (s, 3 H, CH3) 6.54 (d, J = 3.26 Hz, 1 H, Ar) 7.01 (d, J = 9.03 Hz, 2 H, Ar) 
7.29 (d, J = 9.03 Hz, 2 H, Ar) 7.75 (d, J = 3.26 Hz, 1 H, Ar) 15.11 (br, 1 H, exch, NH) 
Anal. Calcd. for C17H20N4O: C, 68.89; H, 6.80; N, 18.90. Found C, 68.78; H, 6.05; N, 
18.59. 
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5-isopropyl-N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-
amine (192) 
Compound 192 (synthesized from 161 and iso-propyl bromide as described for 191): 
yield = 78%; TLC Rf 0.51 (CH3OH: CHCl3; 1:20); grey solid; mp, 244-246 °C;
 1H NMR 
(400 MHz, DMSO-d6)  ppm 0.99 (d, J = 7.28 Hz, 6 H, CH3) 2.69 (s, 3 H, CH3) 2.87 (m, 
1 H, CH) 3.64 (s, 3 H, CH3) 3.79 (s, 3 H, CH3) 6.54 (d, J = 3.26 Hz, 1 H, Ar) 7.01 (d, J = 
9.03 Hz, 2 H, Ar) 7.29 (d, J = 9.03 Hz, 2 H, Ar) 7.75 (d, J = 3.26 Hz, 1 H, Ar) 15.11 (br, 
1 H, exch, NH) Anal. Calcd. for C18H22N4O∙HCl: C, 62.33; H, 6.68; N, 16.15; Cl, 10.22. 
Found C, 62.19; H, 6.69; N, 16.00; Cl, 10.13. 
 
N-(4-methoxyphenyl)-N,2-dimethyl-5-propyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(193) 
Compound 193 (synthesized from 161 and n-propyl bromide as described for 191): yield 
= 83%; TLC Rf = 0.5 (CH3OH: CHCl3; 1:20); light yellow solid; mp, 214-216 °C; 
1H 
NMR (400 MHz, DMSO-d6)  ppm 1.41 - 1.47 (m, 2 H, CH3) 2.69 (s, 3 H, CH3) 2.87 (t, 
J = 7.15 Hz, 2 H, CH2) 3.64 (s, 3 H, CH3) 3.79 (s, 3 H, CH3) 6.54 (d, J = 3.26 Hz, 1 H, 
Ar) 7.01 (d, J = 9.03 Hz, 2 H, Ar) 7.29 (d, J = 9.03 Hz, 2 H, Ar) 7.75 (d, J = 3.26 Hz, 1 H, 
Ar) 15.11 (br, 1 H, exch, NH) Anal. Calcd. for C18H22N4O∙HCl: C, 62.33; H, 6.68; N, 
16.15; Cl, 10.22. Found C, 62.17; H, 6.70; N, 15.98; Cl, 10.12. 
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5-isobutyl-N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(194) 
Compound 194 (synthesized from 161 and iso-butyl bromide as described for 191): yield 
= 80%; TLC Rf 0.55 (CH3OH: CHCl3; 1:20); white solid; mp, 260-261 °C; 
1H NMR (400 
MHz, DMSO-d6)  ppm 0.47 (t, J = 7.28 Hz, 3 H, CH3) 1.30 - 1.42 (m, 2 H, CH2) 2.69 (s, 
3 H, CH3) 2.87 (t, J = 7.15 Hz, 2 H, CH2) 3.64 (s, 3 H, CH3) 3.79 (s, 3 H, CH3) 6.54 (d, J 
= 3.26 Hz, 1 H, Ar) 7.01 (d, J = 9.03 Hz, 2 H, Ar) 7.29 (d, J = 9.03 Hz, 2 H, Ar) 7.75 (d, 
J = 3.26 Hz, 1 H, Ar) 15.11 (br, 1 H, exch, NH) Anal. Calcd. for C19H24N4O∙HCl: C, 
63.23; H, 6.98; N, 15.52; Cl, 9.82. Found C, 63.20; H, 7.01; N, 15.39; Cl, 9.65. 
 
5-butyl-N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(195) 
Compound 195 (synthesized from 161 and n-butyl bromide as described for 191): yield = 
77%; TLC Rf =0.6 (CH3OH: CHCl3; 1:20); white solid; mp, 229-230 °C; 
1H NMR (400 
MHz, DMSO-d6)  ppm 0.69 - 0.75 (m, 3 H, CH3) 0.76 - 0.85 (m, 2 H, CH2) 1.25 - 1.34 
(m, 2 H, CH2) 2.69 (s, 3 H, CH3) 2.94 (t, J = 7.15 Hz, 2 H, CH2) 3.65 (s, 3 H, CH3) 3.79 
(s, 3 H, CH3) 6.54 (d, J = 3.01 Hz, 1 H, Ar) 7.01 (d, J = 9.03 Hz, 2 H, Ar) 7.28 (d, J = 
9.03 Hz, 2 H, Ar) 7.76 (d, J = 3.26 Hz, 1 H, Ar) Anal. Calcd. for C19H24N4O∙HCl: C, 
63.24; H, 6.98; N, 15.52; Cl, 9.82. Found C, 63.29; H, 6.91; N, 15.50; Cl, 9.66. 
 
N-(4-methoxyphenyl)-N,2-dimethyl-6,7-dihydrofuro[3,2-d]pyrimidin-4-amine (196) 
To the solution of N-(4-methoxyphenyl)-N,2-dimethylfuro[3,2-d]pyrimidin-4-amine (181, 
150 mg, 0.557 mmol) in methanol (10 mL) was added palladium hydroxide (45%) on 
  
128 
 
carbon (50 mg). The resulted suspension was hydrogenated (50 psi) in a Parr apparatus at 
room temperature for 24 hours after which the suspension was filtered through a layer of 
celite and washed with methanol (40 mL). The filtrate was evaporated in vacuo and a 
silica gel plug was made. Column chromatography with 10% EtOAc in hexane afforded 
126 mg (84%) as a white solid. TLC Rf = 0.30 (EtOAc/hexane, 1:2); mp, 201-203 °C; 
1H 
NMR (400 MHz, DMSO-d6)  ppm 2.54 (s, 3 H, CH3) 3.29 (t, J = 9.29 Hz, 2 H, CH2) 
3.53 (s, 3 H, CH3) 3.79 (s, 3 H, CH3) 4.43 (t, J = 9.03 Hz, 2 H, CH2) 6.94 - 6.97 (m, 2 H, 
Ar) 7.24 - 7.27 (m, 2 H, Ar) Anal. Calcd. for C15H17N3O2∙HCl∙0.5H2O: C, 56.87; H, 6.05; 
N, 13.26; Cl, 11.19. Found C, 56.94; H, 6.06; N, 13.14; Cl, 11.03. 
  
4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methyl-6,7-dihydrofuro[3,2-
d]pyrimidine (197) 
Compound 197 (synthesized from 185 as described for 196): yield = 92%; TLC Rf = 0.35 
(ethyl acetate/hexane, 1:2); white solid; mp 110-112 °C; 1H NMR (400 MHz, DMSO-d6) 
 ppm 1.87 (quin, J = 6.34 Hz, 2 H, CH2) 2.38 (s, 3 H, CH3) 2.73 (t, J = 6.65 Hz, 2 H, 
CH2) 3.13 (t, J = 9.03 Hz, 2 H, CH2) 3.71 (s, 3 H, CH3) 3.79 - 3.83 (m, 2 H, CH2) 4.47 (t, 
J = 9.03 Hz, 2 H, CH2) 6.62 - 6.66 (m, 1 H, Ar) 6.69 (d, J = 3.01 Hz, 1 H, Ar) 6.74 (d, J = 
8.78 Hz, 1 H, Ar) Anal. Calcd. for C17H19N3O2: C, 68.67; H, 6.44; N, 14.13. Found C, 
68.51; H, 6.50; N, 14.01.  
 
N-ethyl-N-(4-methoxyphenyl)-2-methylfuro[3,2-d]pyrimidin-4-amine (198) 
Compound 198 (synthesized from 182 and ethyl iodide as described for 191): yield = 
92%; TLC Rf = 0.4 (EtOAc/hexane, 1:2); yellow solid; mp, 95-97 °C; 
1H NMR (400 
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MHz, DMSO-d6)  ppm 1.16 (t, J = 7.03 Hz, 3 H, CH3) 2.49 (s, 3 H, CH3) 3.81 (s, 3 H, 
CH3) 4.02 (q, J = 7.03 Hz, 2 H, CH2) 6.79 (d, J = 2.26 Hz, 1 H, Ar) 6.97 - 7.02 (m, 2 H, 
Ar) 7.24 - 7.30 (m, 2 H, Ar) 7.91 (d, J = 2.01 Hz, 1 H, Ar) Anal. Calcd. for 
C16H17N3O2·0.25H2O: C, 66.77; H, 6.13; N, 14.60. Found C, 66.91; H, 5.99; N, 14.47. 
 
N-isopropyl-N-(4-methoxyphenyl)-2-methylfuro[3,2-d]pyrimidin-4-amine (199) 
Compound 199 (synthesized from 182 and iso-propyl iodide as described for 191): yield 
= 73%; TLC Rf = 0.5 (EtOAc/hexane, 1:2); white solid; mp, 154-156 °C; 
1H NMR (400 
MHz, DMSO-d6)  ppm 1.12 (d, J = 6.78 Hz, 6 H, CH3) 2.50 (s, 3 H, CH3) 3.82 (s, 3 H, 
OCH3) 5.37 (dt, J = 13.24, 6.56 Hz, 1 H, CH) 6.78 (d, J = 2.26 Hz, 1 H, Ar) 7.01 (d, J = 
9.03 Hz, 2 H, Ar) 7.23 (d, J = 8.78 Hz, 2 H, Ar) 7.86 (d, J = 2.01 Hz, 1 H, Ar) Anal. 
Calcd. for C17H19N3O2: C, 68.67; H, 6.44; N, 14.13. Found C, 68.40; H, 6.50; N, 14.47. 
 
N-(4-methoxyphenyl)-2-methyl-N-propylfuro[3,2-d]pyrimidin-4-amine (200) 
Compound 200 (synthesized from 182 and n-propyl iodide as described for 191): yield = 
90%; TLC Rf = 0.55 (EtOAc/hexane, 1:2); white solid; mp, 110-112 °C; 
1H NMR (400 
MHz, DMSO-d6)  ppm 0.89 (t, 3 H, CH3) 1.56 - 1.63 (m, 2 H, CH2) 2.46 (s, 3 H, CH3) 
3.80 (s, 3 H, CH3) 3.92 - 3.97 (m, 2 H, CH2) 6.77 (d, J = 2.26 Hz, 1 H, Ar) 6.99 (d, J = 
8.78 Hz, 2 H, Ar) 7.27 (d, J = 9.03 Hz, 2 H, Ar) 7.89 - 7.90 (m, 1 H, Ar) Anal. Calcd. for 
C17H19N3O2·0.1C6H14: 69.09; H, 6.72; N, 13.73. Found C, 69.09; H, 6.67; N, 13.66. 
 
Ethyl 2-(2-cyanophenoxy)acetate (262) 
Ethyl bromoacetate (1.95 mL, 20 mmol) was added dropwise to a stirred solution of 2-
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hydroxy benzonitrile (144, 2.38 g, 20 mmol) and potassium carbonate (2.78 g, 20.1 mmol) 
in ethanol (100 mL) at room temperature and heated to reflux for 6h. Most of the solvent 
was removed in vacuo and a silica gel plug was made. Flash chromatography with EtOAc: 
Hex 0% to 10 % afforded 3.82 g (96%) of brown solid.  TLC Rf = 0.36 (EtOAc: Hexane; 
1:1) mp115, 105–107 °C; 1H NMR (500 MHz, DMSO-d6)  ppm 1.22 (t, J = 7.07 Hz, 3 H, 
CH3) 4.18 (q, J = 7.02 Hz, 2 H, CH2) 5.02 (s, 2 H, CH2) 7.13 (t, J = 7.55 Hz, 1 H, CH) 
7.18 (d, J = 8.49 Hz, 1 H, CH) 7.62 - 7.67 (m, 1 H, CH) 7.76 (dd, J = 7.70, 1.73 Hz, 1 H, 
CH) 
 
Ethyl 3-aminobenzofuran-2-carboxylate (263) 
Ethyl 2-(2-cyanophenoxy)acetate (262, 3.8 g, 19 mmol) was added dropwise to a stirred 
solution of potassium tert-butoxide (2.78 g, 20.1 mmol) in tetrahydrofuran (100 mL) at 
room temperature and stirred for 6h. Most of the solvent was removed in vacuo and a 
silica gel plug was made. Flash chromatography with EtOAc: Hex 0% to 10 % afforded 3 
g (78%) of brown semisolid.  TLC Rf = 0.5 (EtOAc: Hexane; 1:1) 1H NMR (500 MHz, 
DMSO-d6)  ppm 1.32 (t, J = 7.07 Hz, 3 H, CH3) 4.30 (q, J = 7.13 Hz, 2 H, CH2) 6.34 (s, 
2 H, exch, NH2) 7.26 (dt, J = 7.94, 4.05 Hz, 1 H, CH) 7.49 (d, J = 3.46 Hz, 2 H, CH) 7.95 
(d, J = 7.86 Hz, 1 H, CH) 
 
2-methylbenzofuro[3,2-d]pyrimidin-4(3H)-one (264) 
Compound 264 (synthesized from 263 as described for 245): yield 76%; TLC Rf = 0.6 
(MeOH: CHCl3; 1:20); white solid; mp, 200-202 °C; 
1H NMR (400 MHz, DMSO-d6)  
ppm 2.43 (s, 3 H, CH3) 7.16 - 7.22 (m, 1 H, CH) 7.40 - 7.45 (m, 1 H, CH) 7.47 - 7.52 (m, 
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1 H, CH) 7.96 (d, J = 8.03 Hz, 1 H, CH) 12.27 (br, 1 H, exch, NH) 
 
4-chloro-2-methylbenzofuro[3,2-d]pyrimidine (265) 
Compound 265 (synthesized from 264 as described for 238): yield 81%; TLC Rf = 0.7 
(MeOH: CHCl3; 1:20); off-white solid; mp 212-214 °C; 
1H NMR (400 MHz, DMSO-d6) 
 ppm 2.78 (d, J = 0.75 Hz, 3 H, CH3) 7.58 - 7.64 (m, 1 H, CH) 7.84 - 7.89 (m, 1 H, CH) 
7.97 (dd, J = 8.41, 0.63 Hz, 1 H, CH) 8.23 - 8.27 (m, 1 H, CH) 
 
N-(4-methoxyphenyl)-N,2-dimethylbenzofuro[3,2-d]pyrimidin-4-amine (202) 
Compound 202 (synthesized from 265 and 4-methoxy N-methoxy aniline as described 
for 161): TLC Rf = 0.6 (CH3OH: CHCl3; 1:20); white solid; mp, 238-240 °C; 
1H NMR 
(500 MHz, DMSO-d6)  ppm 2.74 (s, 3 H, CH3) 3.72 (s, 3 H, CH3) 3.86 (s, 3 H, CH3) 
7.07 - 7.11 (m, 2 H, Ar) 7.46 (d, J = 8.80 Hz, 2 H, Ar) 7.55 (t, J = 7.55 Hz, 2 H, Ar) 7.67 
- 7.74 (m, 1 H, Ar) 8.33 (d, J = 7.86 Hz, 1 H, Ar) Anal. Calcd. for 
C19H17N3O2∙HCl∙0.05H2O: C, 63.97; H, 5.11; N, 11.78; Cl, 9.94. Found C, 64.13; H, 5.12; 
N, 11.66; Cl, 9.81. 
 
4-(5-methoxyindolin-1-yl)-2-methylbenzofuro[3,2-d]pyrimidine (203) 
Compound 203 (synthesized from 265 and 5-methoxyindoline as described for 161): 
TLC Rf = 0.6 (CH3OH: CHCl3; 1:20); yellow solid; mp, 284-286 °C;
 1H NMR (400 MHz, 
DMSO-d6)  ppm 2.71 (s, 3 H, CH3) 2.84 (t, J = 6.53 Hz, 2 H, CH2) 3.81 (s, 3 H, CH3) 
4.19 - 4.30 (m, 2 H, CH2) 6.81 (dd, J = 8.91, 2.89 Hz, 1 H, Ar) 6.90 (d, J = 3.01 Hz, 1 H, 
Ar) 7.32 (d, J = 9.03 Hz, 1 H, Ar) 7.55 - 7.61 (m, 1 H, Ar) 7.69 - 7.80 (m, 2 H, Ar) 8.32 
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(d, J = 7.28 Hz, 1 H, Ar) Anal. Calcd. for C20H17N3O2∙HCl: C, 65.31; H, 4.93; N, 11.42; 
Cl, 9.64. Found C, 65.25; H, 4.84; N, 11.39; Cl, 9.47.  
 
4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylbenzofuro[3,2-d]pyrimidine 
(204) 
Compound 204 (synthesized from 265 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): TLC Rf = 0.6 (CH3OH: CHCl3; 1:20); light yellow solid; mp 279-
281 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 2.05 (t, J = 6.40 Hz, 2 H, CH2) 2.71 (s, 3 
H, CH3) 2.84 (t, J = 6.53 Hz, 2 H, CH2) 3.81 (s, 3 H, CH3) 4.19 - 4.30 (m, 2 H, CH2) 6.81 
(dd, J = 8.91, 2.89 Hz, 1 H, Ar) 6.90 (d, J = 3.01 Hz, 1 H, Ar) 7.32 (d, J = 9.03 Hz, 1 H, 
Ar) 7.55 - 7.61 (m, 1 H, Ar) 7.69 - 7.80 (m, 2 H, Ar) 8.32 (d, J = 7.28 Hz, 1 H, Ar) Anal. 
Calcd. for C21H19N3O2∙HCl: C, 66.05; H, 5.28; N, 11.00; Cl, 9.28. Found C, 65.90; H, 
5.26; N, 10.85; Cl, 9.08.  
 
7-benzyl-2-methylfuro[3,2-d]pyrimidin-4(3H)-one (270) 
2-Phenyl propionitrile (266) was added to a solution of ethyl formate (1.1eq) and sodium 
ethoxide (1.1 eq) in ethanol (0.1M) and heated to reflux for 2 hours. The resulting 
precipitate was filtered and washed with ether to give crude 267. Diethylchloromalonate 
(1.0 eq) was added to a stirred solution of the crude hydroxyacrylonitrile in DMF (0.1 M). 
After stirring for 5 hours at room temperature, the solvent was removed and the resulting 
oil of 268 was dissolved in ethanol. 1.5-diazabicyclo[4.3.0]non-5-ene (6.8 mL, 55 mmol) 
(1.0 eq) was added and the reaction mixture was heated to reflux and stirred overnight. 
After concentration, the crude product was dissolved in EtOAc and washed with water. 
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The solution was concentrated and an analytical sample was prepared by silica gel 
chromatography (EtOAc–hexane, 1:2). The organic phase was dried over sodium 
sulphate and filtered through a thick pad of silica. The filtrate was evaporated to afford 
crude syrupy 236 which was dissolved in acetonitrile and HCl gas was bubbled through 
for 2 hours. The reaction mixture was neutralized with ammonium hydroxide and the 
solvent was evaporated and flash chromatographed (CHCl3: CH3OH; 100:1 to 50:3; v/v) 
to yield 237 as a white solid (36%). TLC Rf 0.42 (CH3OH: CHCl3; 1:50); mp
198, 240-
242 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 2.35 (s, 3 H, CH3) 3.91 (s, 2 H, CH2) 7.17 
- 7.22 (m, 1 H, Ar) 7.29 (d, J = 4.52 Hz, 4 H, Ar) 7.96 (s, 1 H, Ar) 12.45 (br, 1 H, exch, 
NH) 
 
7-benzyl-4-chloro-2-methylfuro[3,2-d]pyrimidine (271) 
Compound 271 (synthesized from 270 as described for 261): yield = 69%; TLC Rf 0.5 
(CH3OH: CHCl3; 1:50). white solid; mp, 225-227 °C;
 1H NMR (400 MHz, DMSO-d6)  
ppm 2.55 (s, 3 H, CH3) 3.99(s, 2 H, CH2) 7.24 - 7.29 (m, 1 H, Ar) 7.36 (d, J = 4.52 Hz, 4 
H, Ar) 8.12 (s, 1 H, Ar)  
  
7-benzyl-N-(4-methoxyphenyl)-N,2-dimethylfuro[3,2-d]pyrimidin-4-amine (205) 
Compound 205 (synthesized from 271 and 4-methoxy N-methoxy aniline as described for 
161): TLC Rf = 0.6 (CH3OH: CHCl3; 1:50); white solid; mp, 210-212 °C; 
1H NMR 
(DMSO-d6): δ 2.69 (s, 3 H, 2-CH3) 3.7 (s, 3 H, NCH3) 3.89 (s, 3 H, OCH3) 4.11 (s, 2 H, 
CH2) 7.18 (d, 2 H, J = 8.84 Hz, Ar) 7.27 – 7.32 (m, 6 H, Ar) 7.48 (d, 2 H, J = 8.73, Ar) 
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Anal. Calcd. for C22H21N3O2∙HCl∙H2O: C, 63.84; H, 5.84; N, 10.15; Cl, 8.57. Found C, 
64.31; H, 5.76; N, 10.22; Cl, 8.48.  
 
7-benzyl-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylfuro[3,2-
d]pyrimidine (206) 
Compound 205 (synthesized from 271 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): TLC Rf = 0.54 (CH3OH: CHCl3; 1:50); yellow solid; mp, 230-232 °C; 
1H NMR (400 MHz, DMSO-d6)  ppm 1.97 - 2.05 (m, 2 H, CH2) 2.67 (s, 3 H, CH3) 2.76 
- 2.82 (m, 2 H, CH2) 3.79 (s, 3 H, CH3) 4.11 (s, 4 H, CH2) 6.77 - 6.82 (m, 1 H, Ar) 6.92 - 
6.96 (m, 1 H, Ar) 7.12 - 7.24 (m, 2 H, Ar) 7.28 - 7.34 (m, 4 H, Ar) 7.44 - 7.48 (m, 1 H, 
Ar) Anal. Calcd. for C24H23N3O2∙HCl: C, 68.32; H, 5.73; Cl, 8.40; N, 9.96. Found C, 
68.19; H, 5.76; N, 10.04; Cl, 8.30. 
 
N,2-dimethyl-N-phenylfuro[3,2-d]pyrimidin-4-amine (207) 
Compound 207 (synthesized from 252 and N-methyl aniline as described for 161): TLC 
Rf = 0.5 (CH3OH: CHCl3; 1:25); white solid; mp, 199-200 °C;
 1H NMR (400 MHz, 
DMSO-d6)  ppm 1.97 - 2.05 (m, 2 H, CH2) 2.67 (s, 3 H, CH3) 2.76 - 2.82 (m, 2 H, CH2) 
3.79 (s, 3 H, CH3) 4.11 (s, 4 H, CH2) 6.77 - 6.82 (m, 1 H, Ar) 6.92 - 6.96 (m, 1 H, Ar) 
7.12 - 7.24 (m, 2 H, Ar) 7.28 - 7.34 (m, 4 H, Ar) 7.44 - 7.48 (m, 1 H, Ar) Anal. Calcd. for 
C24H23N3O2∙HCl: C, 68.32; H, 5.73; N, 9.96; Cl, 8.40. Found C, 68.19; H, 5.76; N, 10.04; 
Cl, 8.30. 
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N,2-dimethyl-N-(p-tolyl)furo[3,2-d]pyrimidin-4-amine (208) 
Compound 208 (synthesized from 252 and N-methyl p-toluidine as described for 161): 
TLC Rf = 0.5 (CH3OH: CHCl3; 1:25); white solid; mp, 223-225 °C; 
1H NMR (400 MHz, 
DMSO-d6)  ppm 2.68 (s, 3 H, CH3) 3.53 (s, 3 H, CH3) 3.71 (s, 3 H, CH3) 7.10 (d, J = 
2.01 Hz, 1 H, Ar) 7.47 - 7.57 (m, 4 H, Ar) 8.26 (s, 1 H, Ar) Anal. Calcd. for 
C14H12ClN3O·HCl: C, 54.21; H, 4.22; N, 13.54; Cl, 22.86. Found C, 54.27; H, 4.33; N, 
13.38; Cl, 22.71. 
 
N-(4-chlorophenyl)-N,2-dimethylfuro[3,2-d]pyrimidin-4-amine (209) 
Compound 209 (synthesized from 252 and 4-chloro N-methylaniline as described for 
161): TLC Rf = 0.5 (CH3OH: CHCl3; 1:25); white solid; mp, 274-276 °C; 
1H NMR (400 
MHz, DMSO-d6)  ppm 2.67 (s, 3 H, CH3) 3.70 (s, 3 H, CH3) 7.12 (d, J = 2.01 Hz, 1 H, 
Ar) 7.56 - 7.64 (m, 4 H, Ar) 8.32 (br, 1 H, Ar) Anal. Calcd. for C14H12ClN3O·HCl: C, 
54.21; H, 4.22; N, 13.54; Cl, 22.86. Found C, 54.27; H, 4.33; N, 13.38; Cl, 22.71. 
 
N-(3,4-dichlorophenyl)-N,2-dimethylfuro[3,2-d]pyrimidin-4-amine (210) 
Compound 210 (synthesized from 252 and 3,4 dichloro N-methylaniline as described for 
161): TLC Rf = 0.54 (CH3OH: CHCl3; 1:25); off-white solid; mp, 291-293 °C; 
1H NMR 
(400 MHz, DMSO-d6)  ppm 2.67 (s, 3 H, CH3) 3.70 (s, 3 H, CH3) 7.13 (d, J = 2.26 Hz, 
1 H, Ar) 7.57 (dd, J = 8.78, 2.51 Hz, 1 H, Ar) 7.82 (d, J = 8.53 Hz, 1 H, Ar) 7.95 (d, J = 
2.51 Hz, 1 H, Ar) 8.36 (s, 1 H, Ar) Anal. Calcd. for C14H11Cl2N3O·HCl: C, 48.80; H, 
3.51; N, 12.19; Cl, 30.86. Found C, 48.95; H, 3.59; N, 12.07; Cl, 30.77. 
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7-benzyl-4-chloro-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidine (272) 
Compound 272 (synthesized from 261 as described for 241): yield = 83%; TLC Rf 0.5 
(CH3OH: CHCl3; 1:25). white solid; mp, 145-147 °C 
1H NMR (400 MHz, DMSO-d6)  
ppm 2.62 (s, 3 H, CH3) 4.01 (s, 3 H, CH3) 4.03 (s, 2 H, CH2) 7.17 (td, J = 5.65, 2.76 Hz, 
1 H, 6-CH) 7.26 - 7.30 (m, 4 H, C6H5) 7.64 (s, 1 H, C6H5) 
 
7-benzyl-N-(4-methoxyphenyl)-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(211) 
Compound 211 (synthesized from 272 and p-anisidine as described for 161): yield = 79%; 
TLC Rf 0.5 (CH3OH: CHCl3; 1:20). white solid; mp, 291-292 °C; 
1H NMR (DMSO-d6): δ 
2.66 (s, 3 H, 2-CH3) 3.6 (s, 3 H, NCH3) 3.82 (s, 3 H, OCH3) 4.08 (s, 2 H, CH2) 7.08 (d, 2 
H, J = 8.84 Hz, Ar) 7.17 – 7.26 (m, 6 H, Ar and 6-CH) 7.4 (d, 2 H, J = 8.73, Ar) 9.41 (br, 
1H, exch, NH) 14.43 (s, 1H, exch, HCl). Anal. Calcd. for C22H22N4O·HCl: C, 66.91; H, 
5.87; N, 14.19; Cl, 8.98. Found C, 66.88; H, 5.86; N, 14.07; Cl, 8.84. 
 
7-benzyl-N-(4-methoxyphenyl)-N,2,5-trimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(212) 
Compound 212 (synthesized from 272 and 4-methoxy N-methyl aniline as described for 
161): yield = 74%; TLC Rf = 0.5 (CH3OH: CHCl3; 1:20). grey solid; mp, 186-187 °C; 
1H 
NMR (400 MHz, DMSO-d6)  ppm 2.73 (s, 3 H, CH3) 2.80 (s, 3 H, CH3) 3.63 (s, 3 H, 
CH3) 3.78 (s, 3 H, CH3) 4.08 (s, 2 H, CH2) 7.00 (d, J = 9.03 Hz, 2 H, Ar) 7.22 (d, J = 
5.52 Hz, 1 H, Ar) 7.25 - 7.33 (m, 6 H, Ar) 7.37 (s, 1 H, Ar) 8.33 (s, 1 H, Ar) 14.63 (s, 1 H, 
exch, HCl) Anal. Calcd. for C23H24N4O·HCl: C, 67.55; H, 6.16; N, 13.70; Cl, 8.67. 
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Found C, 67.41; H, 6.20; N, 13.59; Cl, 8.61. 
 
1-(7-benzyl-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (213) 
Compound 213 (synthesized from 261 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): yield = 80%; TLC Rf = 0.6 (CH3OH: CHCl3; 1:25). pale yellow solid; 
mp 262-264 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 1.97 - 2.05 (m, 2 H, CH2) 2.67 (s, 
3 H, CH3) 2.76 - 2.82 (m, 2 H, CH2) 3.79 (s, 3 H, CH3) 4.11 (s, 4 H, CH2) 6.77 - 6.82 (m, 
1 H, Ar) 6.92 - 6.96 (m, 1 H, Ar) 7.12 - 7.24 (m, 2 H, Ar) 7.28 - 7.34 (m, 4 H, Ar) 7.44 - 
7.48 (m, 1 H, Ar) 10.88 (s, 1 H, exch, NH) 14.36 (s, 1 H, exch, HCl) Anal. Calcd. for 
C24H24N4O·HCl·0.25H2O: C, 67.75; H, 6.04; N, 13.17; Cl, 8.33. Found C, 67.84; H, 6.21; 
N, 12.95; Cl, 8.06. 
 
1-(7-benzyl-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (214) 
Compound 214 (synthesized from 272 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): yield = 76%; TLC Rf 0.6 (CH3OH: CHCl3; 1:20) white solid; mp, 
130-132 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 2.07 (t, J = 6.53 Hz, 2 H, CH2) 2.72 
(s, 3 H, CH3) 2.79 - 2.88 (m, 2 H, CH2) 2.97 (s, 3 H, CH3) 3.72 - 3.78 (m, 3 H, CH3) 3.96 
- 4.06 (m, 2 H, CH2) 4.13 (s, 2 H, CH2) 6.68 - 6.72 (m, 1 H, Ar) 6.79 (d, J = 9.03 Hz, 1 H, 
Ar) 6.91 (d, J = 2.76 Hz, 1 H, Ar) 7.22 (td, J = 5.84, 2.64 Hz, 1 H, Ar) 7.30 - 7.35 (m, 4 
H, Ar) 7.50 (s, 1 H, Ar) 14.71 (s, 1 H, exch, HCl) 
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4-Chloro-2,5,6-trimethyl-5H-pyrrolo[3,2-d]pyrimidine (273) 
Compound 273 (synthesized from 246 as described for 241): yield = 88%; TLC Rf = 0.5 
(CH3OH: CHCl3; 1:10). off-white solid; mp, 159-161°C 
1H NMR (400 MHz, DMSO-d6) 
 ppm 2.62 (s, 3 H, CH3) 3.65 (s, 3 H, CH3) 4.01 (s, 3 H, CH3) 6.6 (m, 1 H, 7-CH) 7.9 (m, 
1 H, 6-CH) 
 
N-(4-methoxyphenyl)-N,2,5,6-tetramethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (215) 
Compound 215 (synthesized from 273 and 4-methoxy N-methyl aniline as described for 
161): yield = 74%; TLC Rf = 0.62 (CH3OH: CHCl3; 1:10). white solid; mp, 200-201 °C; 
1H NMR (400 MHz, DMSO-d6)  ppm 2.30 (s, 3 H, CH3) 2.67 (s, 3 H, CH3) 2.79 (s, 3 H, 
CH3) 3.62 (s, 3 H, CH3) 3.78 (s, 3 H, CH3) 6.44 (s, 1 H, Ar) 6.98 (d, J = 8.78 Hz, 2 H, Ar) 
7.22 (d, J = 9.03 Hz, 2 H, Ar) 15.09 (br, 1 H, exch, HCl) Anal. Calcd. for 
C15H17N3O2∙HCl∙0.5H2O: C, 61.27; H, 6.47; N, 16.81; Cl, 10.64. Found C, 60.89; H, 6.31; 
N, 16.58; Cl, 10.32.  
 
6-methoxy-1-(2,5,6-trimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-1,2,3,4-
tetrahydroquinoline (216) 
Compound 216 (synthesized from 275 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): yield = 75%; TLC Rf 0.6 (CH3OH: CHCl3; 1:10). white solid; mp, 
242-244 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 1.97 - 2.06 (m, 2 H, CH2) 2.42 (s, 3 
H, CH3) 2.58 (s, 3 H, CH3) 2.72 (s, 3 H, CH3) 2.81 (t, J = 6.40 Hz, 2 H, CH2) 3.79 (s, 3 H, 
CH3) 4.12 (t, J = 6.27 Hz, 2 H, CH2) 6.36 (s, 1 H, Ar) 6.76 (dd, J = 8.78, 2.76 Hz, 1 H, Ar) 
6.91 (d, J = 2.51 Hz, 1 H, Ar) 7.11 (d, J = 9.03 Hz, 1 H, Ar) 14.60 (s, 1 H, exch, HCl) 
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Anal. Calcd. for C19H22N4O∙HCl: C, 63.59; H, 6.46; N, 15.61; Cl, 9.88. Found C, 63.45; 
H, 6.58; N, 15.38; Cl, 9.59.  
 
methyl (6-methyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl) carbamate 
(277) 
Ethyl 3-amino-5-methyl-1H-pyrrole-2-carboxylate (244, 2.68 g, 16 mmol) was dissolved 
in methanol (40 mL), and 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (3.74 g, 
18 mmol) was added followed by acetic acid (4.6 mL). The mixture was stirred at room 
temperature for 24 hours and became a thick paste of 275. To the reaction mixture was 
added 45 mL of sodium methoxide in MeOH (25%), and stirring was continued at room 
temperature for 12 hours. The mixture was neutralized with acetic acid, and the solid was 
collected by filtration and washed well with water. After drying, 277 (2.44 g, 69%) was 
obtained as an off-white powder: mp105 234–236 °C; TLC Rf = 0.22 (CH3OH /CHCl3, 
1:5); 1H NMR (DMSO-d6) δ 2.28 (s, 3 H, CH3), 3.73 (s, 3 H, OCH3), 5.95 (s, 1 H, CH), 
10.90 (s, 1 H, exch, NH), 11.10 (s, 1 H, exch, NH), 11.76 (s, 1 H, exch, NH). 
 
methyl (7-benzyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)carbamate 
(276) 
Compound 276 (synthesized from 259 as described for 277): yield = 73%; TLC Rf 0.6 
(MeOH: CHCl3; 1:15). white solid; mp 287-289 °C; 
1H NMR103 (400 MHz, DMSO-d6) δ 
3.71 (s, 3 H, CH3), 3.88 (s, 2 H, CH2), 7.0−7.3 (m, 6 H, Ar), 11.00 (br, 1 H, exch, NH), 
11.23 (br, 1 H, exch, NH), 11.80 (br, 1 H, exch, NH) 
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2-amino-6-methyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (279) 
A suspension of methyl (6-methyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl) 
carbamate (277, 1 g, 4.5 mmol) in 1 N NaOH (35 mL) was heated to reflux for 3 h. The 
resulting solution was cooled in an ice bath and neutralized with acetic acid. The 
precipitated solid was collected by filtration, washed with brine, and dried in vacuo to 
afford 0.67 g (92%) of 279 as a white solid: mp105 252–254 °C; TLCRf = 0.15 (CH3OH 
/CHCl3, 1:5); 
1H NMR (400 MHz, DMSO-d6)  ppm 2.22 (s, 3 H, CH3) 5.66 - 5.69 (m, 1 
H, 7-CH) 5.70 (br, 2 H, exch, NH2) 10.26 (br, 1 H, exch, NH) 11.19 (br, 1 H, exch, NH) 
 
2-amino-7-benzyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (278) 
Compound 278 (synthesized from 276 as described for 279): yield = 97%; TLC Rf 0.6 
(CH3OH: CHCl3; 1:15). white solid; mp
103 273-274°C 1H NMR (DMSO-d6) δ 3.81 (s, 2 
H, CH2), 5.85 (s, 1 H, exch, NH2), 6.91 (d, J = 2.9 Hz, 2 H, Ar), 7.1−7.3 (m, 5 H, Ar), 
10.39 (br, 1 H, exch, NH), 11.25 (br, 1 H, exch, NH) 
 
N-(6-methyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)pivalamide (281) 
A suspension of 2-amino-6-methyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (279, 1.37 g, 
8 mmol in 30 mL of trimethylacetic anhydride was heated at 100 °C for 2 hours. The 
resulting mixture was cooled, diluted with hexanes and filtered. The solid obtained was 
resuspended in water and ammonia solution was added to adjust the pH to 8. Ethyl 
acetate was added and the organic layer was separated, dried over sodium sulphate and 
the solvent was evaporated to afford 1.33 g (87%) of 281 as a white solid: TLC Rf = 0.47 
(CH3OH /CHCl3, 1:10); mp
105 156–157 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 1.24 
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(s, 9 H, C(CH3)3) 2.31 (s, 3 H, CH3) 6.00 (d, J = 0.75 Hz, 1 H, 7-CH) 10.06 - 10.97 (m, 2 
H, exch, NH, NH) 11.65 (br, 1 H, exch, NH) 
 
N-(7-benzyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)pivalamide (280) 
Compound 280 (synthesized from 278 as described for 281): yield = 97%; TLC Rf = 0.47 
(CH3OH /CHCl3, 1:10); light brown solid; mp 185-187°C 
1H NMR (400 MHz, DMSO-
d6)  ppm 1.25 (s, 9 H, (CH3)3) 3.95 (s, 2 H, CH2) 7.11 (s, 1 H, Ar) 7.13 - 7.19 (m, 1 H, 
Ar) 7.20 - 7.30 (m, 4 H, Ar) 10.77 (br, 1 H, exch, NH) 11.88 (br, 1 H, exch, NH) 12.09 
(br, 1 H, exch, NH) Anal. Calcd. for C18H20N4O2∙H2O: C, 63.14; H, 6.48; N, 16.36. 
Found C, 63.17; H, 6.24; N, 16.30.  
 
N-(4-chloro-6-methyl-5H-pyrrolo[3,2-d]pyrimidin-2-yl)pivalamide (283) 
Phosphorus oxychloride (30 mL) was added to N-(6-methyl-4-oxo-4,5-dihydro-3H-
pyrrolo[3,2-d]pyrimidin-2-yl)pivalamide (281, 1.16 g, 4.67 mmol). The reaction mixture 
was heated at reflux with stirring in an anhydrous atmosphere for 3 h. The dark-orange 
solution was allowed to cool to room temperature and the solvent removed under vacuum 
to afford a brown gum. Aqueous ammonium hydroxide was added to the residue at 0 °C 
with vigorous stirring to attain pH 8 to give a precipitate, which was collected by 
filtration, washed with water, and dried in vacuo. The crude product was purified by 
silica gel column chromatography with 2% MeOH/CHCl3 to afford 1.07 g (86%) of 283 
as a white solid: TLC Rf = 0.35 (CH3OH /CHCl3, 1:10); mp 162–163 °C; 1H NMR (400 
MHz, DMSO-d6)  ppm 1.22 (s, 9 H, C(CH3)3) 3.37(s, 3 H, CH3) 6.35 (d, J = 0.50 Hz, 1 
H, 7-CH) 9.88 (s, 1 H, exch, NH) 12.11 (s, 1 H, exch, NH) 
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N-(7-benzyl-4-chloro-5H-pyrrolo[3,2-d]pyrimidin-2-yl)pivalamide (282) 
Compound 282 (synthesized from 280 as described for 283): yield = 80%; TLC Rf = 0.55 
(CH3OH /CHCl3, 1:10); white solid; mp 171-173°C 
1H NMR (400 MHz, DMSO-d6)  
ppm 1.37 (s, 9 H, (CH3)3) 3.98 (s, 2 H, CH2) 7.15 (s, 1 H, Ar) 7.18 - 7.23 (m, 1 H, Ar) 
7.25 - 7.36 (m, 4 H, Ar) 12.01 (br, 1 H, exch, NH) 12.22 (br, 1 H, exch, NH)  
 
N-(4-((4-methoxyphenyl)(methyl)amino)-6-methyl-5H-pyrrolo[3,2-d]pyrimidin-2-
yl)pivalamide (286) 
Compound 286 (synthesized from 283 as described for 161): yield = 80%; TLC Rf 0.6 
(CH3OH: CHCl3; 1:15). pale yellow solid; mp 287-289 °C; 
1H NMR (400 MHz, DMSO-
d6)  ppm 1.31 (s, 9 H, (CH3)3) 2.29 (s, 3 H, CH3) 3.66 (s, 3 H, CH3) 3.84 (s, 3 H, CH3) 
6.42 - 6.45 (m, 1 H, Ar) 7.10 (s, 2 H, Ar) 7.40 (d, J = 8.78 Hz, 2 H, Ar) 9.67 (s, 1 H, 
exch, NH) 11.03 (s, 1 H, exch, NH) 13.59 (br, 1 H, exch, HCl) Anal. Calcd. for 
C20H25N5O2·HCl: C, 59.47; H, 6.49; N, 17.34; Cl, 8.78. Found C, 59.45; H, 6.54; N, 
17.10; Cl, 8.49. 
 
N-(7-benzyl-4-((4-methoxyphenyl)(methyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-2-
yl)pivalamide (284) 
Compound 284 (synthesized from 282 as described for 285): yield = 81%; TLC Rf 0.6 
(CH3OH: CHCl3; 1:10). white solid; mp 217-218 °C; 
1H NMR (400 MHz, DMSO-d6) 
ppm 1.31 (s, 9 H, (CH3)3) 3.38 (s, 3 H, CH3) 3.80 (s, 3 H, CH3) 3.81 (s, 2 H, CH2) 6.71 (d, 
J = 3.26 Hz, 1 H, Ar) 6.97 - 7.02 (m, 2 H, Ar) 7.13 (m, J = 4.30 Hz, 1 H, Ar) 7.20 - 7.25 
(m, 6 H, Ar) 9.62(s, 1 H, exch, NH) 11.00 (s, 1 H, exch, NH) 13.11 (br, 1 H, exch, HCl) 
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N4-(4-methoxyphenyl)-N4,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine 
(219) 
N-(4-((4-methoxyphenyl)(methyl)amino)-6-methyl-5H-pyrrolo[3,2-d]pyrimidin-2-
yl)pivalamide (286, 50 mg, 0.13 mmol) was suspended in 1 N NaOH (10 mL) and 
methanol (5 mL). The reaction mixture was heated to reflux for 10 hours. The solution 
was cooled to room temperature and neutralized with acetic acid. The resulting 
precipitate was collected by filtration and dried in vacuo. The crude product was purified 
by silica gel column chromatography, eluting with 5% CH3OH /CHCl3 to yield 25 mg 
(73%) of 219 as a white powder: TLC Rf 0.6 (CH3OH: CHCl3; 1:10) mp 217-219 °C; 
1H 
NMR (400 MHz, DMSO-d6)  ppm 2.13 (s, 3 H, CH3) 3.39 (s, 3 H, CH3) 3.79 (s, 3 H, 
CH3) 5.32 (s, 2 H, exch, NH2) 5.69 - 5.73 (m, 1 H, Ar) 6.96 - 7.00 (m, 2 H, Ar) 7.15 - 
7.18 (m, 2 H, Ar) 8.17 (s, 1 H, exch, NH) Anal. Calcd. for C17H19N5O·0.7H2O: C, 63.42; 
H, 6.39; N, 21.75. Found C, 63.67; H, 6.08; N, 21.52. 
 
7-benzyl-N4-(4-methoxyphenyl)-N4-methyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-
diamine (217) 
Compound 217 (synthesized from 284 as described for 219): yield = 83%; TLC Rf 0.6 
(CH3OH: CHCl3; 1:15). white solid; mp 167-169 °C; 
1H NMR (400 MHz, DMSO-d6)  
ppm 3.38 (s, 3 H, CH3) 3.80 (s, 3 H, CH3) 3.81 (s, 2 H, CH2) 5.46 (s, 2 H, exch, NH2) 
6.71 (d, J = 3.26 Hz, 1 H, Ar) 6.97 - 7.02 (m, 2 H, Ar) 7.13 (m, J = 4.30 Hz, 1 H, Ar) 
7.20 - 7.25 (m, 6 H, Ar) 7.86 (d, J = 2.76 Hz, 1 H, exch, NH) Anal. Calcd. for C21H21N5O: 
C, 70.17; H, 5.89; N, 19.48. Found C, 70.11; H, 5.96; N, 19.42. 
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N-(4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-6-methyl-5H-pyrrolo[3,2-
d]pyrimidin-2-yl)pivalamide (287) 
Compound 287 (synthesized from 283 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): yield = 75%; TLC Rf 0.6 (CH3OH: CHCl3; 1:15). white solid; mp 
287-289 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 1.30 (s, 9 H, C(CH3)3) 1.98 - 2.06 
(m, 2 H, CH2) 2.35 (s, 3 H, CH3) 2.80 - 2.87 (m, 2 H, CH2) 3.79 (s, 3 H, CH3) 4.07 - 4.14 
(m, 2 H, CH2) 6.44 - 6.48 (m, 1 H, Ar) 6.74 - 6.79 (m, 1 H, Ar) 6.91 - 6.94 (m, 1 H, Ar) 
7.06 - 7.09 (m, 1 H, Ar) 10.87 (s, 1 H, exch, NH) 11.06(s, 1 H, exch, NH) 13.68 (s, 1 H, 
exch, NH) 
 
N-(7-benzyl-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5H-pyrrolo[3,2-
d]pyrimidin-2-yl)pivalamide (285) 
Compound 285 (synthesized from 282 and 6-methoxy-1,2,3,4-tetrahydroquinoline as 
described for 161): yield = 78%; TLC Rf 0.62 (CH3OH: CHCl3; 1:15). light yellow solid; 
mp 211-213 °C; 1H NMR (400 MHz, DMSO-d6)  ppm 1.30 (s, 9 H, C(CH3)3)1.85 - 1.94 
(m, 2 H, CH2) 2.71 - 2.81 (m, 2 H, CH2) 3.73 (s, 3 H, OCH3) 3.86 (s, 4 H, CH2) 6.64 - 
6.70 (m, 1 H, Ar) 6.75 - 6.81 (m, 2 H, Ar) 6.88 - 6.92 (m, 1 H, Ar) 7.12 - 7.18 (m, 1 H, 
Ar) 7.26 (s, 4 H, Ar) 10.80 (s, 1 H, exch, NH) 11.15(s, 1 H, exch, NH) 13.11 (s, 1 H, 
exch, NH) 
 
4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-6-methyl-5H-pyrrolo[3,2-d]pyrimidin-
2-amine (220) 
Compound 220 (synthesized from 287 as described for 219): yield = 92%; TLC Rf 0.6 
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(CH3OH: CHCl3; 1:10). white solid; mp 268-270 °C; 
1H NMR (400 MHz, DMSO-d6)  
ppm 1.91 (quin, J = 6.27 Hz, 2 H, CH2) 2.26 (s, 3 H, CH3) 2.79 (t, J = 6.40 Hz, 2 H, CH2) 
3.70 - 3.75 (m, 3 H, CH3) 3.77 - 3.82 (m, 2 H, CH2) 5.37 (s, 2 H, exch, NH2) 5.79 (s, 1 H, 
Ar) 6.61 - 6.66 (m, 1 H, Ar) 6.70 - 6.74 (m, 1 H, Ar) 6.75 (d, J = 2.76 Hz, 1 H, Ar) 9.79 
(s, 1 H, exch, NH) Anal. Calcd. for C17H19N5O·0.7H2O: C, 63.42; H, 6.39; N, 21.75. 
Found C, 63.67; H, 6.08; N, 21.52. 
 
7-benzyl-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5H-pyrrolo[3,2-d]pyrimidin-
2-amine (218) 
Compound 218 (synthesized from 285 as described for 219): yield = 90%; TLC Rf 0.6 
(CH3OH: CHCl3; 1:10). grey solid; mp 239-240 °C; 
1H NMR (400 MHz, DMSO-d6)  
ppm 1.85 - 1.94 (m, 2 H, CH2) 2.71 - 2.81 (m, 2 H, CH2) 3.73 (s, 3 H, OCH3) 3.86 (s, 4 H, 
CH2) 5.55 (br, 2 H, exch, NH2) 6.64 - 6.70 (m, 1 H, Ar) 6.75 - 6.81 (m, 2 H, Ar) 6.88 - 
6.92 (m, 1 H, Ar) 7.12 - 7.18 (m, 1 H, Ar) 7.26 (s, 4 H, Ar) 9.36 (br, 1 H, exch, NH) Anal. 
Calcd. for C20H18N4·HCl: C, 68.47; H, 5.46; N, 15.97; Cl, 10.11. Found C, 68.45; H, 5.43; 
N, 15.89; Cl, 9.99. 
 
2-methyl-7-(3,4,5-trimethoxybenzyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (291) 
Compound 291 (synthesized from 288 as described for 260): yield = 35%; TLC Rf 0.6 
(CH3OH: CHCl3; 1:10). white powder; mp 198-200 °C;
 1H NMR (400 MHz, DMSO-d6) 
 ppm 3.60 (s, 3 H, OCH3) 3.71 (s, 6 H, OCH3) 3.86 (s, 2 H, CH2) 6.64 (s, 2 H, CH) 7.13 
(s, 1 H, 6-CH) 10.78 (br, 1 H, exch, NH) 11.85 (br, 1 H, exch, 1H)  
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7-(3,4,5-trimethoxybenzyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one (292) 
Compound 292 (synthesized from 288 as described for 239): yield = 31%; TLC Rf 0.5 
(CH3OH: CHCl3; 1:10). brown solid; mp 205-207 °C;
 1H NMR (400 MHz, DMSO-d6)  
ppm 3.60 (s, 3 H, OCH3) 3.71 (s, 6 H, OCH3) 3.86 (s, 2 H, CH2) 6.64 (s, 2 H, CH) 7.13 
(s, 1 H, CH) 8.15 (s, 1 H, CH) 10.78 (br, 1 H, exch, NH) 11.85 (br, 1 H, exch, 1H)  
 
N-(4-oxo-7-(3,4,5-trimethoxybenzyl)-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-
yl)pivalamide (293)  
Compound 293 (synthesized from 288 as described for 281): yield = 52%; TLC Rf 0.5 
(CH3OH: CHCl3; 1:10). pale yellow solid; mp 193-195 °C; 
1H NMR (400 MHz, DMSO-
d6)  ppm 1.25 (s, 9 H, (CH3)3) 3.60 (s, 3 H, OCH3) 3.71 (s, 6 H, OCH3) 3.86 (s, 2 H, 
CH2) 6.64 (s, 2 H, CH) 7.13 (s, 1 H, 6-H) 10.78 (br, 1 H, exch, NH) 11.85 (br, 1 H, exch, 
NH) 12.05 (br, 1 H, exch, NH) Anal. Calcd. for C21H26N4O5: C, 60.86; H, 6.32; N, 13.52. 
Found C, 60.88; H, 6.18; N, 13.40. 
 
4-chloro-2-methyl-7-(3,4,5-trimethoxybenzyl)-5H-pyrrolo[3,2-d]pyrimidine (294) 
Compound 294 (synthesized from 291 as described for 283): yield = 79%; TLC Rf 0.5 
(CH3OH: CHCl3; 1:10). light brown solid; mp 193-195 °C; 
1H NMR (500 MHz, DMSO-
d6)  ppm 2.66 (s, 3 H, CH3) 3.60 (s, 3 H, OCH3) 3.71 (s, 6 H, OCH3) 4.02 (s, 2 H, CH2) 
6.67 (s, 2 H, CH) 7.82 (s, 1 H, 6-CH) 8.65 (s, 1 H, 2-CH) 12.27 (s, 1 H, exch, NH2) 
 
4-chloro-7-(3,4,5-trimethoxybenzyl)-5H-pyrrolo[3,2-d]pyrimidine (295) 
Compound 295 (synthesized from 292 as described for 283): yield = 82%; TLC Rf 0.4 
  
147 
 
(CH3OH: CHCl3; 1:10). yellow solid; mp 179-180 °C; 
1H NMR (500 MHz, DMSO-d6)  
ppm 3.60 (s, 3 H, OCH3) 3.71 (s, 6 H, OCH3) 4.02 (s, 2 H, CH2) 6.67 (s, 2 H, CH) 7.82 
(s, 1 H, 6-H) 8.65 (s, 1 H, 2-H) 12.27 (s, 1 H, exch, NH2) Anal. Calcd. for C16H14N3O3Cl: 
C, 57.58; H, 4.83; N, 12.59; Cl, 10.62. Found C, 57.57; H, 4.94; N, 12.55; Cl, 10.46. 
 
N-(4-chloro-7-(3,4,5-trimethoxybenzyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)pivalamide 
(296) 
Compound 296 (synthesized from 293 as described for 283): yield = 87%; TLC Rf 0.6 
(CH3OH: CHCl3; 1:10). light yellow solid; mp 179-180 °C; 
1H NMR (500 MHz, DMSO-
d6)  ppm 1.24 (s, 9 H, (CH3)3) 3.59 (s, 3 H, OCH3) 3.72 (s, 6 H, OCH3) 3.96 (s, 2 H, 
CH2) 6.74 (s, 2 H, CH) 7.73 (s, 1 H, 6-CH) 9.98 (s, 1 H, exch, NH) 12.12 (s, 1 H, exch, 
NH) Anal. Calcd. for C21H25N4O4Cl: C, 58.26; H, 5.82; N, 12.94; Cl, 8.19. Found C, 
58.06; H, 5.74; N, 12.86; Cl, 8.05. 
 
N-(4-methoxyphenyl)-N,2-dimethyl-7-(3,4,5-trimethoxybenzyl)-5H-pyrrolo[3,2-
d]pyrimidin-4-amine (222) 
Compound 222 (synthesized from 294 as described for 161): grey solid; mp 98-100 °C; 
1H NMR (500 MHz, DMSO-d6)  ppm 2.61 (s, 3 H, CH3) 3.59 (s, 3 H, CH3) 3.66 (s, 3 H, 
OCH3) 3.73 (s, 6 H, OCH3) 3.84 (s, 3 H, OCH3) 4.00 (s, 2 H, CH2) 6.73 (s, 2 H, Ar) 7.10 
(d, J = 9.12 Hz, 2 H, Ar) 7.42 (d, J = 8.80 Hz, 2 H, Ar) 7.81 (s, 1 H, Ar) 8.72 (d, J = 2.76 
Hz, 1 H, exch, NH) 14.68 (br, 1 H, exch, HCl) 
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N4-(4-methoxyphenyl)-N4-methyl-7-(3,4,5-trimethoxybenzyl)-5H-pyrrolo[3,2-
d]pyrimidine-2,4-diamine (223) 
Compound 222 (synthesized from 296 as described for 161): Intermediate N-(4-((4-
methoxyphenyl)(methyl)amino)-7-(3,4,5-trimethoxybenzyl)-5H-pyrrolo[3,2-d]pyrimidin-
2-yl)pivalamide: 1H NMR (500 MHz, DMSO-d6)  ppm 3.34 (s, 9 H, (CH3)3) 3.59 (s, 3 
H, CH3) 3.60 (br, 3 H, CH3) 3.76 (s, 6 H, OCH3) 3.85 (s, 3 H, CH3) 3.92 (s., 2 H, CH2) 
6.67 (s, 2 H, Ar) 7.10 (d, J = 8.49 Hz, 2 H, Ar) 7.41 (s., 2 H, Ar) 9.03 (br, 1 H, exch, NH) 
11.23 (br, 1 H, exch, NH) 13.39 (br, 1 H, exch, HCl) Anal. Calcd. for 
C29H35N5O5∙HCl∙0.5H2O: C, 60.15; H, 6.44; N, 12.09; Cl, 6.12. Found C, 60.26; H, 6.51; 
N, 11.96; Cl, 5.87. Compound 22 white solid; mp 113-115 °C; 1H NMR (400 MHz, 
DMSO-d6)  ppm 3.38 (s, 3 H, CH3) 3.59 (s, 3 H, OCH3) 3.70 (s, 6 H, OCH3) 3.73 (s, 2 
H, CH2) 3.79 (s, 3 H, OCH3) 5.48 (s, 2 H, exch, NH2) 6.66 (s, 2 H) 6.71 (d, J = 2.76 Hz, 1 
H, exch, NH) 6.99 (d, J = 8.78 Hz, 2 H, Ar) 7.21 (d, J = 9.03 Hz, 2 H, Ar) 7.81 (s, 1 H, 
Ar) Anal. Calcd. for C24H27N5O4∙1.25H2O: C, 61.14; H, 6.29; N, 14.85. Found C, 61.15; 
H, 5.99; N, 14.71.  
 
N-(4-methoxyphenyl)-N-methyl-7-(3,4,5-trimethoxybenzyl)-5H-pyrrolo[3,2-
d]pyrimidin-4-amine (224) 
Compound 222 (synthesized from 295 as described for 161): yellow solid; mp 223-
225 °C; 1H NMR (500 MHz, DMSO-d6)  ppm 3.59 (s, 3 H, CH3) 3.66 (s, 3 H, OCH3) 
3.73 (s, 6 H, OCH3) 3.84 (s, 3 H, OCH3) 4.00 (s, 2 H, CH2) 6.73 (s, 2 H, Ar) 7.10 (d, J = 
9.12 Hz, 2 H, Ar) 7.42 (d, J = 8.80 Hz, 2 H, Ar) 7.47 (s, 1 H, Ar) 8.71 (s, 1 H, Ar) Anal. 
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Calcd. for C24H26N4O4∙HCl: C, 61.21; H, 5.78; N, 11.90; Cl, 7.53. Found C, 61.14; H, 
5.87; N, 11.67; Cl, 7.36.  
 
7-benzyl-N-(4-bromo-2-fluorophenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-
amine (225) 
Compound 225 (synthesized from 261 and 2-fluoro 4-bromo aniline as described for 161): 
yield = 76%; TLC Rf 0.6 (CH3OH: CHCl3; 1:20). white solid; mp 277-279 °C; 
1H NMR 
(400 MHz, DMSO-d6)  ppm 2.61 (s, 3 H, CH3) 4.14 (s, 2 H, CH2) 7.16 - 7.23 (m, 1 H, 
Ar) 7.29 (d, J = 4.02 Hz, 4 H, Ar) 7.51 (d, J = 8.53 Hz, 1 H, Ar) 7.72 - 7.82 (m, 3 H, Ar) 
11.05 (br, 1 H, exch, NH) 12.56 (br, 1 H, exch, NH) 14.68 (br, 1 H, exch, HCl) Anal. 
Calcd. for C20H16N4BrF·HCl: C, 53.65; H, 3.83; N, 12.51; Cl, 7.92; Br, 17.85. Found , 
53.29; H, 3.82; N, 12.14; Cl, 8.04; Br, 17.52. 
 
7-benzyl-N-(4-chloro-2-fluorophenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(226) 
Compound 226 (synthesized from 261 and 2-fluoro 4-chloro aniline as described for 161): 
yield = 67%; TLC Rf 0.7 (CH3OH: CHCl3; 1:20). light brown solid; mp 251-252 °C; 
1H 
NMR (400 MHz, DMSO-d6)  ppm 2.61 (s, 3 H, CH3) 4.15 (s, 2 H, CH2) 7.16 - 7.22 (m, 
1 H, Ar) 7.26 - 7.32 (m, 4 H, Ar) 7.39 (d, J = 8.53 Hz, 1 H, Ar) 7.64 (dd, J = 10.29, 2.26 
Hz, 1 H, Ar) 7.76 (d, J = 2.76 Hz, 1 H, Ar) 7.80 (t, J = 8.53 Hz, 1 H, Ar) 11.19 (br, 1 H, 
exch, NH) 12.71 (br, 1 H, exch, NH) 14.76 (br, 1 H, exch, HCl) Anal. Calcd. for 
C20H16N4ClF·HCl: C, 59.57; H, 4.25; N, 13.89; Cl, 17.58; F, 4.71. Found C, 59.77; H, 
4.15; N, 13.78; Cl, 17.69; F, 4.67. 
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7-benzyl-N-(3-ethynylphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (227) 
Compound 227 (synthesized from 261 and 3-ethynyl aniline as described for 161): yield 
= 78%; TLC Rf 0.7 (CH3OH: CHCl3; 1:20). off-white solid; mp 275-277 °C; 
1H NMR 
(400 MHz, DMSO-d6)  ppm 2.70 (s, 3 H, CH3) 4.13 (s, 2 H, CH2) 7.17 - 7.22 (m, 1 H, 
Ar) 7.26 - 7.32 (m, 6 H, Ar) 7.45 (t, J = 8.03 Hz, 1 H, Ar) 7.74 (d, J = 3.01 Hz, 1 H, Ar) 
8.00 - 8.04 (m, 1 H, Ar) 8.06 (d, J = 1.76 Hz, 1 H, Ar) 11.54 (br, 1 H, exch, NH) 12.84 
(br, 1 H, exch, NH) 14.55 (br, 1 H, exch, HCl) Anal. Calcd. for C22H19N4·HCl: C, 70.49; 
H, 5.11; N, 14.95; Cl, 9.46. Found C, 70.43; H, 5.06; N, 14.79; Cl, 9.34. 
 
7-benzyl-N-(3-bromophenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (228) 
Compound 228 (synthesized from 261 and 3-bromo aniline as described for 161): yield = 
72%; TLC Rf 0.7 (CH3OH: CHCl3; 1:20). light yellow solid; mp 299-300 °C; 
1H NMR 
(400 MHz, DMSO-d6)  ppm 2.71 (s, 3 H, CH3) 4.13 (s, 2 H, CH2) 7.17 - 7.22 (m, 1 H, 
Ar) 7.26 - 7.32 (m, 4 H, Ar) 7.36 - 7.41 (m, 2 H, Ar) 7.75 (d, J = 2.76 Hz, 1 H, Ar) 7.95 - 
7.99 (m, 1 H, Ar) 8.25 (s, 1 H, Ar) 11.62 (br, 1 H, exch, NH) 12.86 (br, 1 H, exch, NH) 
14.62 (br, 1 H, exch, HCl) Anal. Calcd. for C20H17N4Br·HCl: C, 55.90; H, 4.22; N, 13.04; 
Cl, 8.25; Br, 18.59. Found C, 55.97; H, 4.15; N, 12.95; Cl, 8.29; Br, 18.50. 
 
7-benzyl-N-(3-chloro-4-fluorophenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(229) 
Compound 229 (synthesized from 261 and 3-chloro 4-floro aniline as described for 161): 
yield = 75%; TLC Rf 0.55 (CH3OH: CHCl3; 1:20). white solid; mp 289-291 °C; 
1H NMR 
(400 MHz, DMSO-d6)  ppm 2.70 (s, 3 H, CH3) 4.12 (s, 2 H, CH2) 7.15 - 7.34 (m, 5 H, 
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Ar) 7.49 (t, J = 9.16 Hz, 1 H, Ar) 7.72 (d, J = 2.01 Hz, 1 H, Ar) 7.88 - 7.96 (m, 1 H, Ar) 
8.22 (dd, J = 6.40, 2.13 Hz, Ar) 11.74 (br, 1 H, exch, NH) 12.86 (br, 1 H, exch, NH) 
14.63 (br, 1 H, exch, HCl) Anal. Calcd. for C20H16N4ClF·HCl·0.4C3H8O: C, 59.59; H, 
4.76; N, 13.11; Cl, 16.59; F, 4.45. Found C, 59.56; H, 4.57; N, 13.05; Cl, 16.61; F, 4.47. 
 
7-benzyl-N-(3-chloro-4-methoxyphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-
amine (230) 
Compound 230 (synthesized from 261 and 3-chloro 4-methoxy aniline as described for 
161): yield = 76%; TLC Rf 0.6 (CH3OH: CHCl3; 1:20). white solid; mp 307-309 °C; 
1H 
NMR (400 MHz, DMSO-d6)  ppm 2.67 (s, 3 H, CH3) 3.87 (s, 3 H, OCH3) 4.11 (s, 2 H, 
CH2) 7.15 - 7.33 (m, 6 H, Ar) 7.70 (d, J = 2.76 Hz, 1 H, Ar) 7.81 (dd, J = 9.16, 2.64 Hz, 
Ar) 8.04 (d, J = 2.26 Hz, 1 H, Ar) 11.44 (br, 1 H, exch, NH) 12.67 (br, 1 H, exch, NH) 
14.42 (br, 1 H, exch, HCl) Anal. Calcd. for C21H19N4ClO·HCl: C, 60.73; H, 4.85; N, 
13.49; Cl, 13.70. Found C, 60.83; H, 4.78; N, 13.36; Cl, 16.90. 
 
7-benzyl-2-methyl-N-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(231) 
Compound 231 (synthesized from 261 and 3,4,5 trimethoxy aniline as described for 161): 
yield = 71%; TLC Rf 0.5 (CH3OH: CHCl3; 1:20). light yellow solid; mp 270-271 °C; 
1H 
NMR (400 MHz, DMSO-d6)  ppm 2.70 (s, 3 H, CH3) 3.66 (s, 3 H, CH3) 3.80 (s, 6 H, 
OCH3) 4.12 (s, 2 H, CH2) 7.12 - 7.37 (m, 6 H, Ar) 7.70 (d, J = 2.01 Hz, Ar) 11.29 (br, 1 
H, exch, NH) 12.61 (s, 1 H, exch, NH) 14.45 (br, 1 H, exch, HCl) Anal. Calcd. for 
C23H24N4O3·HCl : C, 62.65; H, 5.71; N, 12.71; Cl, 8.04. Found C, 62.41; H, 5.77; N, 
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12.67; Cl, 8.02. 
 
7-benzyl-2-methyl-N-phenyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (232) 
Compound 232 (synthesized from 261 and aniline as described for 161): yield = 75%; 
TLC Rf 0.6 (CH3OH: CHCl3; 1:20). white solid; mp 300-302 °C; 
1H NMR (400 MHz, 
DMSO-d6)  ppm 2.70 (s, 3 H, CH3) 4.13 (s, 2 H, CH2) 7.19 - 7.26 (m, 2 H, Ar) 7.27 - 
7.34 (m, 4 H, Ar) 7.46 (t, J = 7.91 Hz, 2 H, Ar) 7.73 (s, 1 H, Ar) 7.91 (d, J = 7.78 Hz, 2 H, 
Ar) 11.20 (s, 1 H, exch, NH) 12.56 (s, 1 H, exch, NH) 14.42 (s, 1 H, exch, HCl) Anal. 
Calcd. for C20H18N4·HCl: C, 68.47; H, 5.46; N, 15.97; Cl, 10.11. Found C, 68.45; H, 5.43; 
N, 15.89; Cl, 9.99. 
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VI. SUMMARY 
This dissertation describes the design and synthesis of pyrimidine fused heterocycles as 
single agents with combination chemotherapy potential. These efforts led to the 
identification of structural features that are necessary for inhibition of tubulin 
polymerization. Structural modifications also led to the identification of antiangiogenic 
agents which inhibit one or more of the receptor tyrosine kinases (RTKs)- vascular 
endothelial growth factor receptor-2, platelet derived growth factor receptor-β and 
epidermal growth factor receptor. Single agents with both antiangiogenic activities as 
well as cytotoxicity would afford single entities that circumvent pharmacokinetic 
problems of multiple agents, avoid drug-drug interactions, could be used at lower doses 
to alleviate toxicity, devoid of overlapping toxicities, and delay or prevent tumor cell 
resistance. The novel target compounds synthesized as part of this study are listed below: 
1. N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (161) 
2. N-(4-methoxyphenyl)-N-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (162) 
3. N,2-dimethyl-N-phenyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (126) 
4. N-(4-methoxyphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (123) 
5. N-(2,4-dimethoxyphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (125) 
6. 4-(5-methoxyindolin-1-yl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidine (166) 
7. 6-methoxy-1-(2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-1,2,3,4-
tetrahydroquinoline (167) 
8. N-(4-methoxyphenyl)-N,2,5-trimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (170) 
9. N-(4-methoxyphenyl)-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (171) 
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10. N-(2,4-dimethoxyphenyl)-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (172) 
11. 1-(2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (173) 
12. N-(4-methoxyphenyl)-N,2,6-trimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (174) 
13. 4-(5-methoxyindolin-1-yl)-2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidine (175) 
14. 1-(2,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (176) 
15. N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrimido[5,4-b]indol-4-amine (178) 
16. 4-(5-methoxyindolin-1-yl)-2-methyl-5H-pyrimido[5,4-b]indole (179) 
17. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methyl-5H-pyrimido[5,4-b]indole 
(180) 
18. N-(4-methoxyphenyl)-N,2-dimethylfuro[3,2-d]pyrimidin-4-amine (181) 
19. N-(4-methoxyphenyl)-2-methylfuro[3,2-d]pyrimidin-4-amine (182) 
20. N-(2,4-dimethoxyphenyl)-2-methylfuro[3,2-d]pyrimidin-4-amine (183) 
21. 4-(5-methoxyindolin-1-yl)-2-methylfuro[3,2-d]pyrimidine (184) 
22. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylfuro[3,2-d]pyrimidine (185) 
23. 7-benzyl-N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(187) 
24. 7-benzyl-N,2-dimethyl-N-phenyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (188) 
25. 7-benzyl-N-(4-methoxyphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (189) 
26. 7-benzyl-N-(2,4-dimethoxyphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(190) 
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27. 5-ethyl-N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(191) 
28. 5-isopropyl-N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(192) 
29. N-(4-methoxyphenyl)-N,2-dimethyl-5-propyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(193) 
30. 5-isobutyl-N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(194) 
31. 5-butyl-N-(4-methoxyphenyl)-N,2-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(195) 
32. N-(4-methoxyphenyl)-N,2-dimethyl-6,7-dihydrofuro[3,2-d]pyrimidin-4-amine (196) 
33. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methyl-6,7-dihydrofuro[3,2-
d]pyrimidine (197) 
34. N-ethyl-N-(4-methoxyphenyl)-2-methylfuro[3,2-d]pyrimidin-4-amine (198) 
35. N-isopropyl-N-(4-methoxyphenyl)-2-methylfuro[3,2-d]pyrimidin-4-amine (199) 
36. N-(4-methoxyphenyl)-2-methyl-N-propylfuro[3,2-d]pyrimidin-4-amine (200) 
37. N-(4-methoxyphenyl)-N,2-dimethylbenzofuro[3,2-d]pyrimidin-4-amine (202) 
38. 4-(5-methoxyindolin-1-yl)-2-methylbenzofuro[3,2-d]pyrimidine (203) 
39. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylbenzofuro[3,2-d]pyrimidine 
(204) 
40. 7-benzyl-N-(4-methoxyphenyl)-N,2-dimethylfuro[3,2-d]pyrimidin-4-amine (205) 
41. 7-benzyl-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylfuro[3,2-
d]pyrimidine (206) 
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42. N,2-dimethyl-N-phenylfuro[3,2-d]pyrimidin-4-amine (207) 
43. N,2-dimethyl-N-(p-tolyl)furo[3,2-d]pyrimidin-4-amine (208) 
44. N-(4-chlorophenyl)-N,2-dimethylfuro[3,2-d]pyrimidin-4-amine (209) 
45. N-(3,4-dichlorophenyl)-N,2-dimethylfuro[3,2-d]pyrimidin-4-amine (210) 
46. 7-benzyl-N-(4-methoxyphenyl)-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(211) 
47. 7-benzyl-N-(4-methoxyphenyl)-N,2,5-trimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(212) 
48. 1-(7-benzyl-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (213) 
49. 1-(7-benzyl-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-
tetrahydroquinoline (214) 
50. N-(4-methoxyphenyl)-N,2,5,6-tetramethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (215) 
51. 6-methoxy-1-(2,5,6-trimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-1,2,3,4-
tetrahydroquinoline (216) 
52. 7-benzyl-N4-(4-methoxyphenyl)-N4-methyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-
diamine (217) 
53. 7-benzyl-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5H-pyrrolo[3,2-d]pyrimidin-
2-amine (218) 
54. N4-(4-methoxyphenyl)-N4,6-dimethyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine 
(219) 
55. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-6-methyl-5H-pyrrolo[3,2-d]pyrimidin-
2-amine (220) 
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56. N-(4-methoxyphenyl)-N,2-dimethyl-7-(3,4,5-trimethoxybenzyl)-5H-pyrrolo[3,2-
d]pyrimidin-4-amine (222) 
57. N4-(4-methoxyphenyl)-N4-methyl-7-(3,4,5-trimethoxybenzyl)-5H-pyrrolo[3,2-
d]pyrimidine-2,4-diamine (223) 
58. N-(4-methoxyphenyl)-N-methyl-7-(3,4,5-trimethoxybenzyl)-5H-pyrrolo[3,2-
d]pyrimidin-4-amine (224) 
59. 7-benzyl-N-(4-bromo-2-fluorophenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(225) 
60. 7-benzyl-N-(4-chloro-2-fluorophenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(226) 
61. 7-benzyl-N-(3-ethynylphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (227) 
62. 7-benzyl-N-(3-bromophenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (228) 
63. 7-benzyl-N-(3-chloro-4-fluorophenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(229) 
64. 7-benzyl-N-(3-chloro-4-methoxyphenyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-
amine (230) 
65. 7-benzyl-2-methyl-N-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine 
(231) 
66. 7-benzyl-2-methyl-N-phenyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (232) 
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APPENDIX 
 
The biological evaluations of were performed by Dr. Michael Ihnat (Department 
of Pharmaceutical Sciences, University of Oklahoma College of Pharmacy, Oklahoma 
City, OK 73117), Dr. Ernest Hamel (Screening Technologies Branch, Developmental 
Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National 
Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702), Dr. 
Susan Mooberry (Department of Pharmacology, University of Texas Health Science 
Center at San Antonio, San Antonio, TX 78229), National Cancer Institute 
(Developmental Therapeutics Program) and Luceome Biotechnologies (1775 S. Pantano Rd, 
Suite 100, Tucson, AZ 85710).  
Biological evaluations 
 The EC50 (concentration required to cause 50% loss of cellular microtubules) was 
determined in A-10 cells(1). The effects of the compounds on interphase and mitotic 
microtubules were evaluated using indirect immunofluorescence techniques, and the EC50 
values were calculated from a minimum of three experiments.  
 Antiproliferative effects were evaluated against the drug sensitive MDA-MB-435 
melanoma cells using sulforhodamine B assay and the IC50 values (concentration 
required to cause 50% inhibition of proliferation) were calculated. 
 In experiments with purified tubulin, the control compound was combretastatin A-4 
(CSA4), a potent colchicine site agent generously supplied by Dr. G. R. Pettit, Arizona 
State University, Tempe AZ. Tubulin polymerization was measured by turbidimetry at 
350 nm in Beckman DU7400 and DU7500 recording spectrophotometers equipped with 
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temperature controllers. In brief, 10 µM bovine brain tubulin, purified as described 
previously (20), was preincubated for 15 min in a 0.24 mL volume at 30°C containing 
0.75 M monosodium glutamate (adjusted to pH 6.6 with HCl in a 2 M stock solution), 
varying compound concentrations, and 4% (v/v) dimethyl sulfoxide (compound solvent). 
Following the preincubation, which permits detection of activity in slow binding 
compounds such as colchicinoids (19), samples were chilled on ice, and 10 µL of 10 mM 
GTP was added (0.4 mM). The addition of GTP is an absolute requirement for assembly 
under these reaction conditions. All concentrations refer to the final 0.25 mL reaction 
volume. Samples were transferred to cuvettes held at 0°C in the recording 
spectrophotometers, and the temperature was jumped to 30°C, which takes less than a 
minute. Assembly at 30°C was followed for 30 min, and the compound concentration to 
inhibit extent of assembly after 30 min was determined by interpolation of data obtained 
with individual compound concentrations. After determining the likely range for the IC50 
value, 2-4 individual determinations were made, and the average from these 
determinations are presented in Table 1. 
 The binding of [3H]colchicine to tubulin was performed by the DEAE-cellulose filter 
technique (21) with a stack of two filters, as described in detail previously (22). In brief, 
reaction mixtures contained, in a 0.10 mL volume, 1.0 µM purified tubulin, 5.0 µM 
[3H]colchicine, potential inhibitor at 5.0 µM, 5% (v/v) dimethyl sulfoxide (the compound 
solvent), and other components previously found to stabilize the colchicine binding 
activity of tubulin for prolonged periods at 37°C (23). Incubation was at 37°C for 10 min, 
at which time samples were diluted with 2 mL of ice-cold water and poured over the 
DEAE-filters under mild suction, with several rinses of the reaction vessel and of the 
  
187 
 
filtration chamber. The amount of radiolabel bound to the filters was determined by 
liquid scintillation counting, and samples containing test compounds were compared to 
reaction mixtures without compound. The percent inhibition relative to the control was 
determined for each compound in 2-4 independent experiments. 
 
Table 1. Effects in cellular assays and on purified tubulin  
 
EC50 Microtubule  
Depolymerization 
(µM) 
MDA-MB-
435 
IC50±SD 
(nM) 
Inhibition of 
Tubulin 
Assembly 
IC50±SD 
(µM) 
% Colchicine 
Binding inhibited at 
 5µM compound 
concentration 
161 1.2 96.6 ± 5.3 10 ± 0.6  
162 1.4 193 ± 5.3   
163 Not Active Up To 10 µM ND   
164 Not Active Up To 10 µM ND   
165 Not Active Up To 10 µM ND   
174 0.22 30.3  2.7 3.1  0.3 65 ± 1 
219 8.4 298 ± 19.7   
166 0.23 42.7 3.2 3.1  0.08 62 ± 2 
CSA4 0.0131 3.47 ± 0.6 1.2 ± 0.01 98 ± 0.3 
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Table 2. Tumor cell growth inhibition GI50 (10
-8 M) of NCI 60 cell line panel by 161  
Panel/Cell 
line  
GI50 
Panel/Cell 
line  
GI50  
Panel/Cell 
line  
GI50  Panel/Cell line  GI50  
Leukemia  161 
Colon 
Cancer  
161 Melanoma  161  Renal Cancer  161  
CCRF-CEM 33.9  COLO 205 13.4  LOX IMVI 51.2  786-0 44.6  
HL-60(TB) 21.7  HCC-2998 12.9  MALME-3M 13.6  A498 4.45  
K-562  8.69  HCT-116 29.2  M14 16.7  ACHN 71.2  
MOLT-4 40.2  HCT-15 36.3  
MDA-MB-
435 
2.79  CAKI-1 37.2  
RPMI-8226 30.1  HT29 18.9  SK-MEL-2  18.5  RXF 393 9.65  
SR 4.47  KM12 7.56  SK-MEL-28 405  SN12C 86.3  
NSCLC  
 
SW-620 16.5  SK-MEL-5 17.1  TK10 56.6  
A549/ATCC 27.1  
CNS 
Cancer   
UACC-257  37.0  UO-31 43.5  
EKVX 35.2  SF-268 58.6  UACC-62 47.4  
Prostate 
Cancer   
HOP-62 33.7  SF-295 13.0  
Ovarian 
cancer   
PC-3 25.9  
HOP-92 295  SF-539 25.3  IGROVI 29.5  DU-145 21.2  
NCI-H226 55.9  SNB-19 48.9  OVCAR-3 16.0  Breast Cancer  
 
NCI-H23 32.8  SNB-75 24.1  OVCAR-4 252  MCF7 8.67  
NCI-H322M 37.2  U251 26.0  OVCAR-5 45.4  
MDA-MB-
231/ATCC 
46.6  
NCI-H460 19.1  
  
OVCAR-8 39.2  HS 578T 17.9  
NCI-H522 4.56  
  
NCI/ADR-
RES 
66.9  BT-549 24.7  
    
SK-OV-3 23.3  MDA-MB-468 11.6  
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For the vinblastine and GTP binding experiments, ttubulin was freed of unbound 
nucleotide by preparative gel filtration chromatography on Sephadex G-50 (superfine). 
Control compounds were CA, a potent inhibitor of colchicine binding to tubulin, and 
dolastatin 10, a potent inhibitor of both vinblastine binding and nucleotide exchange. 
Both agents were generously provided by Dr. George R. Pettit, Arizona State University. 
The 0.3 mL reaction mixtures contained 10 M (1.0 mg/mL) tubulin, 0.1 M 4-
morpholineethane sulfonate (pH 6.9 in a 1.0 M stock solution with NaOH), 0.5 mM 
MgCl2, 6% DMSO, either 10 µM [
3H]vinblastine (from GE Healthcare) or 50 µM [8-
14C]GTP (from Moravek Biochemicals, repurified to > 99% purity by triethylammonium 
bicarbonate gradient chromatography on DEAE-Sephacel), and the indicated potential 
inhibitor at 50 M. Samples were incubated for 30 min at room temperature for 
vinblastine and at 4 °C for GTP. Duplicate aliquots (0.15 ml) were placed on 
microcolumns of Sephadex G50 (superfine) and were processed by centrifugal gel 
filtration at room temperature or 4 °C. Aliquots of the filtrates were processed for protein 
concentration by the Lowry assay and counted in a liquid scintillation counter. 
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Table 2. Effects of 187 on [3H]Vinblastine and Colchicine Binding to Tubulin and on 
Nucleotide Exchange, as Measured by [8-14C]GTP Binding to Tubulin.  
 
 
% of control ± SD 
Inhibition of colchicine binding 
% Inhibition  SD 
Vinblastine 
binding 
GTP binding 5 µM inhibitor 50 µM inhibitor 
187 100 ± 10 100 ± 10 17 ± 4 55 ± 2 
Dolastatin 10 9 ± 1 4 ± 0   
CA  
  99 ± 1  
 
 
Antibodies 
 The PY-HRP antibody was from BD Transduction Laboratories (Franklin Lakes, NJ). 
Antibodies against VEGFR-2 were purchased from Cell Signaling Technology (Danvers, 
MA).  
 
Phosphotyrosine ELISA 
 Cells used were tumor cell lines naturally expressing high levels of VEGFR-2 (U251). 
Expression levels at the RNA level were derived from the NCI Developmental 
Therapeutics Program (NCI-DTP) web site public molecular target information. Briefly, 
cells at 60–75% confluence are placed in serum-free medium for 18 h to reduce the 
background phosphorylation. Cells were always >98% viable by trypan blue exclusion. 
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Cells were then pretreated for 60 min with a dose-response relation of 100-1.4 µM 
compound followed in ⅓ Log increments by 100 ng/mL VEGF for 10 min. The reaction 
was stopped and cells permeabilized by quickly removing the media from the cells and 
adding ice-cold Tris-buffered saline (TBS) containing 0.05% Triton X-100, protease 
inhibitor cocktail and tyrosine phosphatase inhibitor cocktail. The TBS solution was then 
removed and cells fixed to the plate for 30 min at 60 °C with a further incubation in 70% 
ethanol for an additional 30 min. Cells were exposed to a blocking solution (TBS with 1% 
BSA) for 1 h, washed, and then a horseradish peroxidase (HRP)-conjugated 
phosphotyrosine (PY) antibody was added overnight. The antibody was removed, and the 
cells were washed again in TBS, exposed to an enhanced luminol ELISA substrate 
(Pierce Chemical EMD, Rockford, IL) and light emission was measured using a UV 
Products (Upland, CA) BioChemi digital darkroom. Data were graphed as a percent of 
cells receiving growth factor alone, and IC50 values were calculated from two to three 
separate experiments (n = 8–24) using non-linear regression dose-response relation 
analysis. 
 
OVCAR-8, NCI/ADR-RES and HeLa cells 
The OVCAR-8 and the Pgp overexpressing NCI/ADR-RES cell lines were generously 
provided by the Drug Screening group of the Developmental Therapeutics Program, NCI. 
The wild-type and β-III overexpressing HeLa cells were generous gifts, respectively, of 
Dr. Richard F. Ludueña and Dr. Susan L. Mooberry. The OVCAR-8 and NCI/ADR-RES 
cells were grown in RPMI 1640 medium with 5% fetal bovine serum at 37 °C in a 5% 
CO2 atmosphere for 96 h in the presence of varying compound concentrations. The HeLa 
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cells were grown in MEM supplemented with Earle’s salts, nonessential amino acids, 2 
mM L-glutamine, and 10% fetal bovine serum at 37 °C in a 5% CO2 atmosphere for 96 h 
in the presence of varying compound concentrations. In all cultures, the DMSO 
concentration was 0.5%. Protein was the parameter measured by the sulforhodamine B 
technique,8 and the IC50 was defined as the compound concentration causing a 50% 
reduction in the increase in cell protein as compared with cultures without compound 
addition. 
 
Chorioallantoic membrane assay of angiogenesis 
The CAM assay is a standard assay for testing antiangiogenic agents. The CAM assay 
used in these studies was modified from a procedure by Sheu and Brooks and as 
published previously. Briefly, fertile leghorn chicken eggs (CBT Farms, Chestertown, 
MD) were allowed to grow until 10 days of incubation. The proangiogenic factors human 
VEGF-165 and bFGF (100 ng each) were then added at saturation to a 6 mm microbial 
testing disk (BBL, Cockeysville, MD) and placed onto the CAM by breaking a small hole 
in the superior surface of the egg. Antiangiogenic compounds were added 8 h after the 
VEGF/bFGF at saturation to the same microbial testing disk and embryos allowed to 
incubate for an additional 40 h. After 48 h, the CAMs were perfused with 2% 
paraformaldehyde/3% glutaraldehyde containing 0.025% Triton X-100 for 20 sec, 
excised around the area of treatment, fixed again in 2% paraformaldehyde/3% 
glutaraldehyde for 30 min, placed on Petri dishes, and a digitized image taken using a 
dissecting microscope (Wild M400; Bannockburn, IL) at 7.5X and a SPOT enhanced 
digital imaging system (Diagnostic Instruments, Sterling Heights, MI). A grid was then 
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added to the digital CAM images and the average number of vessels within 5–7 grids 
counted as a measure of vascularity. Sunitinib and semaxanib were used as a positive 
control for antiangiogenic activity. Data were graphed as a percent of CAMs receiving 
bFGF/VEGF only and IC50 values calculated from two to three separate experiments 
(n = 5–11) using non-linear regression dose-response relation analysis.  
 
Table 3: Inhibition of tubulin assembly and cellular VEGFR2 receptor tyrosine kinase 
and the growth of β-III and P-gp overexpressing cells. 
COMPOUND 
Inhibition of 
tubulin 
assembly 
IC50 (nM) 
VEGFR2 
inhibition 
IC50 (nM) 
WT 
HeLa 
IC50 (nM) 
β-III 
overexpressing 
HeLa 
IC50 (nM) 
Parental 
OVCAR-8 
IC50 (nM) 
P-gp 
overexpressing 
NCI/ADR-RES 
IC50 (nM) 
187 21 ± 1 21.3 ± 3.2 280 ± 40 280 ± 40 1000 ± 300 700 ± 200 
188 > 20 (no act) 50.1 ± 8.8 > 10,000 > 10,000   
189 > 20 (no act) 40.6 ± 7.8 > 10,000 > 10,000   
190 > 40 (no act) 30.1 ± 5.1   > 5,000 > 5,000 
CA 
1.2 ± 0.01 
 
1.8 ± 0.4 2.5 ± 0.7 
  
paclitaxel 
  
5.3 ± 2 16 ± 1 
10 ± 0 5,000 ± 0 
semaxinib 
 
12.9     
sunitinib 
 
18.9 ± 2.7     
 
Tubulin immunofluorescence assay  
MDA-MB-435 cells were plated in chamber slides at ~30% confluency and allowed to 
attach overnight. Cells were then treated with drug at the IC50 concentration for 2 h in 
serum free media. After 2 h, drug was removed, cells were washed and then fixed in 3.7% 
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buffered formalin for 10 min. Fixed cells were then washed 3x with PBS, permeabilized 
with 0.5% Triton 100-X in PBS for 10 min at RT then blocked in 10% goat serum for 30 
min at RT. Slides were washed again with PBS 3x and then incubated with anti-alpha-
tubulin Alexa Fluor® 488 (Invitrogen, Carlsbad CA) in PBS containing 10% goat serum 
at a concentration of 2.5 µg/mL for 1 h at RT in the dark. After incubation, cells were 
washed, chambers removed, SlowFade Gold (Molecular Probes/Invitrogen, Carlsbad CA) 
added and a cover slip applied. Slides were imaged using a fluorescent microscope, Leica 
DM4000 B (Wetzlar, Germany) at EX488 nm/EM519 nm.  
 
 
Figure 1. Microtubule Staining by Docetaxel (DCT, COmbretastatin (CBT) and 187 
(RP/AG-119) 
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Cell cycle analysis and apoptosis  
MDA-MB-435 cells were plated at 30% confluence into 6 well plates (Costar, Cambridge, 
MA) and allowed to attach overnight. Drugs were added at their IC50 concentrations for 2 
h in serum free media and then 10% Cosmic Calf Serum was added. Cells were incubated 
for 24-48 h at 37 °C with 5% CO2 and then fixed in 50% ethyl alcohol solution and 
stored at 4 °C for up to a week. After fixation, pelleted cells were re-suspended and 
labeled in PBS containing 0.1% Triton X-100, 100 µg/mL RNase A, and 25 µg/mL 
propidium iodide and then incubated for 30 min at 37 °C. Cells were subjected to flow 
cytometry using a side scatter plot versus fluorescence (EX535 nm/EM617 nm) on a 
FACSCalibur flow cytometer (Becton-Dickenson, San Jose, CA). Analysis of DNA 
content was performed using MODFIT Lt software (Verity Software, Topsham, ME) to 
generate percent G1/G0 phase, S, and G2/M phase. Data were graphed as mean ± standard 
deviation.  
 
Western blot. Cells were treated with drug for 24 and 48 hours. Whole cell lysates were 
made from each sample in M-PER lysis reagent (Pierce-Thermo, Rockland, IL) 
containing phosphate and protease inhibitors (Sigma-Aldrich cocktail II, St Louis, MO), 
and 300mM final concentration of NaCl to lyse the nuclear membrane. Protein 
concentrations were quantified using the bicinchonic acid (BCA) protein assay kit 
(Pierce-Thermo, Rockland, IL) as compared to a standard BSA concentration curve. 
Equal amounts (30µg or 50µg) of cellular protein was loaded onto the SDS-PAGE gels, 
subjected to electrophoresis at 120V, transferred to a nitrocellulose membrane using iBlot 
apparatus (InVitrogen) for 20V for 7 min, blocked in Superblock (Pierce-Thermo,  
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Figure 2. Effect of 187 [RP/AG-119] on cell cycle (panels A and B), cell cycle protein 
expression (panel C) and apoptotic protein expression (panel D) 
Rockland, IL) and incubated with primary antibody overnight at 4°C in Superblock 
according to manufacturer’s instructions. Membranes were then washed three times in 
TBS containing 0.25% Tween-20, incubated with the secondary antibody (Cell Signaling 
Technology, Beverly, MA), washed again three times and ECL (Western Dura Substrate, 
Pierce-Thermo, Rockford, IL) added. Membranes were imaged using a digital charge-
coupled device (CCD) camera digital darkroom (FluorChem HD, Cell Biosciences, Santa 
Clara, CA). Loading controls used were either anti-vinculin antibody (Sigma Chemical; 
product V9131; 1:4000 dilution) or anti ß-actin antibody (Cell Signaling cat#4970, 
Beverly, MA; 1:1000 dilution). Primary antibodies used were Bax (Cell Signaling 
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cat#9661), cleaved caspase-3 (Cell Signaling #9664), cleaved PARP (Cell Signaling 
#5625, P-Chk1 (Cell Signaling #2341), P-Chk2 (Cell Signaling #2661); cyclin A1 (Cell 
Signaling # ); cyclin B1 (Cell Signaling #4138), cyclin E1 (Cell Signaling #4129); and 
were all diluted 1:1000 per manufacturer’s recommendations. 
 
Maximum tolerated dose in mice  
To determine the maximum tolerated dose (MTD) of compounds and drugs, a dose 
finding study was performed using BALBc/J mice (Jackson Laboratories, Bar Harbor, 
ME). Drugs were first dissolved at 50 mg/mL in DMSO and frozen in aliquots at -80 °C. 
Solutol-15 (BASF, Ludwigshafen, Germany) was melted at 60 °C for 5-10 min, then 
mixed in a ratio of 1 part DMSO/drug to 1.8 parts solutol-15 to 7.2 parts sterile dextrose 
5% in water (D5W). This solvent mixture was used for all drugs. Starting at 10 mg/kg and 
15 mg/kg body weight (n = 2 mice per treatment), mice were weighed and doses 
increased in 10 mg/kg increments every other day until weight loss was observed. At this 
point the MTD was estimated to be the approximate dose of first weight loss. The MTD 
of docetaxel was found to be 35 mg/kg, sunitinib 30 mg/kg and 187 [RP/AG-119] 25 
mg/kg, temozolomide 30 mg/kg.  
 
MDA-MB-435 flank tumor model 
Human MDA-MB-435 BLBCs (500,000) in media were implanted into the lateral flank 
of 8 wk old female NCr athymic nu/nu nude mice (Charles River, Wilmington, DE). 
Tumor sizes (length, width, depth) were measured twice weekly. When volumes reached 
75-100 mm3, (day 7 after implantation) treatment with drugs at their MTD (above) was 
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begun and animal weights and tumor volumes measured twice weekly. At the end of the 
experiment, animals were humanely euthanized using the AALAC approved method of 
carbon dioxide asphyxiation. Tumors were removed, fixed in neutral buffered formalin, 
paraffin embedded, sectioned and sections stained against CD31/PECAM-1 using an 
antibody from Abcam (ab28364) and staining done using a Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA). Vessel density was assessed by counting the number of 
CD31-positive vessels in a 200x microscope field in a blinded fashion and graphed as a 
percent vessel density of carrier treated animals.  
 
 
Figure 3: Treatment with 187 [RP/AG-119] decreased primary tumor growth and tumor 
vascular density in MDA-MB-435 flank xenograft model. * P<0.05, ** P<0.01, *** 
P<0.001 by one way ANOVA with Neuman-Keuls post test. Human BLBCs, MDA-MB-
435, were implanted into the lateral flank of NCr athymic nu/nu nude mice at 500,000 
cells, and the mice were treated with carrier, docetaxel, sunitinib, or 3∙HCl twice weekly 
at their MTD’s until the end of the experiment. Data is representative of 6-8 animals. (A) 
Tumor size was assessed by measuring tumor length, width, and depth twice weekly 
using Vernier calipers. Tumor volume was calculated with the ellipsoid formula: 
volume = 0.52 (length x width x depth) and graphically represented as days after 
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implantation. Statistics on this graphs were two way ANOVA with repeated measures 
post test. (B) Tumor vascular density was examined at the end of the experiment by 
staining tumor sections with CD31/PECAM-1 antibodies and a Vectastain ABC kit. 
Vascular density was determined by counting CD31-positive vessels and graphed as 
percent vessel density as compared with carrier treated animals. (C) Graphical 
representation of percent change in animal weight as determined by measuring animal 
weight at the beginning and end of the experiment.  
 
U251 flank xenograftraft model 
Human U251 glioblastoma cells (500,000) in media were implanted into the lateral flank 
of 8 wk old male NCr athymic nu/nu nude mice (Charles River, Wilmington, DE). Tumor 
sizes (length, width, depth) were measured twice weekly. When volumes reached 75-100 
mm3 (day 8 after implantation), treatment with drugs at their MTD (above) was begun 
and animal weights and tumor volumes measured twice weekly. At the end of the 
experiment, animals were humanely euthanized using the AALAC approved method of 
carbon dioxide asphyxiation. Tumors were removed, fixed in neutral buffered formalin, 
paraffin embedded, sectioned and sections stained against CD31/PECAM-1 using an 
antibody from Abcam (ab28364) and staining done using a Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA Vessel density was assessed by counting the number of 
CD31-positive vessels in a 200x microscope field in a blinded fashion and graphed as a 
percent vessel density of carrier treated animals.  
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Figure 4: Treatment with 187 [RP/AG-119] decreased primary tumor growth and tumor 
vascular density in U251 flank xenograft mouse model. * P<0.05, ** P<0.01, *** 
P<0.001 by one way ANOVA with Neuman-Keuls post test. U251 human glioma cells 
were implanted into the lateral flank of NCr athymic nu/nu nude mice at 500,000 cells, 
and the mice were treated with carrier temozolomide or 187 [RP/AG-119] twice weekly 
at their MTD’s until the end of the experiment. Data is representative of 6-8 animals. (A) 
Tumor size was determined as described in the legend of Figure 3. Statistics on this graph 
were two way ANOVA with repeated measures post test. (B) Tumor vascular density was 
examined at the end of the experiment as described in the legend of Figure 3.(C) 
Graphical representation of percent change in animal weight as determined by measuring 
animal weight at the beginning and end of experiment. 
 
4T1 triple negative breast orthotopic allograft model 
4T1-Luc2GFP dual luciferase/GFP tagged cells were purchased from Caliper Life 
Sciences (Hopkinton, MA) and maintained in Dulbecco’s modification of minimal 
essential media (DMEM) containing 10% Cosmic Calf Serum (Hyclone, Logan, UT). 
750 cells (verified by fluorescence imaging to be >98% GFP positive and counted three 
times on a TC10 automated cell counter (BioRad, Hercules, CA)) in 100 µL PBS with 1 
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mM EDTA were implanted subcutaneously into the left fat pad #4 of 8 wk old female 
BALBc/J mice using a tuberculin syringe. The MTD of drugs were delivered to animals 
twice weekly on Tuesday and Friday starting three days after implantation beginning 
when tumors had reached 75-100 mm3 (day 7 after implantation). Tumor sizes (length, 
width, depth) were measured three times weekly. Animal weights were also taken twice 
weekly. At day 33 post implantation, the experiment was ended due to moribund animals 
in the untreated group. At the end of the experiment, animals were humanely euthanized 
using the AALAC approved method of carbon dioxide asphyxiation. Tumors and lungs 
were removed and fresh lungs imaged using a LumaScope fluorescent imaging system 
(Bulldog Bio, Portsmouth, NH) at 25x magnification with the number of metastases per 
lung counted by hand from captured images.  
 
 
Figure 5: Treatment with 187 [RP/AG-119] decreased primary tumor growth and lung 
metastases in the 4T1 orthotopic breast model. 4T1-Lucerase/GFP tagged cells were 
implanted orthotopically into BALB/c mice at 7,500 cells, and the mice were treated with 
carrier, docetaxel or 187 [RP/AG-119] at their MTD’s twice weekly until the end of the 
experiment. (A) Tumor volume was as described in the legend of Figure 3. (B) Animal 
weights were recorded before each treatment and graphed as percent weight change. (C) 
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After 32 days, animals were euthanized and lungs were excised and immediately imaged 
at 25x using the LumaScope fluorescent imaging system. The number of metastases in 
both lungs was counted visually and represented graphically. 
 
Table 4. Tumor cell inhibitory activity (NCI) GI50 (nM) of 187  
Panel/  
Cell line  
GI50 
(nM) 
Panel/ 
Cell line  
GI50 
(nM) 
Panel/ 
Cell line  
GI50 
(nM) 
Panel/ 
Cell line  
GI50 
(nM) 
Leukemia  187 
Colon 
Cancer  
187 Melanoma   187 
Renal 
Cancer  
187 
CCRF-CEM  306  
COLO 
205  
252  
LOX 
IMVI  
485  786 - 0  547  
HL-60(TB)  222  
HCC-
2998  
896  M14  297  A498  136  
K-562  258  
HCT-
116  
459  
MDA-MB-
435  
117  ACHN  741  
MOLT-4  398  HCT-15  385  SK-MEL-2  352  CAKI-1  316  
RPMI-8226  480  HT29  309  
SK-MEL-
28  
917  RXF 393  362  
SR  277  KM12  435  SK-MEL-5  357  SN12C  543  
NSCLC   SW-620   331  UACC-62  318  TK10  644  
A549/ATCC  713  
CNS 
Cancer  
 
Ovarian 
cancer  
 UO-31  488  
EKVX  310  SF-268  791  IGROVI  432  
Prostate 
Cancer  
 
HOP-62  396  SF-295  249  OVCAR-3  236  PC-3  642  
HOP-92  1320  SF-539  257  OVCAR-4  1260  DU-145  347  
NCI-H226  776  SNB-19  531  OVCAR-5  1190  
Breast 
Cancer  
 
NCI-H23  441  SNB-75  164  OVCAR-8  676  MCF7  347  
NCI-H322M  381  U251  371  
NCI/ADR-
RES  
268  
MDA-MB-
231/ATCC  
699  
NCI-H460  331    SK-OV-3  371  HS 578T  291  
NCI-H522  181  
    MDA-MB-
468  
197  
 
 
